

1 November 2019

Dear Supplier

INVITATION TO TENDER – SUPPLY OF PHARMACEUTICALS TO DHB HOSPITALS AND/OR TO COMMUNITY PHARMACIES

PHARMAC invites tenders for the supply of certain pharmaceuticals to DHB hospitals and/or to community pharmacies in New Zealand.

This invitation to tender incorporates the following schedules:

- (a) Schedule 1 sets out the definitions used in this invitation;
- (b) Schedule 2 specifies the pharmaceuticals for which you may submit a Tender Bid in relation to community supply and/or hospital supply;
- (c) Schedule 3 describes the process PHARMAC intends to follow in relation to this tender, and provides instructions on how to submit a Tender Bid in relation to community supply and/or hospital supply;
- (d) Schedule 4 sets out terms that will apply if your Tender Bid in relation to community and/or hospital supply is awarded Sole Supply Status and/or Hospital Supply Status;
- (e) Schedule 5 sets out the additional terms that will apply if your Tender Bid in relation to community supply is awarded Sole Supply Status;
- (f) Schedule 6 sets out the additional terms that will apply if your Tender Bid in relation to hospital supply is awarded Hospital Supply Status; and
- (g) Schedule 7 sets out the additional special terms that will apply if your Tender Bid in relation to a particular pharmaceutical is awarded Sole Supply Status and/or Hospital Supply Status.

This invitation to tender also incorporates the information on the Electronic Portal referred to in this invitation.

If you wish to submit a Tender Bid in relation to community supply and/or hospital supply, you must submit it via the Electronic Portal to PHARMAC no later than **4pm** (New Zealand time) on **Thursday 12 December 2019**.

If you have any inquiries about this invitation you should contact the **Tender Analyst** at tender@pharmac.govt.nz (Emma Clarke on (04) 830 1987).

We look forward to receiving your tender.

Yours sincerely,



Lisa Williams
Director of Operations

Contents

Schedule 1: Definitions and interpretation	4
1. Definitions	4
2. Interpretation.....	11
Schedule 2: Products to be tendered.....	12
1. Information about Tender Items.....	12
2. List of Products	15
Schedule 3: Tender Process	45
1. General.....	45
2. Information about submitting a Tender Bid.....	50
3. What to include in your Offer Letter and Tender Submission Form	51
4. How to submit a Tender Bid	53
5. Evaluation.....	54
6. Conformity.....	55
7. Decision.....	56
8. Back-up supply	57
9. Dealing with information	57
10. Miscellaneous	58
Schedule 4: Contract terms for both Sole Supply Status and Hospital Supply Status	60
1. General.....	60
2. Crown Direction	61
3. Audit.....	62
4. Miscellaneous	62
Schedule 5: Additional contract terms for Sole Supply Status	66
1. Effect of Sole Supply Status.....	66
2. Consents	68
3. Price	69
4. Shelf-life of Pharmaceutical	70
5. Out-of-stock arrangements.....	71
6. Termination and restrictions	74
7. Guarantee	74

Schedule 6: Additional contract terms for Hospital Supply Status	75
1. Effect of Hospital Supply Status	75
2. Consents	82
3. Price	83
4. Invoicing and Payment.....	84
5. Emergency and disaster supply	86
6. Defective and short-dated Pharmaceuticals.....	86
7. Out-of-stock arrangements.....	87
8. Termination and restrictions	90
9. Guarantee	90
10. Access by PHARMAC to price and volume data.....	90
11. PCTs.....	91
Schedule 7: Additional Special Terms	93
1. Lacosamide	93

Schedule 1: Definitions and interpretation

1. Definitions

In this Invitation:

Additional Stock Pharmaceutical (or ASP) means a Pharmaceutical, marked with a “@”, for which the supplier of the successful Tender Bid would be required:

- (a) to hold additional stock; and
- (b) to report to PHARMAC on the level of that additional stock each Quarter;

Aggregated Tender Bid means a Tender Bid for more than one Tender Item, which PHARMAC is to consider in aggregate, and can include a Tender Bid for more than one Tender Item of the same Chemical Entity but not aggregation within a single Tender Item;

Agreement means:

- (a) Schedule Four; and
- (b) in relation to a Pharmaceutical with Sole Supply Status, Schedule Five; or
- (c) in relation to a Pharmaceutical with Hospital Supply Status, Schedule Six,

and includes, to the extent applicable, the other Schedules (including but not limited to Schedule Seven) and the information on the Electronic Portal comprising the Invitation;

Alternative Pharmaceutical means an alternative brand of a Pharmaceutical that PHARMAC, following consultation with PTAC or its sub-committees, considers to be an acceptable substitute for that Pharmaceutical;

Back-up Supply Agreement means an alternative agreement or arrangement negotiated by PHARMAC, at its sole discretion, with a supplier other than the supplier with Sole Supply Status and/or Hospital Supply Status in respect of a particular Tender Item, to cover the contingency that Sole Supply Status and/or Hospital Supply Status is suspended or withdrawn under the terms of this Agreement in respect of that Tender Item, or that the Tender Item is otherwise out of stock or unavailable for supply;

Chemical Entity means any pharmaceutical that contains, and is described generically according to, the relevant active ingredient specified in Schedule Two and the Electronic Portal. For the avoidance of doubt, the term Chemical Entity does not include any Medical Device;

Combined Community/Hospital Tender Bid means a Community Tender Bid and a Hospital Tender Bid that you submit in combination for the same Tender Item;

Community Tender Bid means a Tender Bid in relation to community supply;

Confidential Information means all information exchanged between us under this Invitation or in relation to your Tender Bid, including during all negotiations relating to your Tender Bid;

Schedule 1

Consents means all consents, permits, licences and authorisations, whether statutory or otherwise, required for the supply of the Tender Item in New Zealand (including Ministry of Health market approval);

Contract Manufacturer means a manufacturer or a supplier that is a party to a contract with the relevant DHB Hospital to compound Pharmaceuticals, on request from that DHB Hospital;

Cost Brand Source Product means a pharmaceutical where there is no price agreed upon by PHARMAC, but the pharmaceutical is subsidised by the Funder at the price obtained by pharmacies;

Crown Direction means any ministerial direction given to PHARMAC under section 103 of the Crown Entities Act 2004;

CTPP means Containered Trade Product Pack SNOMED CT code, which is the unique identifier that describes the packaged, branded product and the container it is dispensed in, as used within the New Zealand Medicines Terminology;

Deadline means 4 pm, Thursday 12 December 2019 (New Zealand time);

Designated Delivery Point means at a DHB Hospital's discretion:

- (a) a delivery point agreed between you and the relevant DHB Hospital, to which delivery point you must supply the Pharmaceutical directly at the Price; and/or
- (b) any delivery point designated by the relevant DHB Hospital or PHARMAC, such delivery point being within 30km of your national distribution centre;

DHB Hospital means a DHB, including its hospital or associated provider unit for which that DHB purchases pharmaceuticals;

District Health Board (or DHB) has the same meaning as in the New Zealand Public Health and Disability Act 2000;

DV Limit means, for a particular Pharmaceutical, the National Discretionary Variance (DV) Limit or the Individual DV Limit;

DV Pharmaceutical means a discretionary variance Pharmaceutical, being an Alternative Pharmaceutical that does not have Hospital Supply Status, and includes a pharmaceutical which (unless PHARMAC specifies otherwise in Schedule Two of this Agreement and the Electronic Portal, or we agree otherwise in writing):

- (a) is listed as a DV Pharmaceutical, in association with the relevant Pharmaceutical having Hospital Supply Status, in the then current Section H of the Pharmaceutical Schedule; or
- (b) in the case of a pharmaceutical that is not a Medical Device, is the same Chemical Entity, at the same strength, and in the same or a similar presentation or form, as the relevant Pharmaceutical with Hospital Supply Status, but which is not yet listed as a DV Pharmaceutical.

For the avoidance of doubt, a pharmaceutical which:

- (c) in the case of a pharmaceutical that is not a Medical Device, is a different Chemical Entity from the Pharmaceutical with Hospital Supply Status; and

Schedule 1

- (d) is not listed as a DV Pharmaceutical in the then current Section H of the Pharmaceutical Schedule,

is not a DV Pharmaceutical;

Electronic Portal means the electronic tender system available via the internet address provided to you by PHARMAC through which you are required to submit your Tender Bid(s);

End Date means the last day of the Hospital Supply Status Period, or Sole Supply Period, as applicable;

Evaluation Committee means a committee established by PHARMAC to evaluate Tender Bids;

Final Transition Period means, in respect of a Pharmaceutical with Sole Supply Status or Hospital Supply Status, as applicable, the period of three calendar months beginning on the day after the relevant End Date;

First Transition Period means, in respect of a Pharmaceutical with Sole Supply Status or Hospital Supply Status, the period beginning on the first day of the month following the Market Notification Date and ending on the day prior to five months from the Start Date (or such different or longer period as PHARMAC determines under clause 1.2 of Schedule Three);

Funder means the body or bodies responsible, pursuant to the New Zealand Public Health and Disability Act 2000, for the funding of pharmaceuticals listed on the Pharmaceutical Schedule (which may be, without limitation, one or more District Health Boards and/or the Ministry of Health) and their successors;

GTIN means the Global Trade Item Number for a Pharmaceutical;

Hospital Supply Status means the status of being the brand of the relevant Pharmaceutical listed in Section H of the Pharmaceutical Schedule as having such status, which Pharmaceutical DHB Hospitals must (or in the case of Medical Devices, may) purchase, subject to any DV Limit for that Pharmaceutical, for the Hospital Supply Status Period;

Hospital Supply Status Period means the period beginning on the day after the end of the First Transition Period and ending on 30 June 2023;

Hospital Tender Bid means a Tender Bid in relation to hospital supply;

Individual DV Limit means, for:

- (a) a particular Pharmaceutical; and
- (b) a particular DHB Hospital,

the discretionary variance limit, being a percentage of the Individual Total Market Volume, which equals the percentage of the National DV Limit for that Pharmaceutical, up to which that DHB Hospital may purchase DV Pharmaceuticals of that Pharmaceutical. The Individual DV Limit is set:

- (c) for the number of months during which the Hospital Supply Status Period applies during the period ending on 30 June 2021 and
- (d) the number of months during which the Hospital Supply Status Period applies during the twelve month period ending on 30 June 2022 and

Schedule 1

- (e) the number of months during which the Hospital Supply Status Period applies during the twelve month period ending on 30 June 2023.

Individual Total Market Volume means for:

- (a) a particular Pharmaceutical; and
- (b) a particular DHB Hospital,

in any given period, in accordance with data available to PHARMAC, the sum of:

- (c) the total number of Units of the relevant Pharmaceutical with Hospital Supply Status purchased by the relevant DHB Hospital; and
- (d) the total number of Units of all the relevant DV Pharmaceuticals, listed in Section H in association with that Pharmaceutical, purchased by that DHB Hospital;

Invitation means this invitation to tender and includes the cover letter, each of the Schedules and the information on the Electronic Portal referred to in this invitation;

Lead Time means the number of months (being whole months only) indicated on your Tender Bid that, if your Tender Bid is accepted, you would require following the Successful Tenderer Notification Date in order to source sufficient stock of your brand of the Tender Item to meet the entire market demand for the Tender Item as at the Start Date. For the avoidance of doubt, the Lead Time does not affect, and should incorporate the extra time needed to allow for, your obligations in clause 3.1 of Schedule 5 and clause 3.1 of Schedule 6;

Market Notification Date means the date on which PHARMAC notifies the market that your Tender Bid, in respect of a particular Tender Item, has been accepted, being greater than one month prior to the Start Date;

Medical Device means a medical device as that term is defined in the Medicines Act 1981;

National DV Limit means, for a particular Pharmaceutical, the discretionary variance limit, being the specified percentage of the National Total Market Volume up to which all DHB Hospitals may collectively purchase DV Pharmaceuticals of that Pharmaceutical. The National DV Limit is set for DHB Hospitals nationally:

- (a) for the number of months during which the Hospital Supply Status Period applies during the period ending on 30 June 2021; and
- (b) the number of months during which the Hospital Supply Status Period applies during the twelve month period ending on 30 June 2022; and
- (c) the number of months during which the Hospital Supply Status Period applies during the twelve month period ending on 30 June 2023.

National Total Market Volume means, for a particular Pharmaceutical in any given period, in accordance with data available to PHARMAC, the sum of:

- (a) the total number of Units of the relevant Pharmaceutical with Hospital Supply Status purchased by all DHB Hospitals; and
- (b) the total number of Units of all the relevant DV Pharmaceuticals, listed in Section H in association with that Pharmaceutical, purchased by all DHB Hospitals;

Schedule 1

Offer Letter means the letter of offer which must be attached to your Tender Submission Form, in the form set out in the Electronic Portal;

OPPs means PHARMAC's then current Operating Policies and Procedures and any relevant supplements, as applicable;

PCT means Pharmaceutical Cancer Treatment. Tender Items that are PCTs are indicated with "PCT" in the list in clause 2 of Schedule Two and the Electronic Portal;

Pharmaceutical means the relevant Tender Item (which may be a Medical Device) for which you have submitted, and PHARMAC has accepted on behalf of the Funder, a Tender Bid;

Pharmacode means the unique six or seven digit identifier assigned to a pharmaceutical and notified to you by the Pharmacy Guild. Suppliers must apply to the Pharmacy Guild of New Zealand to receive a Pharmacode for each presentation of their pharmaceutical before it is listed;

Potential Out-of-Stock Event means:

- (a) in relation to community or hospital supply, your stock of the Pharmaceutical in New Zealand falls below two-thirds of your most recent three months' total Unit sales of the Tender Item, or, where the Pharmaceutical is designated an ASP, your stock of the Pharmaceutical in New Zealand falls below your most recent four months' total Unit sales of the Tender Item; or
- (b) in relation to community or hospital supply, forecast sales demand in respect of the next two-month period is greater than your stock of the Pharmaceutical, or, where the Pharmaceutical is designated an ASP, forecast sales demand in respect of the next four-month period is greater than your stock of the Pharmaceutical; or
- (c) in relation to hospital supply, your stock of the Pharmaceutical in New Zealand falls below the average volume of stock of the Pharmaceutical required to supply the entire New Zealand DHB Hospital market for the Pharmaceutical for any given two-month period, or, where the Pharmaceutical is designated an ASP, your stock of the Pharmaceutical in New Zealand falls below the average volume of stock of the Pharmaceutical required to supply the entire New Zealand DHB Hospital market for the Pharmaceutical for any given four-month period; or
- (d) in relation to community supply, your stock of the Pharmaceutical in New Zealand falls below one-sixth of the Unit Volume, or, where the Pharmaceutical is designated an ASP, your stock of the Pharmaceutical in New Zealand falls below one-third of the Unit Volume;
- (e) in relation to community or hospital supply, your stock of the Pharmaceutical in New Zealand is insufficient to enable you to fully fill all orders as they are received (without restricting quantities that may be ordered); or
- (f) in relation to New Zealand manufactured products if either:
 - (i) forecast sales demand in respect of the next two-month period is greater than your stock of the Pharmaceutical; or
 - (ii) you have insufficient stock to enable you to fully fill all orders as they are received; or

Schedule 1

- (iii) your stock of the active pharmaceutical ingredient taking into account manufacturing and stock on hand falls below two months stock for the Pharmaceutical in New Zealand;

For the avoidance of doubt, references to 'your stock' in (a) to (f) above refer to stock physically held by you or on your behalf in New Zealand and do not include stock held in New Zealand by wholesalers or other parties;

Price means the price (in New Zealand dollars and exclusive of GST) at which the Pharmaceutical is to be supplied, or made available for sale and supply, by you to:

- (a) in relation to community supply, wholesalers and other such distributors, and at which the Pharmaceutical is to be subsidised by the Funder, being the price specified in your successful Tender Submission Form, unless there has been a subsequent price change in accordance with the terms of the Invitation, in which case the Price will be the price notified to you by PHARMAC upon acceptance of your Tender Bid; or
- (b) in relation to hospital supply, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding), being the price specified in your successful Tender Submission Form, unless there has been a subsequent price change in accordance with the terms of the Invitation, in which case the Price will be the price notified to you by PHARMAC upon acceptance of your Tender Bid;

PTAC means the Pharmacology and Therapeutics Advisory Committee;

Quarter means the periods:

- (a) 1 January until 31 March;
- (b) 1 April until 30 June;
- (c) 1 July until 30 September; and
- (d) 1 October until 31 December;

Section B means the relevant section or sections of the Pharmaceutical Schedule relating to community pharmaceuticals;

Section H means the relevant section or sections of the Pharmaceutical Schedule identified as such, which relate to pharmaceuticals for use in hospitals;

Sole Supply Period means the period beginning on the day after the expiry of the First Transition Period and ending on 30 June 2023;

Sole Supply Status means, in relation to community supply, the status of being the sole subsidised supplier of the particular Tender Item for the Sole Supply Period;

Start Date means:

- (a) in relation to a Tender Item for which your Tender Bid has been accepted unconditionally, the first day of the month following the date that represents:
 - (i) the Successful Tenderer Notification Date; plus
 - (ii) the Lead Time; or

Schedule 1

- (b) in relation to a Tender Item for which your Tender Bid has received conditional acceptance, in terms of clause 7.4 of Schedule Three, the first day of the month following the date that represents:
 - (i) the date that such acceptance ceases to be conditional; plus
 - (ii) the Lead Time; or
- (c) such other date that is negotiated between you and PHARMAC under clause 1.6 of Schedule Three;

Successful Tenderer Notification Date means the date on which PHARMAC notifies you, in relation to a Tender Item for which you have submitted a Tender Bid, that your Tender Bid has been accepted;

Tender Bid means the Offer Letter together with the Tender Submission Form submitted through the Electronic Portal for a particular Tender Item, including the Lead Time, and includes a Community Tender Bid, a Hospital Tender Bid and a Combined Community/Hospital Tender Bid;

Tender Item means:

- (a) in the case of a pharmaceutical that is not a Medical Device, the form and strength of a Chemical Entity (or entities, if applicable) for which you may submit a Tender Bid; or
- (b) in respect of a Medical Device, an item conforming to the individual specifications described for such item in the product list in clause 2 of Schedule Two for which you may submit a Tender Bid;

Tender Submission Form means the form on which you must submit your bid for each Tender Item, as set out in the Electronic Portal;

Transition Periods collectively refers to the First and Final Transition Periods;

Unit means an individual unit of a Tender Item (e.g. tablet, 1 ml of an oral liquid, ampoule, syringe, bag, suture or needle, roll or a dressing);

Unit Price means the relevant Price specified for a pack (or equivalent grouping for any Medical Device) of that Tender Item in Section H of the Pharmaceutical Schedule, divided by the number of Units in the pack specified in the Pharmaceutical Schedule as being the listed pack size for that Tender Item (and where that Tender Item is not listed on the Pharmaceutical Schedule, the price and pack size in the most recent issue of the Pharmaceutical Schedule published prior to that Tender Item being delisted);

Unit Subsidy means the subsidy specified for a pack of that Tender Item in Sections A to G of the Pharmaceutical Schedule, divided by the number of Units in the pack specified in the Pharmaceutical Schedule as being the subsidised pack size for that Tender Item (and where that Tender Item is not listed on the Pharmaceutical Schedule, the subsidy and pack size specified in the most recent issue of the Pharmaceutical Schedule published prior to that Tender Item being delisted); and

Unit Volume means, in relation to community supply, the approximate number of Units of the Tender Item subsidised by PHARMAC, and claimed for by community pharmacies, in one year, as specified in Schedule Two and the Electronic Portal.

Schedule 1

2. Interpretation

In the construction of this Invitation, unless the context otherwise requires:

- (a) a reference to a clause or a Schedule is a reference to a clause of, or a Schedule to, this Invitation;
- (b) a reference to a statute, code of conduct or other law includes any regulations and other instruments under it and consolidations, amendments, re-enactments or replacements of any of them (whether before or after the date of this Agreement);
- (c) the singular includes the plural and vice versa;
- (d) the word person includes an individual, a body corporate, an association of persons (whether corporate or not), a trust, a state and an agency of state, in each case, whether or not having a separate legal personality;
- (e) a reference to a person includes a reference to the person's executors, administrators, successors, substitutes, (including, but not limited to, persons taking by novation) and permitted assignees;
- (f) words importing one gender include the other genders;
- (g) headings in this Agreement or in the Electronic Portal are for convenience only and have no legal effect; and
- (h) unless the context requires otherwise, references to the **"listing"** of a Pharmaceutical:
 - (i) in relation to hospital supply, are to the listing of that Pharmaceutical in Section H of the Pharmaceutical Schedule and are deemed to include any written notification by PHARMAC of that Pharmaceutical being the subject of a national supply contract negotiated by PHARMAC on behalf of DHBS, where such written notification is in advance of the actual listing of that Pharmaceutical in Section H of the Pharmaceutical Schedule (and references to "list", "listed", "delist", "delisted", and "delisting" are to be interpreted accordingly);
 - (ii) in relation to community supply, are to the actual listing of that Pharmaceutical in Sections A to G of the Pharmaceutical Schedule (and references to "list", "listed", "delist", "delisted", and "delisting" are to be interpreted accordingly).

Schedule 2: Products to be tendered

1. Information about Tender Items

1.1 List of Tender Items

This Schedule sets out the Tender Items and information about the Tender Items. While PHARMAC has taken all reasonable care in preparing the information contained in this Schedule, it accepts no liability for any errors or omissions in the information.

1.2 Patents

- (a) Where possible, PHARMAC has identified Tender Items that it understands may be the subject of a patent that it believes is due to expire after the Deadline.
- (b) Where PHARMAC has been advised of the existence of a patent prior to sending out this Invitation, it has shown this in the attached list by the use of a + symbol.
- (c) However, PHARMAC makes no representation as to the patent status of the Tender Items and accepts no liability for any patent infringement that might occur as a result of this tender process or PHARMAC's acceptance of a Tender Bid, including infringement of process patents.

1.3 Unit Volume and market value figures

- (a) Except where indicated otherwise, the Unit Volume figures, in relation to community supply, are based on actual volumes for the year ending 30 June 2019.
- (b) Market value figures, in relation to community supply, are expressed as the Unit Volume in the year ending 30 June 2019, multiplied by the Unit Subsidy as at 1 July 2019.
- (c) The figures referred to in paragraphs (a) and (b):
 - (i) are approximate and indicative only. PHARMAC makes no representation as to the accuracy of these figures or as to the level of sales or likely sales of any Tender Item. In particular, if these figures change at any time during the period from PHARMAC's pre-tender consultation until decisions have been made about the acceptance of Tender Bids for all Tender Items, PHARMAC is not obliged to notify you of any such change; and
 - (ii) unless specified by PHARMAC do not include DHB Hospital volumes. For the avoidance of doubt, PHARMAC makes no representation as to the size of the DHB Hospital market for any Tender Item, in relation to hospital supply.
- (d) You acknowledge and agree that in submitting your Tender Bid you will rely on your own knowledge, skill and independent advice or assessment of the market size for any Tender Item and PHARMAC is to have no liability in that regard.

1.4 Special terms

Where there are any special terms relating to a particular Tender Item, those terms are indicated in the column entitled "Comments" in the list and/or Schedule Seven. Special Authority restrictions have been noted for Tender Items where applicable in the list. Further restrictions

Schedule 2

on the supply of Tender Items within the Pharmaceutical Schedule may apply. You acknowledge and agree that in submitting your Tender Bid you will rely on your own knowledge and assessment of any restrictions applicable to a Tender Item within the Pharmaceutical Schedule.

1.5 Subsidies

- (a) The level at which each Tender Item, in relation to community supply, is specified in the attached list as being subsidised per Unit as at 1 July 2019.
- (b) Subsidies of Tender Items, in relation to community supply, may change before a Tender Bid is accepted.
- (c) Where a “*” symbol is indicated next to the Unit Subsidy in the attached list, there is no fully funded product available, in relation to community supply, for that Tender Item as at 1 July 2019.

1.6 DV Limits

Where there is a DV Limit relating to a particular Tender Item, in relation to hospital supply, that limit is indicated as a percentage amount in the column entitled “DV Limit” in the attached list and is also shown in the Electronic Portal.

1.7 Tender Items subject to sole supply arrangements

Where a Tender Item is underlined in the list of products below, that item is subject to a sole supply contract as at the date of this Invitation. Accordingly, the subsidy for those items is fixed until 30 June 2020 (unless otherwise indicated) and, for items that are the subject of a sole supply contract, the listing of a new brand, in relation to community supply, could only occur after that date. This information is not available in the Electronic Portal.

1.8 Hospital only products

Where an “H” is indicated, you may submit a Tender Bid for Hospital Supply Status for that Tender Item.

1.9 Community only Products

Where a “C” is indicated, you may submit a Tender Bid for Sole Supply Status for that Tender Item.

1.10 Community and Hospital Products

Where a “C” and an “H” are indicated, you may submit a Tender Bid for Sole Supply Status and/or a Tender Bid for Hospital Supply Status for that Tender Item. You may also submit a Combined Community/Hospital Tender Bid in accordance with clause 2.5 of Schedule Three.

1.11 PCTs

Where a “PCT” is indicated, you may submit a Tender Bid for Hospital Supply Status for that Tender Item on the basis that, if PHARMAC accepts your Tender Bid, the Tender Item would be listed in Section B and/or Part II of Section H of the Pharmaceutical Schedule subject to clause 11 of Schedule Six. This information is also shown in the Electronic Portal.

Where a Tender Item is indicated as being a “PCT” product, it is the preference of PHARMAC that products have post-compounding stability data greater than 48 hours.

Schedule 2

1.12 Capsule and tablet form

Unless otherwise stated, where a Tender Item specifies either:

- (a) a capsule; or
- (b) a tablet,

form of the Chemical Entity, your brand of the relevant Chemical Entity for which you submit a bid may be in either tablet or capsule form, provided that:

- (c) your brand of the relevant Chemical Entity is the same strength as the Tender Item; and
- (d) where the Tender Item specifies both the tablet and capsule form of that Chemical Entity as separate line items, you must submit a bid for the same form and strength for each line item.

1.13 Pack size preference

Where a Tender Item is specified as being available for a Tender Bid for Sole Supply Status, it is the preference of PHARMAC that the pack size for such a Tender Item is a 30 or 90 day pack where the Tender Item is in a tablet or capsule form.

Notwithstanding the preference of PHARMAC for Tender Items to be in pack sizes as specified above, pack sizes may be specified in the comments column in the attached list or you may submit, and PHARMAC will consider and may accept, a Tender Bid for any pack size, including larger pack sizes, following its evaluation of Tender Bids under clause 5 of Schedule Three.

1.14 Pack size for use in DHB Hospitals

Where a Tender Item is specified as being available for a Tender Bid for Hospital Supply Status, it is the preference of DHB Hospitals that the pack size for such a Tender Item is:

- (a) 500 ml or less, where the Tender Item is in liquid form;
- (b) 200 tablets or capsules, where the Tender Item is in tablet or capsule form; and
- (c) 10 injections, where the Tender Item is in injection form.

Notwithstanding the preference of DHB Hospitals for Tender Items to be in pack sizes as specified in paragraphs (a) to (c) above, pack sizes may be specified in the comments column in the attached list or you may submit, and PHARMAC will consider and may accept, a Tender Bid for any pack size, including larger pack sizes, following its evaluation of Tender Bids under clause 5 of Schedule Three. For the avoidance of doubt, DHB Hospitals do not have a pack (or other equivalent grouping) size preference for Medical Devices and you may submit, and PHARMAC will consider and may accept, a Tender Bid for any pack size (or other equivalent grouping) following its evaluation of Tender Bids under clause 5 of Schedule Three.

1.15 Pack size for oral contraceptives

Where an oral contraceptive is included in Schedule Two and on the Electronic Portal, 21 and 28 calendar packs would be considered as different Tender Items (where applicable).

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Acetazolamide						
Tab 250 mg	678,254	\$115,507	\$0.1703	C H 1%		
Acitretin						
Cap 10 mg	485,329	\$144,468	\$0.2977	C H 1%	Special Authority restrictions may apply. There may be a preference for a blister pack.	
Cap 25 mg	110,925	\$76,464	\$0.6893	C H 1%	Special Authority restrictions may apply. There may be a preference for a blister pack.	
Ajmaline						
Inj 50 mg per 10 ml				H 1%		
Albendazole						
Tab	728	\$5,693	\$7.8200	C H 1%	Current restrictions may apply. Note units and unit subsidy corresponds to the currently listed tab 400 mg presentation. All strengths received as tender bids will be reviewed.	
Alfacalcidol						
Cap 0.25 mcg	212,304	\$55,878	\$0.2632	C H 1%		
Cap 1 mcg	59,469	\$52,321	\$0.8798	C H 1%		
Oral drops 2 mcg per ml	14,300	\$43,386	\$3.0340	C H 1%		
Alfentanil						
Inj 0.5 mg per ml, 2 ml ampoule				H 1%		
Allopurinol						
Tab 100 mg	24,913,555	\$226,215	\$0.0091	C H 1%	Preference for a scored tablet.	
Tab 300 mg	18,259,581	\$377,973	\$0.0207	C H 1%	Preference for a scored tablet.	
Alprostadil						
Inj 10 mcg				H 1%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.	
Inj 20 mcg				H 1%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.	
Ambrisentan (current access)						
Tab 10 mg	8,726	\$1,333,624	\$152.8333 #	C H 1%	A confidential rebate applies. Longer transition periods may apply to this product. Current restrictions may apply. PHARMAC would only award a tender for either current or widened access	
Tab 5 mg	2,064	\$315,448	\$152.8333 #	C H 1%	A confidential rebate applies. Longer transition periods may apply to this product. Current restrictions may apply. PHARMAC would only award a tender for either current or widened access	
Ambrisentan (widened access)						
Tab 10 mg				C H 1%	PHARMAC would only award a tender for either current or widened access	
Tab 5 mg				C H 1%	PHARMAC would only award a tender for either current or widened access	
Amikacin						
Inj 15 mg per ml				H 1%	Current restrictions may apply.	
Inj 5 mg per ml				H 1%	Current restrictions may apply.	
Amiloride						
Tab 5 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.	
Amiloride with Frusemide						
Tab 5 mg with frusemide 40 mg	131,641	\$40,573	\$0.3082	C H 1%		
Amiloride with Hydrochlorothiazide						
Tab 5 mg with hydrochlorothiazide 50 mg	780,263	\$78,026	\$0.1000	C H 1%		
Aminophylline						
Inj 25 mg per ml, 10 ml	1,522	\$37,858	\$24.8740	C H 1%		

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Amisulpride						
Oral liq	16,607	\$18,138	\$1.0922		C H 1%	Units and subsidy shown are for oral liq 100 mg per ml presentation.
Amitriptyline						
Tab 10 mg	21,203,948	\$415,597	\$0.0196		C H 1%	There may be a preference for a scored and/or dispersible tablet.
Tab 25 mg	7,692,530	\$116,926	\$0.0152		C H 1%	
Tab 50 mg	2,695,084	\$67,647	\$0.0251		C H 1%	
Amlodipine						
Tab 2.5 mg	9,723,478	\$167,244	\$0.0172		C H 1%	
Tab 5 mg	19,130,890	\$254,823	\$0.0133		C H 1%	
Tab 10 mg	10,008,765	\$176,154	\$0.0176		C H 1%	
Amorolfine						
Nail soln 5%	102,470	\$326,879	\$3.1900		C H 1%	
Amoxicillin						
Grans for oral liq 125 mg per 5 ml	10,735,059	\$128,821	\$0.0120		C H 1%	Preference may be given to products which include a measuring device.
Grans for oral liq 250 mg per 5 ml	52,496,249	\$687,701	\$0.0131		C H 1%	Preference may be given to products which include a measuring device.
Inj 250 mg	83	\$89	\$1.0670		C H 1%	
Inj 500 mg	1,039	\$1,289	\$1.2410		C H 1%	
Inj 1 g	6,575	\$11,368	\$1.7290		C H 1%	
Amoxicillin clavulanate						
Tab amoxicillin 500 mg with potassium clavulanate 125 mg	12,460,903	\$1,171,325	\$0.0940	@	C H 1%	
Grans for oral liq amoxicillin 125 mg with potassium clavulanate 31.25 mg per 5 ml	3,392,735	\$129,942	\$0.0383	@	C H 1%	PHARMAC reserves the right to award one or more strengths of amoxicillin with clavulanic acid oral liquids. Additional Stock Pharmaceutical. Preference for a 100 ml packsize.
Grans for oral liq amoxicillin 250 mg with potassium clavulanate 62.5 mg per 5 ml	9,783,600	\$215,239	\$0.0220	@	C H 1%	PHARMAC reserves the right to award one or more strengths of amoxicillin with clavulanic acid oral liquids. Additional Stock Pharmaceutical. Preference for a 100 ml packsize.
Amphotericin B						
Inj 50 mg (non-liposomal)					H 1%	Current restrictions may apply.
Liposomal inj 50 mg					H 1%	Current restrictions may apply.
Anastrozole						
Tab 1 mg	839,535	\$141,042	\$0.1680		C H 1%	
Atropine sulphate						
Eye drops 1%	117,225	\$135,668	\$1.1573		C H 1%	
Aztreonam						
Inj 1 g					H 1%	Current restrictions may apply.
Baclofen						
Inj 0.05 mg per ml, 1 ml			\$11.5500		C H 1%	
Bee venom allergy treatment						
Inj with diluent	280	\$85,400	\$305.0000		C H 1%	
Maintenance kit	7	\$1,995	\$285.0000		C H 1%	
Bendroflumethiazide [Bendrofluazide]						
Tab 2.5 mg	18,703,545	\$467,589	\$0.0250		C H 1%	
Tab 5 mg	2,699,541	\$110,249	\$0.0408		C H 1%	
Benzatropine Mesylate						
Inj 1 mg per ml, 2 ml	1,527	\$29,013	\$19.0000		C H 1%	

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name				Unit Subsidy	DV Limit	Comments
Line Item	Units	Cost				
Benzoyl peroxide						
Soln/Gel/Cream/Lotion 5%					C H 1%	Note this product may require Medsafe registration prior to an award. Not currently listed in Section B of the Pharmaceutical Schedule.
Benzylpenicillin Sodium [Penicillin G]						
Inj 3 g					C H 1%	Not currently listed on the Pharmaceutical Schedule.
<u>Inj 600 mg</u>	7,001	\$7,246	\$1.0350		C H 1%	
Betahistine dihydrochloride						
<u>Tab 16 mg</u>	3,403,959	\$117,096	\$0.0344		C H 1%	
Betamethasone						
Inj 4 mg per ml, 1 ml					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Tab 500 mcg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Betamethasone Dipropionate						
Crm 0.05% (pack size 30 g or less)					H 1%	
Crm 0.05% (pack size greater than 30 g)	381,445	\$75,271	\$0.1973		C H 1%	
Crm 0.05% in propylene glycol base	195,990	\$28,287	\$0.1443		C H 1%	
Oint 0.05% (pack size 30 g or less)					H 1%	
Oint 0.05% (pack size greater than 30 g)	336,510	\$66,404	\$0.1973		C H 1%	
Oint 0.05% in propylene glycol base	42,450	\$6,127	\$0.1443		C H 1%	
Betamethasone Sodium Phosphate with Betamethasone Acetate						
Inj 3.9 mg with betamethasone acetate 3 mg per ml, 1ml	1,477	\$5,672	\$3.8400		C H 1%	
Betaxolol hydrochloride						
Eye drops 0.25%	17,555	\$41,430	\$2.3600		C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".
Eye drops 0.5%	8,060	\$12,090	\$1.5000		C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".
Bicalutamide						
<u>Tab 50 mg</u>	591,119	\$80,221	\$0.1357		C H 1%	
Bismuth trioxide						
Tab	59,243	\$17,192	\$0.2902		C H 1%	Units and subsidy shown based on tab 120 mg presentation. All strengths reviewed as tender bids will be reviewed.
Bisoprolol Fumarate						
<u>Tab 2.5 mg</u>	7,473,391	\$293,106	\$0.0392		C H 1%	There may be a preference for a scored tablet.
<u>Tab 5 mg</u>	4,279,912	\$244,897	\$0.0572		C H 1%	
<u>Tab 10 mg</u>	1,546,159	\$161,481	\$0.1044		C H 1%	
Brimonidine Tartrate with Timolol Maleate						
Eye drops 0.2% with timolol maleate 0.5%	233,335	\$863,340	\$3.7000		C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy expressed as "per ml".
Budesonide						
Nebuliser soln 250 mcg per ml, 2 ml ampoule					H 1%	
<u>Metered aqueous nasal spray, 50 mcg per dose</u>	3,301,800	\$42,758	\$0.0130		C H 1%	
<u>Metered aqueous nasal spray, 100 mcg per dose</u>	16,540,400	\$237,355	\$0.0144		C H 1%	
<u>sole supply</u>						

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Budesonide						
Nebuliser soln, 500 mcg per ml, 2 ml					H 1%	
Budesonide (current access)						
Cap 3 mg modified release	348,983	\$645,619	\$1.8500		C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Budesonide (widened access)						
Cap 3 mg modified release					C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Bupivacaine hydrochloride						
Inj 2.5 mg per ml, 20 ml ampoule					H 1%	
Inj 5 mg per ml, 20 ml ampoule					H 1%	
Inj 1.25 mg per ml, 100 ml bag					H 1%	
Inj 1.25 mg per ml, 200 ml bag					H 1%	
Inj 1.25 mg per ml, 500ml bag					H 1%	
<u>Inj 2.5 mg per ml, 100 ml bag</u>					H 1%	
Inj 2.5 mg per ml, 200 ml bag					H 1%	
<u>Inj 5 mg per ml, 4 ml</u>					H 1%	
Inj 0.25%, 20 ml sterile pack					H 1%	
Inj 0.5%, 10 ml sterile pack					H 1%	
Inj 0.5%, 20 ml sterile pack					H 1%	
Bupropion hydrochloride						
<u>Tab modified-release 150 mg</u>	2,336,836	\$856,847	\$0.3667		C H 1%	
Buserelin Acetate						
Inj 1 mg per ml, 5.5 ml					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Calamine						
Lotn, BP	3,551,427	\$22,978	\$0.0065		C H 1%	Preference for a 200 ml pack or less. Note this product requires Medsafe registration prior to an award.
Calcium carbonate						
<u>Tab</u>	7,640,999	\$229,841	\$0.0301		C H 1%	Preference for tab 1.25 g - 1.5 g.
Calcium folinate						
Tab 15 mg	15,497	\$161,572	\$10.4260		PCT C H 1%	
Calcium Gluconate						
Gel 2.5%					H 1%	Preference for a pack size of 40 g - 100 g
Inj 10%, 10 ml	769	\$2,461	\$3.2000		C H 1%	
Capsaicin (current access)						
Crn 0.025%	1,610,100	\$364,366	\$0.2263 #		C H 1%	Current restrictions may apply. Please note the widening of access refers to the crn 0.075% presentation only.
Crn 0.075%	349,020	\$96,951	\$0.2778		C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Capsaicin (widened access)						
Crn 0.025%	1,610,100	\$364,366	\$0.2263 #		C H 1%	Current restrictions may apply. Please note the widening of access refers to the crn 0.075% presentation only. This tender item is listed under widened access for the purpose of aggregate bidding in the e-portal.
Crn 0.075%					C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Captopril						
Oral liq 5 mg per ml	158,365	\$158,348	\$0.9999		C H 1%	Current restrictions may apply.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments	
Carbimazole							
Tab 5 mg	4,385,351	\$473,618	\$0.1080		C H 1%		
Carboprost							
Inj 250 mcg per ml, 1ml					H 1%		
Carmellose sodium							
Paste	26,008	\$7,907	\$0.3040 *		C H 1%	Preference for product containing gelatin and pectin. Units subsidy and cost shown is weighted.	
Powder	1,288	\$390	\$0.3029		C H 1%	Preference for product containing gelatin and pectin.	
Eye drops 0.5%					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.	
Eye drops 1%					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.	
Carvedilol							
Tab 12.5 mg	2,309,449	\$88,521	\$0.0383		C H 1%		
Tab 25 mg	2,747,468	\$135,093	\$0.0492		C H 1%		
Tab 6.25 mg	2,422,107	\$90,417	\$0.0373		C H 1%		
Cefazolin sodium							
Inj 2 g					C H 1%	Not currently listed on the Pharmaceutical Schedule.	
Inj 500 mg	130	\$88	\$0.6780		C H 1%		
Inj 1 g	25,938	\$17,067	\$0.6580		C H 1%		
Cefotaxime							
Inj 500 mg					H 1%		
Inj 1 g					H 1%		
Cefoxitin Sodium							
Inj 1 g					H 1%		
Ceftazidime							
Inj 1 g					H 1%	Current restrictions may apply.	
Cefuroxime sodium							
Inj 750 mg					H 1%		
Inj 1.5 g					H 1%		
Chloramphenicol							
Inj 1 g					H 1%	Current restrictions may apply.	
Chlorhexidine gluconate							
Crn 1% obstetric					H 1%	Preference for a small tube for single use, under 100 g. Note that this product requires Medsafe registration prior to an award.	
Lotn 1% obstetric					H 1%	Note that this product requires Medsafe registration prior to an award.	
Soln 4%	2,363,497	\$18,813	\$0.0080		C 1%	500mL pump preferred. Note that this product requires Medsafe registration prior to an award.	
Chloroquine phosphate							
Tab 250 mg					H 1%	Current restrictions may apply.	
Chlorpheniramine Maleate							
Inj 10 mg per ml					H 1%		
Oral liq 2 mg per 5 ml	2,776,924	\$44,764	\$0.0161		C H 1%		
Choline salicylate							
Oral gel	93,345	\$12,819	\$0.1373		C H 1%		
Cidofovir							
Inj 75 mg per ml, 5 ml					H 1%	Current restrictions may apply.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV	Limit	Comments
Cimetidine						
Tab 200 mg				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Tab 400 mg				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Ciprofloxacin						
Ear drops 0.3%				C H	1%	Not currently listed in the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction
<u>Tab 250 mg</u>	184,729	\$9,567	\$0.0518	C H	1%	There may be a preference for a scored, dispersible tablet.
<u>Tab 500 mg</u>	1,050,803	\$74,681	\$0.0711	C H	1%	There may be a preference for a scored, dispersible tablet.
<u>Tab 750 mg</u>	24,782	\$2,788	\$0.1125	C H	1%	There may be a preference for a scored, dispersible tablet.
Citric acid with magnesium oxide and sodium picosulfate						
Powder for oral soln 12 g with magnesium oxide 3.5 g and sodium picosulfate 10 mg per sachet				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Clarithromycin						
Inj 500 mg				H	1%	Current restrictions may apply.
<u>Tab 250 mg</u>	152,329	\$43,306	\$0.2843	C H	1%	Current restrictions may apply.
<u>Tab 500 mg</u>	128,574	\$95,512	\$0.7429	C H	1%	Current restrictions may apply.
Clobazam						
Liq				C H	1%	Not currently listed in the Pharmaceutical Schedule.
Clobetasone butyrate						
Crn 0.05% (pack size 30 g or less)	414,780	\$74,382	\$0.1793	C H	1%	
Clonidine						
<u>TDDS 2.5 mg, 100 mcg per day</u>	54,159	\$100,194	\$1.8500	C H	1%	
<u>TDDS 5 mg, 200 mcg per day</u>	22,617	\$56,769	\$2.5100	C H	1%	
<u>TDDS 7.5 mg, 300 mcg per day</u>	15,313	\$47,241	\$3.0850	C H	1%	
Clotrimazole						
<u>Crn 1%</u>	3,529,820	\$123,544	\$0.0350	C H	1%	
Soln 1%	13,300	\$2,899	\$0.2180	C H	1%	
Codeine phosphate						
Tab 15 mg	10,588,029	\$608,812	\$0.0575	C H	1%	
Tab 30 mg	25,187,423	\$1,712,745	\$0.0680	C H	1%	
Tab 60 mg	1,641,362	\$221,584	\$0.1350	C H	1%	
Colecalciferol						
Cap/Tab 1.25 mg	2,797,539	\$582,811	\$0.2083	C H	1%	
Colistin Sulphomethate						
Inj 150 mg	6,193	\$402,545	\$65.0000	C H	1%	Current restrictions may apply.
Condoms						
Female, non-latex				C		Not currently listed in Section B of the Pharmaceutical Schedule.
Male 55 mm - 58 mm, non-latex				C		Not currently listed in Section B of the Pharmaceutical Schedule. Special Authority restrictions may apply.
Cyclopentolate hydrochloride						
Eye drops 1%	81,315	\$47,488	\$0.5840	C H	1%	
Cycloserine						
Cap 250 mg	5,073	\$65,670	\$12.9450	C H	1%	Current restrictions may apply. Unit subsidy and cost shown is weighted.
Cyproterone acetate with ethinyloestradiol						
<u>Tab 2 mg with ethinyloestradiol 35 mcg and 7 inert tablets</u>	10,724,252	\$298,134	\$0.0278	C H	1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Danazol						
Cap 100 mg	17,891	\$12,225	\$0.6833		C H 1%	
Cap 200 mg	10,066	\$9,848	\$0.9783		C H 1%	
Darunavir						
<u>Tab 400 mg</u>	93,617	\$522,695	\$5.5833		C H 1%	There may be a preference for a dispersible tablet. Current restrictions may apply.
<u>Tab 600 mg</u>	34,087	\$270,423	\$7.9333		C H 1%	There may be a preference for a dispersible tablet. Current restrictions may apply.
Desmopressin						
Inj 15 mcg per ml, 1 ml					H 1%	
Inj 4 mcg per ml, 1 ml	4,984	\$33,483	\$6.7180		C H 1%	Current restrictions may apply.
Nasal drops 100 mcg per ml	6,095	\$95,155	\$15.6120		C H 1%	
<u>Nasal spray 10 mcg per dose</u>	88,074	\$351,562	\$3.9917		C H 1%	
Tab 100 mcg	93,303	\$77,752	\$0.8333		C H 1%	Current restrictions may apply.
Tab 200 mcg	38,989	\$70,765	\$1.8150		C H 1%	Current restrictions may apply.
Dexmedetomidine hydrochloride						
<u>Inj 100 mcg per ml, 2 ml vial</u>				+	H 1%	Patent may exist for this product.
Dextrochlorpheniramine Maleate						
Oral liq 2 mg per 5 ml	8,680	\$154	\$0.0177		C H 1%	Restrictions may apply. Not currently listed in Section H of the Pharmaceutical Schedule.
Tab 2 mg	144,878	\$7,316	\$0.0505	*	C H 1%	Restrictions may apply. Not currently listed in Section H of the Pharmaceutical Schedule.
Diazepam						
<u>Tab 2 mg</u>	2,977,194	\$89,614	\$0.0301		C H 1%	There may be a preference for a scored tablet.
<u>Tab 5 mg</u>	4,372,379	\$141,490	\$0.0324		C H 1%	
Diazoxide						
Cap 100 mg	5,680	\$15,904	\$2.8000		C H 1%	Current restrictions may apply.
Cap 25 mg	12,623	\$13,885	\$1.1000		C H 1%	Current restrictions may apply.
Inj 15 mg per ml, 20 ml					H 1%	
Oral liq 50 mg per ml	1,020	\$21,080	\$20.6667		C H 1%	Current restrictions may apply.
Diclofenac sodium						
Inj 25 mg per ml, 3 ml	26,508	\$69,981	\$2.6400		C H 1%	
Suppos 12.5 mg	6,207	\$1,266	\$0.2040		C H 1%	
Suppos 25 mg	5,141	\$1,254	\$0.2440		C H 1%	
Suppos 50 mg	76,076	\$32,104	\$0.4220		C H 1%	
Suppos 100 mg	108,712	\$76,098	\$0.7000		C H 1%	
Diflucortolone Valerate						
Crm 0.1%	83,150	\$14,917	\$0.1794		C H 1%	
Fatty oint 0.1%	102,050	\$18,308	\$0.1794		C H 1%	
Diltiazem hydrochloride						
Tab 30 mg	573,933	\$26,401	\$0.0460		C H 1%	
Tab 60 mg	250,677	\$21,308	\$0.0850		C H 1%	
Dinoprostone						
Gel 1 mg					H 1%	
Gel 2 mg					H 1%	
Disulfiram						
Tab 200 mg	410,596	\$310,287	\$0.7557		C H 1%	
Docetaxel						
<u>Inj 20 mg</u>				PCT	H 1%	Preference for products where stability data >48 hours post-compounding.

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Docetaxel					
<u>Inj 80 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding.
Docosate Sodium					
<u>Tab 50 mg</u>	631,635	\$14,591	\$0.0231	C H 1%	
<u>Tab 120 mg</u>	1,468,970	\$45,979	\$0.0313	C H 1%	
Donepezil hydrochloride					
<u>Tab 5 mg</u>	1,252,728	\$60,407	\$0.0482	C H 1%	
<u>Tab 10 mg</u>	1,143,682	\$84,381	\$0.0738	C H 1%	
Dorzolamide hydrochloride					
Eye drops 2%	10,360	\$20,243	\$1.9540	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml
Dosulepin [Dothiepin] Hydrochloride					
Cap 25 mg	2,486,655	\$160,389	\$0.0645	C H 1%	
Tab 75 mg	897,357	\$100,414	\$0.1119	C H 1%	
Doxazosin mesylate					
<u>Tab 2 mg</u>	16,549,583	\$223,419	\$0.0135	C H 1%	
<u>Tab 4 mg</u>	12,277,102	\$223,198	\$0.0182	C H 1%	
Doxepin hydrochloride					
Cap 10 mg	1,140,913	\$71,878	\$0.0630	C H 1%	
Cap 25 mg	1,316,629	\$90,321	\$0.0686	C H 1%	
Cap 50 mg	666,208	\$56,961	\$0.0855	C H 1%	
Doxycycline					
Inj 100 mg per 20 ml				H 1%	
Tab 20 mg - 50 mg	337,765	\$32,652	\$0.0967	C H 1%	There may be a preference for a scored, dispersible tablet. Note units and unit price expressed is for the 50 mg presentation.
Econazole Nitrate					
Crn 1%	26,940	\$1,347	\$0.0500	C H 1%	
Foaming soln 1%, 10 ml sachets	59,642	\$196,620	\$3.2967	C H 1%	
Emulsifying ointment					
Oint BP (pack size of 200 g or less)				H 1%	
<u>Oint BP (pack size greater than 200 g)</u>	39,032,964	\$280,257	\$0.0072	C H 1%	
Ephedrine					
Inj 3 mg per ml, 10 ml prefilled syringe				H 1%	
<u>Inj 30 mg per ml, 1ml</u>				H 1%	
Epoprostenol (current access)					
Inj 1.5 mg vial	330	\$24,159	\$73.2100	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Inj 500 mcg vial	30	\$1,098	\$36.6100	C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access.
Epoprostenol (widened access)					
Inj 1.5 mg vial				C H 1%	PHARMAC would only award a tender for either current or widened access.
Inj 500 mcg vial				C H 1%	PHARMAC would only award a tender for either current or widened access.
Ergometrine maleate					
Inj 250 mcg per ml, 1 ml ampoule	200			C H 1%	
<u>Inj 500 mcg per ml, 1 ml</u>	1,140	\$23,940	\$21.0000	C H 1%	
Erlotinib hydrochloride					
Tab 100 mg	15,290	\$389,392	\$25.4667	+ C H 1%	Current restrictions may apply.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Erlotinib hydrochloride						
Tab 150 mg	22,388	\$855,222	\$38.2000	+	C H 1%	Current restrictions may apply.
Erythromycin Ethyl Succinate						
Grans for oral liq 200 mg per 5 ml	2,919,752	\$145,988	\$0.0500		C H 1%	Preference may be given to products which include a measuring device.
Grans for oral liq 400 mg per 5 ml	3,573,851	\$241,950	\$0.0677		C H 1%	Preference may be given to products which include a measuring device.
Tab 400 mg	3,226,556	\$546,901	\$0.1695		C H 1%	
Escitalopram						
Tab 10 mg	10,461,567	\$414,697	\$0.0396		C H 1%	There may be a preference for a scored tablet.
Tab 20 mg	3,898,476	\$264,551	\$0.0679		C H 1%	
Ethambutol hydrochloride						
Tab 100 mg	33,493	\$28,714	\$0.8573		C H 1%	Current restrictions may apply.
Tab 400 mg	124,591	\$109,773	\$0.8811		C H 1%	Current restrictions may apply.
Ethinylestradiol with Desogestrel						
Tab 20 mcg with desogestrel 150 mcg	285,320	\$22,486	\$0.0788		C H 1%	
Tab 30 mcg with desogestrel 150 mcg	276,052	\$21,756	\$0.0788		C H 1%	
Ethinylestradiol with levonorgestrel						
Tab 20 mcg with levonorgestrel 100 mcg	6,976,816	\$180,989	\$0.0259		C H 1%	Note units and unit subsidy expressed are based on a product inclusive of 7 inert tablets (per month).
Tab 30 mcg with levonorgestrel 150 mcg	27,156,080	\$572,292	\$0.0211		C H 1%	Note units and unit subsidy expressed are based on a product inclusive of 7 inert tablets (per month).
Tab 50 mcg with levonorgestrel 125 mcg	401,604	\$45,180	\$0.1125		C H 1%	Note units and unit subsidy expressed are based on a product inclusive of 7 inert tablets (per month).
Etoposide						
Inj 20 mg per ml, 5 ml					PCT H 20%	PHARMAC will award sole supply for the whole etoposide market to either etoposide or etoposide phosphate. Sole supply would be across both markets. The alternative product would be delisted.
Etoposide phosphate						
Inj 100 mg (of etoposide base)					PCT H 1%	Preference for products where stability >48 hours post-compounding. PHARMAC will award solesupply for the whole etoposide market to either etoposide or etoposide phosphate. Sole supply would be across both markets. The alternative product would be delisted
Etravirine						
Tab 200 mg	38,896	\$499,165	\$12.8333 #		C H 1%	Special Authority restrictions may apply.
Exemestane						
Tab 25 mg	364,480	\$176,164	\$0.4833		C H 1%	
Ezetimibe (current access)						
Tab 10 mg	7,177,230	\$478,506	\$0.0667		C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Ezetimibe (widened access)						
Tab 10 mg					C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of Special Authority criteria.
Ezetimibe with simvastatin (current access)						
Tab 10 mg with simvastatin 10 mg	59,065	\$10,140	\$0.1717		C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Ezetimibe with simvastatin (current access)						
Tab 10 mg with simvastatin 20 mg	93,388	\$19,145	\$0.2050		C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Tab 10 mg with simvastatin 40 mg	201,285	\$47,972	\$0.2383		C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Tab 10 mg with simvastatin 80 mg	167,862	\$45,603	\$0.2717		C H 1%	Current restrictions may apply. PHARMAC would only award a tender for either current or widened access
Ezetimibe with simvastatin (widened access)						
Tab 10 mg with simvastatin 10 mg					C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Tab 10 mg with simvastatin 20 mg					C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Tab 10 mg with simvastatin 40 mg					C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Tab 10 mg with simvastatin 80 mg					C H 1%	PHARMAC would only award a tender for either current or widened access. Widened access would result in the removal of all restrictions.
Famotidine						
Inj					C H 1%	Not currently listed on the Pharmaceutical Schedule.
Tab 20 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule.
Tab 40 mg					C H 1%	Not currently listed on the Pharmaceutical Schedule.
Febuxostat						
Tab 120 mg	102,192	\$144,162	\$1.4107		C H 1%	Current restrictions may apply.
Tab 80 mg	527,245	\$743,785	\$1.4107		C H 1%	Current restrictions may apply.
Fentanyl						
<u>Patches 100 mcg per hour</u>	31,292	\$71,346	\$2.2800		C H 1%	
<u>Patches 12.5 mcg per hour</u>	195,321	\$115,239	\$0.5900		C H 1%	
<u>Patches 25 mcg per hour</u>	151,954	\$111,230	\$0.7320		C H 1%	
<u>Patches 50 mcg per hour</u>	62,427	\$83,028	\$1.3300		C H 1%	
Patches 6.25 mcg per hour					C H 1%	Not currently listed on the Pharmaceutical Schedule.
<u>Patches 75 mcg per hour</u>	17,672	\$32,693	\$1.8500		C H 1%	
Fexofenadine						
Tab 120 mg	146,339	\$69,359	\$0.4740	*	C H 1%	
Tab 60 mg	68,566	\$14,879	\$0.2170	*	C H 1%	
Finasteride						
<u>Tab 5 mg</u>	4,457,716	\$214,416	\$0.0481		C H 1%	Preference for a blister pack. May be subject to Special Authority restrictions.
Flucloxacillin Sodium						
Inj 2 g					C H 1%	Not currently listed on the Pharmaceutical Schedule.
<u>Inj 250 mg</u>	140	\$126	\$0.9000		C H 1%	
<u>Inj 500 mg</u>	1,474	\$1,386	\$0.9400		C H 1%	
<u>Inj 1 g</u>	4,698	\$4,905	\$1.0440		C H 1%	
Fluconazole						
Powder for oral suspension 10 mg per ml	22,615	\$63,645	\$2.8143		C H 1%	
<u>Cap 50 mg</u>	102,255	\$7,632	\$0.0746		C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Fluconazole					
Cap 150 mg	69,303	\$22,870	\$0.3300	C H 1%	
Cap 200 mg	62,367	\$11,315	\$0.1814	C H 1%	
Flucytosine					
Cap 500 mg				H 1%	Current restrictions may apply.
Fludrocortisone Acetate					
Tab 100 mcg	1,357,292	\$194,364	\$0.1432	C H 1%	
Flumetasone pivalate with clioquinol					
Ear drops 0.02% with clioquinol 1%	40,403	\$24,026	\$0.5947	C H 1%	
Fluorometholone					
Eye drops 0.1%	156,125	\$94,476	\$0.6051	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Unit subsidy shown is weighted and expressed as "per ml"
Flupenthixol Decanoate					
Inj 100 mg per ml, 1 ml	8,081	\$66,054	\$8.1740	C H 1%	
Inj 20 mg per ml, 1 ml	3,841	\$10,094	\$2.6280	C H 1%	
Inj 20 mg per ml, 2 ml	4,457	\$18,630	\$4.1800	C H 1%	
Foscarnet sodium					
Inj 24 mg per ml				H 1%	Current restrictions may apply.
Fosfomycin					
Powder for oral solution, 3 g sachet				H 1%	Current restrictions may apply.
Framycetin sulphate					
Ear/Eye drops 0.5%	22,184	\$11,452	\$0.5163	C H 1%	
Gemcitabine hydrochloride					
Inj 1 g				PCT H 1%	
Gemfibrozil					
Tab 600 mg	388,213	\$126,557	\$0.3260	C H 1%	
Gentamicin Sulphate					
Inj 10 mg per ml	1,802	\$9,010	\$5.0000	C H 1%	
Inj 40 mg per ml, 2 ml	13,625	\$8,175	\$0.6000	C H 1%	
Gliclazide					
Tab 80 mg	27,123,429	\$558,200	\$0.0206	C H 1%	
Glucagon Hydrochloride					
Inj 1 mg syringe kit	20,712	\$662,784	\$32.0000	C H 1%	There may be a preference for a graduated and/or prefilled syringe.
Glucose [Dextrose]					
Gel 40%				H 1%	
Inj 50%, 10 ml - 20 ml	11,152	\$65,797	\$5.9000	C H 1%	Inj 50%, 10 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 10 ml ampoule.
Inj 50%, 90 ml - 100 ml	377	\$5,467	\$14.5000	C H 1%	Inj 50%, 90 ml is currently listed on the Pharmaceutical Schedule. Units and subsidy are shown per 90 ml ampoule.
Solution 15 g				H 1%	Not currently listed in the Pharmaceutical Schedule.
Tab 1.5 g				H 1%	
Tab 3.1 g				H 1%	
Tab 4 g				H 1%	
Glucose with sucrose and fructose					
Gel 19.7% with sucrose 35% and fructose 19.7%, 18 g sachet				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Glycerol					
Liq BP	1,466,006	\$9,617	\$0.0066	C H 1%	There may be a preference for a pack size of 500 mL or less.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Glyceryl trinitrate						
Spray 400 mcg per dose	1,519,050	\$33,799	\$0.0223		C H 5%	
Inj 1 mg per ml, 5 ml - 10 ml					H 1%	
Inj 5 mg per ml, 10 ml					H 1%	
Goserelin						
Implant 10.8 mg, syringe	22,291	\$3,956,653	\$177.5000		C H 1%	
Implant 3.6 mg, syringe	7,914	\$526,123	\$66.4800		C H 1%	
Granisetron						
<u>Inj 1 mg per ml</u>					H 1%	
Hydrocortisone						
<u>Powder</u>	51,681	\$103,259	\$1.9980		C H 1%	Current restrictions may apply. Note this product requires Medsafe registration prior to an award.
Hydrocortisone Acetate						
Rectal foam 10%, CFC-free	196,082	\$246,728	\$1.2583		C H 1%	
Hydrocortisone butyrate						
Cream/lipocream 0.1% (pack size 30 g or less)	1,782,150	\$122,077	\$0.0685		C H 1%	
Hydrocortisone with wool fat and mineral oil						
<u>Lotn 1% with wool fat hydrous 3% and mineral oil</u>	10,735,808	\$453,910	\$0.0423		C H 1%	Preference for a pack size of 300 g or less.
Hydrogen Peroxide						
Crm 1%	2,421,080	\$1,709,844	\$0.7062 #		C H 1%	Preference for a pack size of 50 g or more. Preference for tube packaging. Unit subsidy shown is weighted. This product requires Medsafe registration prior to an award.
Soln 3% (10 vol)	20,902	\$293	\$0.0140		C H 1%	Preference for pack size less than 200 ml. This product requires Medsafe registration prior to an award.
Hydroxyurea						
Cap 500 mg	1,183,849	\$375,990	\$0.3176	PCT	C H 1%	
Hyoscine N-butylbromide						
Inj 20 mg, 1 ml	165,260	\$316,308	\$1.9140		C H 1%	
<u>Tab 10 mg</u>	5,837,717	\$510,800	\$0.0875		C H 1%	
Hypromellose						
Eye drops 0.3%	3,221,700	\$493,983	\$0.1533		C H 1%	Will consider bids for products with or without dextran. Note units and unit subsidy are expressed for a product with dextran 0.1%.
Eye drops 0.5%	49,995	\$6,666	\$0.1333		C H 1%	
Ibuprofen						
<u>Tab 200 mg</u>	55,473,390	\$649,593	\$0.0117		C H 1%	
Imatinib mesilate						
<u>Cap 400 mg</u>	69,190	\$455,501	\$6.5833		C H 1%	For non-GIST indications only.
<u>Cap 100 mg</u>	194,485	\$317,658	\$1.6333		C H 1%	For non-GIST indications only.
Imipramine Hydrochloride						
Tab 10 mg	802,853	\$87,993	\$0.1096		C H 1%	
Tab 25 mg	434,940	\$76,549	\$0.1760		C H 1%	
Imiquimod						
<u>Crm 5%</u>	468,198	\$423,719	\$0.9050		C H 1%	Units are per sachet
Indapamide						
Tab 2.5 mg	1,495,414	\$43,202	\$0.0289		C H 1%	
Insulin pen needles						
29 g x 12.7 mm	288,041	\$30,244	\$0.1050		C	
31 g x 5 mm	4,226,036	\$496,559	\$0.1175		C	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Insulin pen needles						
31 g x 6 mm	285,191	\$27,093	\$0.0950	C		
31 g x 8 mm	4,325,208	\$454,147	\$0.1050	C		
32 g x 4 mm	4,423,898	\$464,509	\$0.1050	C		
Insulin syringes, disposable with attached needle						
Syringe 0.3 ml with 29 g x 4 mm needle				C	Not currently listed in the Pharmaceutical Schedule.	
Syringe 0.3 ml with 29 g x 6 mm needle				C	Not currently listed in the Pharmaceutical Schedule.	
Syringe 0.5 ml with 29 g x 4 mm needle				C	Not currently listed in the Pharmaceutical Schedule.	
Syringe 0.5 ml with 29 g x 6 mm needle				C	Not currently listed in the Pharmaceutical Schedule.	
Syringe 1 ml with 29 g x 4 mm needle				C	Not currently listed in the Pharmaceutical Schedule.	
Syringe 1 ml with 29 g x 6 mm needle				C	Not currently listed in the Pharmaceutical Schedule.	
Syringe 0.3 ml with 29 g x 12.7 mm needle	13,079	\$1,700	\$0.1300	*	C	
Syringe 0.3 ml with 31 g x 8 mm needle	122,956	\$15,986	\$0.1300	*	C	
Syringe 0.5 ml with 29 g x 12.7 mm needle	40,309	\$5,241	\$0.1300	*	C	
Syringe 0.5 ml with 31 g x 8 mm needle	132,247	\$17,194	\$0.1300		C	
Syringe 1 ml with 29 g x 12.7 mm needle	25,269	\$3,286	\$0.1300		C	
Syringe 1 ml with 31 g x 8 mm needle	47,037	\$6,115	\$0.1300		C	
Iodine supplement						
Tab 150 mcg elemental	10,398,089	\$541,844	\$0.0521	C H	1%	
Ipratropium Bromide						
<u>Aqueous nasal spray, 0.03%</u>	820,620	\$252,201	\$0.3073	C H	1%	
Irbesartan						
Tab/Cap 150 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule.
Tab/Cap 300 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule.
Tab/Cap 75 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule.
Irbesartan with hydrochlorothiazide						
Tab/Cap 150 mg with hydrochlorothiazide 12.5 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule.
Tab/Cap 300 mg with hydrochlorothiazide 12.5 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule.
Tab/Cap 300 mg with hydrochlorothiazide 25 mg				C H	1%	Not currently listed in the Pharmaceutical Schedule.
Iron sucrose						
Inj 20 mg per ml, 5 ml ampoule				H	1%	
Isosorbide mononitrate						
<u>Tab 20 mg</u>	522,644	\$98,257	\$0.1880	C H	1%	
Tab long-acting 40 mg	616,548	\$154,137	\$0.2500	C H	1%	
<u>Tab long-acting 60 mg</u>	7,063,699	\$650,637	\$0.0921	C H	1%	
Ispaghula (psyllium) husk						
<u>Powder/granules</u>	84,910,500	\$1,027,417	\$0.0121	C H	1%	Units and unit subsidy shown are as per the 500 g presentation currently listed and expressed as 'per g'.
Ivabradine (current access)						
Tab 5 mg				C H	1%	Not currently listed in Section B of the Pharmaceutical Schedule. Restrictions would be the same as the current Section H restrictions. PHARMAC would only award a tender for either current or widened access.

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name									
Line Item	Units	Cost	Unit Subsidy			DV Limit	Comments		
Ivabradine (current access)									
Tab 7.5 mg						C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions would be the same as the current Section H restrictions for the tab 5 mg presentation. PHARMAC would only award a tender for either current or widened access.		
Ivabradine (widened access)									
Tab 5 mg						C H 1%	Widened access would extend to patients with inappropriate sinus tachycardia. PHARMAC would only award a tender for either current or widened access.		
Tab 7.5 mg						C H 1%	Not currently listed on the Pharmaceutical Schedule. Widened access would extend to patients with inappropriate sinus tachycardia. PHARMAC would only award a tender for either current or widened access.		
Ivermectin									
Tab 3 mg	13,317	\$57,263	\$4.3000			C H 1%	Current restrictions may apply.		
Ketoconazole									
<u>Shampoo 2%</u>	6,192,800	\$185,165	\$0.0299			C H 1%	Current restrictions may apply.		
Tab 200 mg	1,650					PCT C H 1%	Current restrictions may apply.		
Lacosamide (current access)									
Inj 10 mg per ml, 20 ml						H 1%			
Tab 50 mg	203,368	\$363,738	\$1.7886 #	+		C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access. Refer to Schedule 7 for additional special terms.		
Tab 100 mg	130,755	\$467,540	\$3.5757 #	+		C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access. Refer to Schedule 7 for additional special terms.		
Tab 150 mg	35,658	\$191,280	\$5.3643 #	+		C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access. Refer to Schedule 7 for additional special terms.		
Tab 200 mg	90,607	\$648,083	\$7.1527 #	+		C H 1%	Special Authority restrictions may apply. PHARMAC would only award a tender for either current or widened access. Refer to Schedule 7 for additional special terms.		
Lacosamide (widened access)									
Tab 50 mg						+ C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access. PHARMAC reserves the right to engage in further consultation prior to a decision. Refer to Schedule 7 for additional special terms.		
Tab 100 mg						+ C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access. PHARMAC reserves the right to engage in further consultation prior to a decision. Refer to Schedule 7 for additional special terms.		
Tab 150 mg						+ C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access. PHARMAC reserves the right to engage in further consultation prior to a decision. Refer to Schedule 7 for additional special terms.		
Tab 200 mg						+ C H 1%	Restrictions may apply. PHARMAC would only award a tender for either current or widened access. PHARMAC reserves the right to engage in further consultation prior to a decision. Refer to Schedule 7 for additional special terms.		

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Lamivudine						
Tab 300 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.	
Tab 100 mg	167,660	\$25,149	\$0.1500	C H 1%	Special Authority restrictions may apply.	
Tab 150 mg	25,095	\$21,958	\$0.8750	C H 1%	Special Authority restrictions may apply. Not currently listed in Section H of the Pharmaceutical Schedule.	
Latanoprost with timolol						
Eye drops 0.005% with timolol 0.5%				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Leflunomide						
Tab 10 mg	545,215	\$52,706	\$0.0967	C H 1%	There may be a preference for a scored tablet.	
Tab 20 mg	727,181	\$70,297	\$0.0967	C H 1%		
Levocabastine						
Eye drops 0.5 mg per ml	94,332	\$205,408	\$2.1775	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml	
Levodopa with Carbidopa						
Tab 100 mg with carbidopa 25 mg	8,846,843	\$1,589,778	\$0.1797	C H 1%	Longer transition periods may apply to this product.	
Tab 250 mg with carbidopa 25 mg	383,897	\$125,419	\$0.3267	C H 1%	Longer transition periods may apply to this product.	
Tab long-acting 200 mg with carbidopa 50 mg	1,724,476	\$640,643	\$0.3715	C H 1%	Longer transition periods may apply to this product. Pharmacokinetic data required.	
Levofloxacin						
Tab 500 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction	
Levonorgestrel						
Subdermal implant	14,547	\$1,555,365	\$106.9200	C H 1%	Longer transition periods may apply to this product. Training should be provided to clinicians if awarded.	
Levosimendan						
Inj 2.5 mg per ml, 5 ml				H 1%		
Lidocaine [Lignocaine]						
Crm 4%	420	\$425	\$1.0125	C H 1%	Current restrictions may apply. Unit subsidy and cost shown is weighted.	
Lidocaine [lignocaine] hydrochloride with adrenaline and tetracaine hydrochloride						
Soln 4% with adrenaline 0.1 % and tetracaine hydrochloride 0.5%, 5 ml syringe				H 1%		
Lidocaine [lignocaine] hydrochloride with phenylephrine hydrochloride						
Nasal spray 5% with phenylephrine hydrochloride 0.5%				H 1%		
Lithium carbonate						
Cap (immediate-release) 250 mg	1,883,509	\$177,427	\$0.0942	C H 1%		
Tab (immediate-release) 250 mg	1,631,731	\$111,937	\$0.0686	C H 1%		
Tab long-acting 400 mg	1,874,775	\$359,957	\$0.1920	C H 1%		
Lopinavir with ritonavir						
Tab 100 mg with ritonavir 25 mg			\$3.0625	C H 1%	Special Authority restrictions may apply.	
Tab 200 mg with ritonavir 50 mg	49,912	\$192,577	\$3.8583	C H 1%	Special Authority restrictions may apply.	
Losartan						
Tab 12.5 mg	2,995,283	\$49,572	\$0.0166	C H 1%		
Tab 25 mg	5,772,519	\$111,987	\$0.0194	C H 1%		

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Losartan						
Tab 50 mg	9,460,623	\$225,257	\$0.0238		C H 1%	
Tab 100 mg	5,008,331	\$137,729	\$0.0275		C H 1%	
Macrogol 3350 with potassium chloride, sodium bicarbonate and sodium chloride						
<u>Powder for oral soln 13.125 g with potassium chloride 46.6 mg, sodium bicarbonate 178.5 mg and sodium chloride 350.7 mg</u>	6,171,772	\$1,394,820	\$0.2260		C H 1%	May be subject to Special Authority restrictions.
Magnesium						
Cap/Tab (150 mg elemental)					H 1%	
Magnesium hydroxide						
Paste/oral liq	481,782	\$21,786	\$0.0452		C H 1%	Note units and unit subsidy expressed are for the paste presentation.
Magnesium sulphate						
Inj 0.4 mmol per ml, 250 ml bag					H 1%	
<u>Inj 2 mmol per ml, 5ml</u>	21,384	\$21,833	\$1.0210		C H 1%	
Malathion						
Lotn 0.5%					H 1%	
Shampoo 1%					H 1%	
Maprotiline Hydrochloride						
Tab 25 mg	48,399	\$12,129	\$0.2506		C H 1%	
Tab 75 mg	2,300	\$1,611	\$0.7003		C H 1%	
Mebendazole						
Tab 100 mg	62,567	\$63,063	\$1.0079		C H 1%	
Mebeverine hydrochloride						
Tab 135 mg	2,522,841	\$504,568	\$0.2000		C H 1%	
Medroxyprogesterone acetate						
Tab 2.5 mg	667,874	\$83,484	\$0.1250		C H 1%	
Tab 5 mg	809,971	\$113,396	\$0.1400		C H 1%	
Tab 10 mg	1,722,717	\$410,575	\$0.2383		C H 1%	
Tab 100 mg	23,825	\$24,063	\$1.0100		C H 1%	Not currently listed in Section H of the Pharmaceutical Schedule.
Melatonin						
Tab 3 mg					H 1%	Current restrictions may apply.
Tab modified-release 2 mg	2,588,510	\$2,434,934	\$0.9407	+	C H 1%	Current restrictions may apply.
Menthol						
Crystals	38,524	\$11,403	\$0.2960		C H 1%	Current restrictions may apply.
Meropenem						
<u>Inj 500 mg</u>					H 1%	Current restrictions may apply.
<u>Inj 1 g</u>					H 1%	Current restrictions may apply.
Mesalazine						
Tab long-acting 500 mg	9,359,944	\$5,527,047	\$0.5905	+	C H 1%	
Metaraminol tartrate						
Inj 0.5 mg per ml, 10 ml					H 1%	Not currently listed in the Pharmaceutical Schedule.
Inj 0.5 mg per ml, 10 ml prefilled syringe					H 1%	Not currently listed in the Pharmaceutical Schedule.
Inj 0.5 mg per ml, 20 ml prefilled syringe					H 1%	
Inj 0.5 mg per ml, 5 ml prefilled syringe					H 1%	Not currently listed in the Pharmaceutical Schedule.
Inj 0.5 mg per ml, 6 ml prefilled syringe					H 1%	Not currently listed in the Pharmaceutical Schedule.
Inj 1 mg per ml, 1 ml					H 1%	
Inj 1 mg per ml, 10 ml prefilled syringe					H 1%	
Inj 10 mg per ml, 1 ml					H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Methotrexate						
<u>Inj 100 mg per ml, 50 ml</u>		\$69,031	\$79.9900	PCT C H 1%	Preference for products where stability data >48 hours post-compounding.	
Methyldopa						
Tab 250 mg	709,171	\$107,085	\$0.1510	C H 1%		
Methylprednisolone aceponate						
Crm 0.1%	666,765	\$220,032	\$0.3300	C H 1%		
Oint 0.1%	402,825	\$132,932	\$0.3300	C H 1%		
Metoclopramide hydrochloride						
Oral liq 5 mg per 5 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.	
<u>Tab 10 mg</u>	5,683,386	\$73,884	\$0.0130	C H 1%		
Metronidazole						
Gel 0.75%				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Special Authority restrictions for use on odiferous wounds only may apply.	
Inj 5 mg per ml, 100 ml				H 1%	Preference for a bag presentation with space to add another antibiotic.	
Oral liq 200 mg per 5 ml	243,167	\$60,792	\$0.2500	C H 1%		
Suppos 500 mg	6,295	\$15,411	\$2.4480	C H 1%		
Tab 200 mg	408,021	\$42,638	\$0.1045	C H 1%	There may be a preference for a scored, dispersible tablet.	
Tab 400 mg	1,983,763	\$360,053	\$0.1815	C H 1%		
Metypapone						
Cap 250 mg	27,790	\$289,016	\$10.4000	C		
Miconazole nitrate						
<u>Crm 2% (15 g - 20 g pack)</u>	2,778,570	\$137,067	\$0.0493	C H 1%		
Lotn/tincture 2%	25,050	\$3,641	\$0.1453	C H 1%		
<u>Vaginal crm 2% with applicator</u>	437,880	\$42,474	\$0.0970	C H 1%	Single use applicators preferred.	
Mifepristone						
Tab 200 mg				H 1%		
Misoprostol						
Tab 200 mcg	51,453	\$17,794	\$0.3458	C H 1%		
Mitomycin C						
Inj 2 mg - 5 mg				PCT H 1%	Units and subsidy shown are per inj 5 mg presentation.	
Inj 10 mg - 20 mg				PCT H 1%	Not currently listed on the Pharmaceutical Schedule.	
Morphine						
<u>Inj 1 mg per ml, 10 ml syringe</u>				H 1%	Morphine sulphate inj 1 mg per ml, 10 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.	
<u>Inj 1 mg per ml, 100 ml bag</u>				H 1%	Morphine sulphate inj 1 mg per ml, 100 ml bag is currently listed in Section H of the Pharmaceutical Schedule.	
Inj 1 mg per ml, 2 ml syringe				H 1%	Morphine sulphate inj 1 mg per ml, 2 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.	
<u>Inj 1 mg per ml, 50 ml syringe</u>				H 1%	Morphine sulphate inj 1 mg per ml, 50 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.	
<u>Inj 10 mg per ml, 1 ml</u>	216,651	\$193,686	\$0.8940	C H 1%	Units and subsidy shown are for morphine sulphate inj 10 mg per ml, 1 ml.	
Inj 10 mg per ml, 100 mg cassette				H 1%	Morphine sulphate inj 10 mg per ml, 100 ml cassette is currently listed in Section H of the Pharmaceutical Schedule.	
Inj 10 mg per ml, 100 ml bag				H 1%	Morphine sulphate inj 10 mg per ml, 100 ml bag is currently listed in Section H of the Pharmaceutical Schedule.	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Morphine						
Inj 100 mg per 5 ml				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
<u>Inj 15 mg per ml, 1 ml</u>	5,323	\$5,067	\$0.9520	C H 1%	Units and subsidy shown are for morphine sulphate inj 15 mg per ml, 1 ml.	
Inj 2 mg per ml, 30 ml syringe				H 1%	Morphine sulphate inj 2 mg per ml, 30 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.	
Inj 20 mg per ml				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Inj 200 mcg in 0.4 ml syringe				H 1%	Morphine sulphate inj 200 mcg in 0.4 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.	
<u>Inj 30 mg per ml, 1 ml ampoule</u>	55,059	\$68,163	\$1.2380	C H 1%	Units and subsidy shown are for morphine sulphate inj 30 mg per ml, 1 ml ampoule.	
Inj 300 mcg in 0.3 ml syringe				H 1%	Morphine sulphate inj 300 mcg in 0.3 ml syringe is currently listed in Section H of the Pharmaceutical Schedule.	
Inj 50 mg per 5 ml				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Inj 80 mg per ml	15,933	\$136,132	\$8.5440	C H 1%	Units and subsidy shown are for morphine tartrate inj 80 mg per ml, 1.5 ml ampoule.	
<u>Tab immediate-release 10 mg</u>	3,311,056	\$927,096	\$0.2800	C H 1%	May be a preference for blister packs. Units and subsidy shown are for morphine sulphate tab immediate-release 10 mg.	
<u>Tab immediate-release 20 mg</u>	717,509	\$396,065	\$0.5520	C H 1%	May be a preference for blister packs. Units and subsidy shown are for morphine sulphate tab immediate-release 20 mg.	
Moxifloxacin						
Tab 400 mg	16,365	\$170,196	\$10.4000	C H 1%	Current restrictions may apply.	
Mucilaginous Laxatives						
<u>Dry</u>	2,365,600	\$28,624	\$0.0121	C H 1%	Not currently listed in Section H of the Pharmaceutical Schedule.	
Mupirocin						
Intra-nasal oint 2%				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply.	
Topical oint 2% (pack size 5 g or less)	312,120	\$137,333	\$0.4400	C H 1%	Current restrictions may apply.	
Naltrexone hydrochloride						
<u>Tab 50 mg</u>	202,357	\$759,175	\$3.7517	C H 1%	Current restrictions may apply.	
Neostigmine metisulfate						
<u>Inj 2.5 mg per ml, 1 ml</u>	11,139	\$21,832	\$1.9600	C H 1%		
Nicardipine hydrochloride						
Inj 2.5 mg per ml, 10 ml vial				H 1%	Current restrictions may apply.	
Nicotinic acid						
<u>Tab 50 mg</u>	587,719	\$24,214	\$0.0412	C H 1%		
<u>Tab 500 mg</u>	499,019	\$89,274	\$0.1789	C H 1%		
Nifedipine						
<u>Tab long-acting 10 mg</u>	808,802	\$143,295	\$0.1772	C H 1%		
Tab long-acting 20 mg	606,380	\$58,152	\$0.0959	C H 1%		
<u>Tab long-acting 30 mg</u>	606,111	\$63,442	\$0.1047	C H 1%		
<u>Tab long-acting 60 mg</u>	174,023	\$32,890	\$0.1890	C H 1%		
Nitazoxanide						
Tab 500 mg				C H 1%	There may be a preference for a scored tablet. Restrictions may apply. Not currently listed in Section B of the Pharmaceutical Schedule.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name	Units	Cost	Unit Subsidy	DV Limit	Comments
Line Item					
Nitazoxanide					
Oral 100 mg per 5 ml				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Restrictions may apply.
Nitrofurantoin					
Tab modified-release				C H 1%	Not currently listed in the Pharmaceutical Schedule.
Noradrenaline					
Inj 0.06 mg per ml, 100 ml bag				H 1%	
Inj 0.06 mg per ml, 50 ml syringe				H 1%	
Inj 0.06 mg per ml, 50 ml vial				H 1%	Not currently listed on the Pharmaceutical Schedule.
Inj 0.1 mg per ml, 100 ml bag				H 1%	
Inj 0.1 mg per ml, 50 ml syringe				H 1%	
Inj 0.12 mg per ml, 100 ml bag				H 1%	
Inj 0.12 mg per ml, 50 ml syringe				H 1%	
Inj 0.12 mg per ml, 50 ml vial				H 1%	Not currently listed on the Pharmaceutical Schedule.
Inj 0.16 mg per ml, 100 ml bag				H 1%	Not currently listed on the Pharmaceutical Schedule.
Inj 0.16 mg per ml, 50 ml syringe				H 1%	
Inj 0.16 mg per ml, 50 ml vial				H 1%	Not currently listed on the Pharmaceutical Schedule.
Inj 1 mg per ml, 100 ml bag				H 1%	
Norfloxacin					
Tab 400 mg	116,506	\$157,283	\$1.3500	C H 1%	
Nystatin					
<u>Oral liq 100,000 u per ml</u>	1,804,344	\$146,603	\$0.0813	C H 1%	
<u>Vaginal crm 100,000 u per 5 g with applicator(s)</u>	137,775	\$8,174	\$0.0593	C H 1%	Units and unit subsidy expressed as 'per g'.
Octreotide (somatostatin analogue)					
<u>Inj 50 mcg per ml, 1 ml</u>	5,154	\$31,584	\$6.1280	C H 1%	
<u>Inj 100 mcg per ml, 1 ml</u>	10,414	\$38,928	\$3.7380	C H 1%	
<u>Inj 500 mcg per ml, 1 ml</u>	6,193	\$89,799	\$14.5000	C H 1%	
Oestradiol					
Tab 1 mg	358,232	\$52,710	\$0.1471	C H 1%	
Tab 2 mg	242,844	\$35,732	\$0.1471	C H 1%	
TDDS 25 mcg per day	277,999	\$212,669	\$0.7650	C H 1%	
TDDS 50 mcg per day	351,736	\$309,528	\$0.8800	C H 1%	
TDDS 75 mcg per day	62,077	\$61,379	\$0.9888	C H 1%	
TDDS 100 mcg per day	116,333	\$115,024	\$0.9888	C H 1%	
Oestradiol with norethisterone					
Tab 1 mg with 0.5 mg norethisterone acetate	946,512	\$182,544	\$0.1929	C H 1%	
Tab 2 mg with 1 mg norethisterone acetate	374,724	\$72,269	\$0.1929	C H 1%	
Tab 2 mg with 1 mg norethisterone acetate (10), and 2 mg (oestradiol tab (12) and 1 mg oestradiol tab (6)	199,472	\$38,470	\$0.1929	C H 1%	
Oestriol					
<u>Crn 1 mg per g with applicator(s)</u>	2,996,475	\$1,322,434	\$0.4413	C H 1%	Applicator(s) should be multiple use and a measured dose.
<u>Pessaries 500 mcg</u>	377,813	\$172,785	\$0.4573	C H 1%	
<u>Tab 1 mg - 2 mg</u>	202,071	\$47,149	\$0.2333	C H 1%	Units and unit subsidy are based per 2 mg tablet. Preference for 2 mg tablets to be scored.
Oestrogens					
Conjugated, equine tab 300 mcg	301,032	\$32,361	\$0.1075	C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments
Oestrogens					
Conjugated, equine tab 625 mcg	361,885	\$53,248	\$0.1471	C H 1%	
Olanzapine					
<u>Orodispersible tab 5 mg</u>	327,645	\$14,626	\$0.0446	C H 1%	
<u>Orodispersible tab 10 mg</u>	501,323	\$36,702	\$0.0732	C H 1%	
<u>Tab 2.5 mg</u>	1,753,925	\$40,095	\$0.0229	C H 1%	
<u>Tab 5 mg</u>	2,310,253	\$94,882	\$0.0411	C H 1%	
<u>Tab 10 mg</u>	2,813,308	\$165,788	\$0.0589	C H 1%	
Omeprazole					
<u>Cap 10 mg</u>	6,478,406	\$142,525	\$0.0220	C H 1%	
<u>Cap 20 mg</u>	94,070,208	\$2,048,849	\$0.0218	C H 1%	
<u>Cap 40 mg</u>	27,541,594	\$954,867	\$0.0347	C H 1%	
Ondansetron					
<u>Tab disp 4 mg</u>	2,710,840	\$257,530	\$0.0950	C H 1%	
<u>Tab disp 8 mg</u>	1,214,301	\$173,645	\$0.1430	C H 1%	
Ondansetron hydrochloride					
Inj 2 mg per ml, 2 ml				H 1%	
Inj 2 mg per ml, 4 ml				H 1%	
Oxazepam					
<u>Tab 10 mg</u>	703,033	\$43,377	\$0.0617	C H 1%	
<u>Tab 15 mg</u>	216,931	\$18,504	\$0.0853	C H 1%	
Oxybutynin					
Oral liq 1 mg per ml	430,056	\$54,918	\$0.1277	C H 1%	Preference for pack size 500 ml or less
Tab 5 mg	7,796,945	\$138,006	\$0.0177	C H 1%	
Paclitaxel					
<u>Inj 30 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding.
<u>Inj 100 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding.
Inj 150 mg				PCT H 1%	Preference for products where stability data >48 hours post-compounding.
<u>Inj 300 mg</u>				PCT H 1%	Preference for products where stability data >48 hours post-compounding.
Paliperidone (one-monthly depot injection)					
Inj 25 mg syringe	932	\$181,041	\$194.2500 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Inj 50 mg syringe	2,683	\$729,642	\$271.9500 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Inj 75 mg syringe	5,138	\$1,836,424	\$357.4200 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Inj 100 mg syringe	12,180	\$5,299,762	\$435.1200 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Inj 150 mg syringe	13,654	\$5,941,128	\$435.1200 #	+ C H 1%	Special Authority restrictions may apply. Training requirements may apply.
Paliperidone (three-monthly depot injection)					
Inj 175 mg syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Training requirements may apply.
Inj 250 - 300 mg syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Training requirements may apply.
Inj 350 mg syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Training requirements may apply.
Inj 500 mg or greater syringe				C H 1%	Not currently listed on the Pharmaceutical Schedule. Restrictions may apply. Training requirements may apply.

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Palonosetron						
Inj 250 mcg					H 1%	Not currently listed in the Pharmaceutical Schedule.
Pamidronate disodium						
<u>Inj 3 mg per ml, 10 ml</u>	334	\$1,997	\$5.9800		C H 1%	
<u>Inj 6 mg per ml, 10 ml</u>	32	\$481	\$15.0200		C H 1%	
<u>Inj 9 mg per ml, 10 ml</u>	86	\$1,466	\$17.0500		C H 1%	
Pantoprazole						
Inj 40 mg					H 1%	
Paper wasp venom						
Inj with diluent for extract	17	\$5,185	\$305.0000		C H 1%	Current restrictions may apply.
Treatment kit	8	\$2,440	\$305.0000		C H 1%	Current restrictions may apply.
Paracetamol						
<u>Tab 500 mg, blister pack</u>	322,666,350	\$2,297,384	\$0.0071		C H 10%	
<u>Tab 500 mg, bottle pack</u>	39,814,788	\$251,629	\$0.0063		C H 10%	
Inj 10 mg per ml, 100 ml					H 1%	
<u>Oral liq 120 mg per 5 ml</u>	59,768,233	\$319,760	\$0.0054		C H 20%	Preference may be given to products which include a measuring device.
<u>Oral liq 250 mg per 5 ml</u>	260,057,606	\$1,510,935	\$0.0058		C H 20%	Preference may be given to products which include a measuring device.
Paracetamol with codeine						
<u>Tab paracetamol 500 mg with codeine phosphate 8 mg</u>	45,559,133	\$829,632	\$0.0182		C H 1%	
Paraffin liquid with soft white paraffin						
Eye oint with soft white paraffin					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Paraffin liquid with wool fat liquid						
Eye oint 3% with wool fat liq 3%	233,232	\$241,894	\$1.0371		C H 1%	
Paraldehyde						
Inj 5 ml	10	\$3,000	\$300.0000		C H 1%	
Paromomycin						
Cap 250 mg	1,672	\$13,167	\$7.8750		C H 1%	Special Authority restrictions may apply.
Pericyazine						
Tab 10 mg	158,872	\$70,621	\$0.4445		C H 1%	
Tab 2.5 mg	269,301	\$33,632	\$0.1249		C H 1%	
Perindopril						
Tab 2 mg - 2.5 mg	841,748	\$105,218	\$0.1250		C H 1%	Units and subsidy shown are tab 2 mg presentation. Bids for erbumine and/or arginine salts will be considered. Preference for the same salt across all strengths.
Tab 4 mg - 5 mg	1,701,191	\$272,190	\$0.1600		C H 1%	Units and subsidy shown are per tab 4 mg presentation. Bids for erbumine and/or arginine salts will be considered. Preference for the same salt across all strengths.
Tab 8 mg - 10 mg					C H 1%	Not currently listed in the Pharmaceutical Schedule. Bids for erbumine and/or arginine salts will be considered. Preference for the same salt across all strengths.
Permethrin						
<u>Crm 5%</u>	818,430	\$135,041	\$0.1650		C H 1%	
<u>Lotion 5%</u>	1,718,580	\$211,385	\$0.1230		C H 1%	
Pethidine hydrochloride						
Inj 5 mg per ml, 10 ml					H 1%	Preservative free desirable
Inj 10 mg per ml, 100 ml bag					H 1%	
Inj 10 mg per ml, 50 ml syringe					H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Pethidine hydrochloride						
Inj 5 mg per ml, 100 ml bag				H 1%		
<u>Inj 50 mg per ml, 1 ml</u>	4,500	\$4,482	\$0.9960	C H 1%		
<u>Inj 50 mg per ml, 2 ml</u>	15,882	\$16,263	\$1.0240	C H 1%		
Phenelzine sulphate						
Tab 15 mg	97,741	\$115,334	\$1.1800	C H 1%		
Phenothrin						
Shampoo 0.5%	4,545,400	\$258,179	\$0.0568 #	C H 1%		
Phenoxybenzamine						
Cap 10 mg	20,536	\$44,495	\$2.1667	C H 1%		
Phenoxybenzamine hydrochloride						
Inj 50 mg per ml, 2 ml ampoule				H 1%		
Phentolamine Mesylate						
Inj 10 mg per ml, 1 ml				H 1%		
Inj 5 mg per ml, 1 ml				H 1%		
Phenylephrine hydrochloride						
Inj 10 mg per ml, 1 ml				H 1%		
Phenytoin Sodium						
Inj 50 mg per ml, 2 ml	591	\$10,476	\$17.7260	C H 1%		
Inj 50 mg per ml, 5 ml	542	\$14,517	\$26.7840	C H 1%		
Pimecrolimus						
Crm 1%				C H 1%	PHARMAC reserves the right to award tenders for one, some or all presentations of topical tacrolimus or pimecrolimus. This item is not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.	
Pine tar with triethanolamine lauryl sulphate and fluorescein						
<u>Soln 2.3% with triethanolamine lauryl sulphate and fluorescein sodium</u>	30,616,628	\$236,360	\$0.0077	C H 1%		
Piperacillin with tazobactam						
Inj 4 g with tazobactam 500 mg				H 1%	Current restrictions may apply. PHARMAC will consider other 8:1 (piperacillin:tazobactam) presentations if cost effective.	
Pivmecillinam						
Tab 200 mg				C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions.	
Podophyllotoxin						
Soln 0.5%	10,756	\$103,253	\$9.6000	C H 1%		
Poloxamer						
<u>Oral drops 10%</u>	268,350	\$33,812	\$0.1260	C H 1%		
Polyvinyl alcohol						
Eye drops 1.4%	502,410	\$87,756	\$0.1747	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml	
Eye drops 3%	264,195	\$64,815	\$0.2453	C H 1%	For products containing BAK, PHARMAC reserves its right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml	
Poractant Alfa						
Soln 120 mg per 1.5 ml vial				H 1%		
Soln 240 mg per 3 ml vial				H 1%		

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Potassium citrate						
Tab					C H 1%	Not currently listed on the Pharmaceutical Schedule. Any listing may be subject to Special Authority restrictions.
Potassium permanganate						
Crystals/Tab					H 1%	Note this product may require Medsafe registration prior to an award.
Povidone Iodine						
Oint 10%	601,920	\$78,731	\$0.1308		C H 1%	
Pravastatin						
Tab 10 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule
<u>Tab 20 mg</u>	3,404,128	\$160,675	\$0.0472		C H 1%	
<u>Tab 40 mg</u>	1,711,585	\$137,954	\$0.0806		C H 1%	
Praziquantel						
Tab 600 mg	838	\$7,119	\$8.5000		C H 1%	
Prazosin Hydrochloride						
Tab 1 mg	540,258	\$29,876	\$0.0553		C H 1%	
Tab 2 mg	302,659	\$21,186	\$0.0700		C H 1%	
Tab 5 mg	105,335	\$12,324	\$0.1170		C H 1%	
Prednisone						
<u>Tab 1 mg</u>	11,460,408	\$244,794	\$0.0214		C H 1%	
<u>Tab 2.5 mg</u>	2,186,502	\$52,870	\$0.0242		C H 1%	
<u>Tab 20 mg</u>	6,381,097	\$370,486	\$0.0581		C H 1%	
<u>Tab 5 mg</u>	12,725,443	\$282,250	\$0.0222		C H 1%	
Pregnancy tests - HCG urine						
Pregnancy test - HCG urine - Dipstick					C	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine.
<u>Pregnancy tests - HCG urine - Cassette</u>	430,840	\$129,252	\$0.3000		C	PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine.
Pregnancy tests - HCG urine - Midstream					C	Not currently listed on the Pharmaceutical Schedule. PHARMAC reserves the right to award one, some or all of the tenders for pregnancy tests - HCG urine.
Prilocaine Hydrochloride						
Inj 2%, 5 ml ampoule					H 1%	
Primaquine phosphate						
Tab 7.5 - 15 mg	484	\$1,011	\$2.0893		C H 1%	Tab 7.5 mg is currently listed in Section B of the Pharmaceutical Schedule. Units shown are for tab 7.5 mg. Special Authority restrictions may apply. There may be a preference for a scored tablet.
Procaine penicillin						
<u>Inj 1.5 mega u</u>	1,141	\$28,183	\$24.7000		C H 1%	
Prochlorperazine						
<u>Tab 5 mg</u>	3,544,873	\$90,040	\$0.0254		C H 1%	
Progesterone						
Cap 100 mg	40,853	\$22,469	\$0.5500		C H 1%	Must be compatible for intra-vaginal use. Current restrictions may apply. PHARMAC reserves the right to amend access.
Propafenone hydrochloride						
Tab 150 mg	70,262	\$57,474	\$0.8180		C H 1%	
Propylthiouracil						
Tab 50 mg	244,586	\$85,605	\$0.3500		C H 1%	Current restrictions may apply.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Protonamide						
Tab 250 mg	4,194	\$12,792	\$3.0500	C H 1%	Current restrictions may apply.	
Pyrazinamide						
Tab 500 mg	110,557	\$65,228	\$0.5900	C H 1%	Current restrictions may apply. There may be a preference for a scored tablet or a tablet that is dispersable in water.	
Pyridoxine hydrochloride						
Tab 25 mg	805,333	\$24,160	\$0.0300	C H 1%		
Tab 50 mg	1,721,516	\$46,929	\$0.0273	C H 1%		
Pyrimethamine						
Tab 25 mg	1,594	\$1,178	\$0.7390	C H 1%	Current restrictions may apply. There may be preference for a scored tablet or tablet that is dispersable in water.	
Quetiapine						
Tab 100 mg	3,766,707	\$144,378	\$0.0383	C H 1%		
Tab 12.5 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 200 mg	1,202,142	\$76,805	\$0.0639	C H 1%		
Tab 25 mg	21,927,295	\$436,134	\$0.0199	C H 1%	There may be a preference for a scored tablet.	
Tab 300 mg	471,530	\$50,298	\$0.1067	C H 1%		
Quinine dihydrochloride						
Inj 600 mg				H 1%	Current restrictions may apply.	
Ranitidine hydrochloride						
Inj	23,266	\$40,716	\$1.7500	C H 1%	Units and subsidy shown are for inj 25 mg per ml, 2 ml presentation.	
Oral liq 150 mg per 10 ml	1,940,548	\$33,242	\$0.0171	C H 1%		
Tab 150 mg	9,480,166	\$244,778	\$0.0258	C H 1%		
Tab 300 mg	2,771,295	\$100,931	\$0.0364	C H 1%		
Rasagiline						
Tab 1 mg				C H 1%	Not currently listed on the Pharmaceutical Schedule. Pricing should be similar to selegine.	
Remifentanil hydrochloride						
Inj 1 mg				H 1%		
Inj 2 mg				H 1%		
Rifabutin						
Cap 150 mg	7,247	\$66,431	\$9.1667	C H 1%		
Rifampicin						
Cap 150 mg	87,949	\$49,032	\$0.5575	C H 1%	Current restrictions may apply.	
Cap 300 mg	162,478	\$188,881	\$1.1625	C H 1%	Current restrictions may apply.	
Inj 600 mg				H 1%	Current restrictions may apply.	
Oral liq 100 mg per 5 ml	65,974	\$13,195	\$0.2000	C H 1%	Current restrictions may apply.	
Rifampicin with isoniazid, pyrazinamide and ethambutol						
Tab 150 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 275 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 400 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 75 mg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Rifaximin						
Tab 200 mg - 550 mg	110,031	\$1,228,025	\$11.1607	C H 1%	Current restrictions may apply. Tab 550 mg is currently listed on the Pharmaceutical Schedule. Units shown are for tab 550 mg.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Risperidone						
Inj 25 mg vial	4,184	\$568,940	\$135.9800	C H 1%	Current restrictions may apply.	
Inj 37.5 mg vial	5,614	\$1,003,278	\$178.7100	C H 1%	Current restrictions may apply.	
Inj 50 mg vial	7,058	\$1,535,538	\$217.5600	C H 1%	Current restrictions may apply.	
<u>Oral liquid 1 mg per ml</u>	364,509	\$93,070	\$0.2553	C H 1%		
<u>Tab 0.5 mg</u>	3,021,952	\$93,681	\$0.0310	C H 1%		
<u>Tab 1 mg</u>	2,148,916	\$73,772	\$0.0343	C H 1%		
<u>Tab 2 mg</u>	1,030,494	\$39,334	\$0.0382	C H 1%		
<u>Tab 3 mg</u>	419,373	\$17,475	\$0.0417	C H 1%		
<u>Tab 4 mg</u>	202,907	\$11,600	\$0.0572	C H 1%		
Rizatriptan						
<u>Tab orodispersible 10 mg</u>	1,732,489	\$303,757	\$0.1753	C H 1%		
Ropivacaine hydrochloride						
Inj 1 mg per ml, 100 ml bag				H 1%	Not currently listed in the Pharmaceutical Schedule.	
Inj 1 mg per ml, 200 ml bag				H 1%	Not currently listed in the Pharmaceutical Schedule.	
<u>Inj 2 mg per ml, 10 ml</u>				H 1%		
<u>Inj 2 mg per ml, 20 ml</u>				H 1%		
<u>Inj 2 mg per ml, 100 ml</u>				H 1%		
<u>Inj 2 mg per ml, 200 ml</u>				H 1%		
<u>Inj 7.5 mg per ml, 10 ml</u>				H 1%		
<u>Inj 7.5 mg per ml, 20 ml</u>				H 1%		
<u>Inj 10 mg per ml, 10 ml</u>				H 1%		
<u>Inj 10 mg per ml, 20 ml</u>				H 1%		
Ropivacaine hydrochloride with fentanyl						
Inj 1 mg with fentanyl 2 mcg per ml, 100 ml bag				H 1%	Not currently listed in the Pharmaceutical Schedule.	
Inj 1 mg with fentanyl 2 mcg per ml, 200 ml bag				H 1%	Not currently listed in the Pharmaceutical Schedule.	
Inj 2 mg with fentanyl 2 mcg per ml, 100 ml bag				H 1%	Sterile bag preferred.	
Inj 2 mg with fentanyl 2 mcg per ml, 200 ml bag				H 1%	Sterile bag preferred.	
Rosuvastatin						
Tab 5 mg				C H 1%	Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.	
Tab 10 mg				C H 1%	Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.	
Tab 20 mg				C H 1%	Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.	
Tab 40 mg				C H 1%	Not currently listed on Pharmaceutical Schedule. Any listing may be subject to a Special Authority restriction.	
Salicylic Acid						
Powder	267,095	\$20,171	\$0.0755	C H 1%	Note this product may require Medsafe registration prior to an award.	
Selexipag						
Tab 200 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 400 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 600 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 800 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy	DV Limit	Comments	
Selexipag						
Tab 1000 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 1200 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 1400 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Tab 1600 mcg				C H 1%	Not currently listed in the Pharmaceutical Schedule.	
Silver Sulphadiazine						
<u>Crm 1% (pack size of 100 g or less)</u>	507,750	\$109,674	\$0.2160	C H 1%	Crm 1% 50 g is currently listed on the Pharmaceutical Schedule. Units shown are for crm 1% 50 g.	
Simvastatin						
<u>Tab 10 mg</u>	3,916,152	\$41,355	\$0.0106	C H 1%		
<u>Tab 20 mg</u>	17,822,711	\$301,026	\$0.0169	C H 1%		
<u>Tab 40 mg</u>	15,707,911	\$458,985	\$0.0292	C H 1%		
<u>Tab 80 mg</u>	1,057,851	\$70,527	\$0.0667	C H 1%		
Sodium Acid Phosphate						
Enema 16% with sodium phosphate 8%	53,673	\$134,182	\$2.5000	C H 1%	Not currently listed in Section H of the Pharmaceutical Schedule.	
Sodium alginate with magnesium alginate						
Powder for oral soln	981,191	\$173,671	\$0.1770	C H 1%	Note this product is currently described as 'Alginic acid - sodium alginate 225 mg and magnesium alginate 87.5 mg per sachet' in Section B of the Pharmaceutical Schedule.	
Sodium alginate with sodium bicarbonate and calcium carbonate						
Oral liq	18,442,191	\$55,327	\$0.0030	C H 1%	Note this product is currently described as 'sodium alginate oral liq 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg per 10 ml'.	
Tab 500 mg	523,703	\$15,711	\$0.0300	C H 1%	Note this product is currently described as sodium alginate tab 500 mg with sodium bicarbonate 267 mg and calcium carbonate 160 mg in Section B of the Pharmaceutical Schedule.	
Sodium Citro-Tartrate						
<u>Grans effervescent 4 g sachets</u>	2,245,275	\$187,638	\$0.0836	C H 1%		
Sodium cromoglicate						
Nasal spray, 4%				H 1%		
Sodium fusidate [fusidic acid]						
Eye drops 1%	304,605	\$322,272	\$1.0580	C H 1%	Units and unit subsidy expressed as "per ml".	
Streptomycin sulphate						
Inj 400 mg per ml, 2.5 ml				H 1%	Current restrictions may apply.	
Sulfadiazine Sodium						
Tab 500 mg	904	\$8,769	\$9.7000	C H 1%	Current restrictions may apply. Not currently listed in Section H of the Pharmaceutical Schedule.	
Suxamethonium chloride						
50 mg per ml, prefilled syringe				H 1%		
<u>Inj 50 mg per ml, 2 ml</u>				H 1%		
Tacrolimus						
Oint 0.03%				C H 1%	PHARMAC reserves the right to award tenders for one, some or all presentations of topical tacrolimus or pimecrolimus. This item is not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.	

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name							
Line Item	Units	Cost	Unit Subsidy	DV Limit		Comments	
Tacrolimus							
Oint 0.1%				C H 1%		PHARMAC reserves the right to award tenders for one, some or all presentations of topical tacrolimus or pimecrolimus. This item is not currently listed on the Pharmaceutical Schedule. Special Authority restrictions may apply.	
Tadalafil							
Tab/Cap 2.5 mg				C H 1%		Not currently listed on the Pharmaceutical Schedule. The same restrictions as for sildenafil would apply.	
Tab/Cap 5 mg				C H 1%		Not currently listed on the Pharmaceutical Schedule. The same restrictions as for sildenafil would apply.	
Tab/Cap 10 mg				C H 1%		Not currently listed on the Pharmaceutical Schedule. The same restrictions as for sildenafil would apply.	
Tab/Cap 20 mg				C H 1%		Not currently listed on the Pharmaceutical Schedule. The same restrictions as for sildenafil would apply.	
Talc							
Powder				H 1%			
Soln (slurry) 100 mg per ml, 50 ml				H 1%			
Tamoxifen citrate							
Tab 10 mg	37,883	\$7,419	\$0.1958	C H 1%			
Tab 20 mg	1,897,967	\$177,137	\$0.0933	C H 1%			
Temazepam							
Tab 10 mg	2,965,431	\$150,644	\$0.0508	C H 1%		There may be a preference for a scored tablet.	
Terazosin hydrochloride							
Tab 1 mg	900,315	\$18,970	\$0.0211	C H 1%			
Tab 2 mg	4,326,477	\$64,897	\$0.0150	C H 1%			
Tab 5 mg	3,148,718	\$68,642	\$0.0218	C H 1%			
Terbinafine							
Tab 250 mg	2,091,669	\$198,709	\$0.0950	C H 1%			
Teriflunomide (current access)							
Tab 14 mg	10,668	\$602,978	\$56.5221 #	+ C H 1%		Current restrictions will apply. PHARMAC will only award a tender for current or widened access.	
Teriflunomide (widened access)							
Tab 14 mg				+ C H 1%		PHARMAC would only award current or widened access. Wider access may remove the gradient EDSS stopping requirements and may also extend the current entry and stopping criteria to higher EDSS state. Tender award may be subject to further consultation.	
Terlipressin							
Inj 0.1 mg per ml, 8.5 ml ampoule				H 1%			
Inj 0.2 mg per ml, 5 ml				H 1%		Not currently listed on the Pharmaceutical Schedule.	
Inj 1 mg per 8.5 ml ampoule				H 1%			
Testosterone cypionate							
Inj long-acting 100 mg per ml, 10 ml	1,645	\$125,843	\$76.5000	C H 1%			
Tetracaine [amethocaine] hydrochloride							
Gel 4%				H 1%			
Tetracycline							
Cap 500 mg	27,811	\$42,643	\$1.5333	C H 1%		Current restrictions may apply.	
Tab 250 mg				H 1%			

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Thiamine hydrochloride						
Inj 100 mg per ml, 1 ml					H	
Tab 100 mg					C H 1%	Currently not listed in Section B of the Pharmaceutical Schedule.
<u>Tab 50 mg</u>	7,189,359	\$351,560	\$0.0489		C H 1%	
Inj 100 mg per ml, 2 ml					H 1%	
Thiotepa						
Inj 100 mg					PCT C H 1%	
Inj 15 mg					PCT C H 1%	
Thyrotropin alfa						
Inj 900 mcg vial					H 1%	
Ticagrelor						
Tab 90 mg	3,212,040	\$5,162,198	\$1.6071	+	C H 1%	Current restrictions may apply.
Timolol						
Tab 10 mg	53,822	\$5,678	\$0.1055		C H 1%	This is listed in Section H of the Pharmaceutical Schedule as timolol maleate.
Timolol maleate						
<u>Eye drops 0.25%</u>	150,105	\$42,930	\$0.2860		C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market.
<u>Eye drops 0.5%</u>	127,565	\$36,484	\$0.2860		C H 1%	For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market.
Tobramycin						
Powder BP					H 1%	Current restrictions may apply.
Solution for inhalation 60 mg per ml, 5 ml	22,037	\$865,739	\$39.2857 #		C H 1%	A confidential rebate applies. Current restrictions may apply.
Inj 100 mg per ml, 5 ml					H 1%	Current restrictions may apply.
Tolterodone tartrate						
Tab 1 mg	172,458	\$44,839	\$0.2600		C H 1%	Restrictions may apply.
Tab 2 mg	187,421	\$48,729	\$0.2600		C H 1%	Restrictions may apply.
Tramadol hydrochloride						
Oral soln 10 mg per ml					C H 1%	There may be a preference for a bottle ≤100 ml. Not currently listed in Section B of the Pharmaceutical Schedule.
Inj 10 mg per ml, 100 ml bag					H 1%	
<u>Cap 50 mg</u>	32,166,452	\$723,745	\$0.0225		C H 1%	
<u>Inj 50 mg per ml, 1 ml</u>					H 1%	
<u>Inj 50 mg per ml, 2 ml</u>					H 1%	
<u>Tab sustained-release 100 mg</u>	4,947,813	\$383,456	\$0.0775		C H 1%	
<u>Tab sustained-release 150 mg</u>	458,485	\$48,141	\$0.1050		C H 1%	
<u>Tab sustained-release 200 mg</u>	359,802	\$49,473	\$0.1375		C H 1%	
Tranlycypromine Sulphate						
Tab 10 mg	200,964	\$92,202	\$0.4588		C H 1%	
Travoprost						
<u>Eye drops 0.004%</u>	49,739	\$223,633	\$4.4961		C H 1%	This product is currently subject to a confidential rebate. For products containing BAK, PHARMAC reserves the right to list a BAK or preservative free product for a restricted market. Units and unit subsidy shown are per ml.
Triamcinolone acetonide						
<u>0.1% in Dental Paste USP</u>	133,845	\$142,679	\$1.0660		C H 1%	
<u>Inj 10 mg per ml, 1 ml</u>	4,204	\$17,489	\$4.1600		C H 5%	PHARMAC reserves the right to list a preservative free product for a restricted market.

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Triamcinolone acetonide						
Inj 10 mg per ml, 1 ml preservative-free					C H 1%	Not currently listed in the Pharmaceutical Schedule. Restrictions may apply.
<u>Inj 40 mg per ml, 1 ml</u>	76,559	\$782,433	\$10.2200		C H 1%	PHARMAC reserves the right to list a preservative free product for a restricted market.
<u>Crn 0.02%</u>	2,388,500	\$150,476	\$0.0630		C H 1%	
<u>Oint 0.02%</u>	1,387,100	\$88,081	\$0.0635		C H 1%	
Triamcinolone acetonide with gramicidin, neomycin and nystatin						
Ear drops 1 mg with nystatin 100,000 u, neomycin sulphate 2.5 mg and gramicidin 250 mcg per g	583,643	\$401,546	\$0.6880		C H 1%	
Triazolam						
Tab 125 mcg	1,755,183	\$89,514	\$0.0510		C H 1%	There may be a preference for a scored tablet.
Tab 250 mcg	1,498,410	\$61,435	\$0.0410		C H 1%	
Triclosan						
Soln 1%	2,122,500	\$25,046	\$0.0118		C	Preference for pack size of 500 ml or less. Subsidy by endorsement only. Note this product may require Medsafe registration prior to an award.
Trimethoprim						
Tab 100 mg					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Ursodeoxycholic acid						
<u>Cap 250 mg - 300 mg</u>	913,008	\$346,486	\$0.3795		C H 1%	Current restrictions may apply. Cap 250 mg is currently listed on the Pharmaceutical Schedule. Units shown are for cap 250 mg.
Valganciclovir						
Oral liq					C H 1%	Not currently listed in the Pharmaceutical Schedule.
Vancomycin hydrochloride						
Inj 1 g					C H 1%	Not currently listed on the Pharmaceutical Schedule.
<u>Inj 500 mg</u>	7,366	\$17,457	\$2.3700		C H 1%	Current restrictions may apply.
Verapamil hydrochloride						
Inj 2.5 mg per ml, 2 ml	2,481	\$12,405	\$5.0000		C H 1%	
Tab 40 mg	234,206	\$16,418	\$0.0701		C H 1%	
Tab 80 mg	89,019	\$10,451	\$0.1174		C H 1%	
Vitamins						
Cap/tab (fat soluble vitamins A, D, E, K)	219,824	\$85,731	\$0.3900		C H 1%	Current restrictions may apply.
Water-based lubricant						
Single use sachets, 4 ml/g or larger					C	Not currently listed in Section B of the Pharmaceutical Schedule. Restrictions may apply. Preference for a small pack size.
Wool fat with mineral oil						
Lotn hydrous 3% with mineral oil, 1000 ml	1,013,381	\$5,675	\$0.0056	*	C	
Lotn hydrous 3% with mineral oil, 250 ml	1,408,000	\$7,885	\$0.0056	*	C	Not currently listed in Section H of the Pharmaceutical Schedule.
Xylometazoline hydrochloride						
Aqueous nasal spray 0.05%					H 1%	
Aqueous nasal spray 0.1%					H 1%	
Nasal drops 0.05%					H 1%	
Nasal drops 0.1%					H 1%	
Yellow jacket wasp venom						
Inj with diluent for extract	14	\$4,270	\$305.0000		C H 1%	

sole supply

#=rebate *=part charge @=ASP +=patent

SCHEDULE TWO: PRODUCTS TO BE TENDERED

Chemical Name						
Line Item	Units	Cost	Unit Subsidy		DV Limit	Comments
Yellow jacket wasp venom						
Treatment kit	1	\$305	\$305.0000		C H 1%	
Zinc						
Crn (pack size 50 g or less)					C	Not currently listed in Section B of the Pharmaceutical Schedule.
Crn (pack size greater than 50 g)					C	Not currently listed in Section B of the Pharmaceutical Schedule.
Oint (pack size 50 g or less)					C	Not currently listed in Section B of the Pharmaceutical Schedule.
Oint (pack size greater than 50 g)					C	Not currently listed in Section B of the Pharmaceutical Schedule.
Paste (pack size 50 g or less)					C	Not currently listed in Section B of the Pharmaceutical Schedule.
Zinc and castor oil						
Crn (pack size 50 g or less)					C	Not currently listed in Section B of the Pharmaceutical Schedule.
Crn (pack size greater than 50 g)					C	Not currently listed in Section B of the Pharmaceutical Schedule.
<u>Oint (pack size 50 g or less)</u>					C	Not currently listed in Section B of the Pharmaceutical Schedule.
<u>Oint (pack size greater than 50 g)</u>	19,302,265	\$164,069	\$0.0085		C	Units and subsidy shown are per the 500 g pack size currently listed.
Zolmitriptan						
Nasal Spray					C H 1%	Not currently listed in the Pharmaceutical Schedule. May be subject to Special Authority restrictions.
Zopiclone						
Tab 3.75 mg (pack size 30 tabs or less)					C H 1%	Not currently listed on the Pharmaceutical Schedule.
Tab 7.5 mg (pack size 30 tabs or less)					H 1%	Tablets should be scored.
Zuclopenthixol Acetate						
Inj 50 mg per ml, 1 - 2 ml					H 1%	
Zuclopenthixol Decanoate						
Inj 200 mg per ml	28,811	\$114,092	\$3.9600		C H 1%	
Inj 500 mg per ml					C H 1%	Not currently listed in Section B of the Pharmaceutical Schedule.
Zuclopenthixol hydrochloride						
Tab 10 mg	200,728	\$63,129	\$0.3145		C H 1%	There may be a preference for a scored tablet.

Schedule 3: Tender Process

1. General

1.1 Sole Supply Period and Hospital Supply Status Period

- (a) Hospital Tender Bids are to be submitted on the basis that if your Hospital Tender Bid is accepted, you will have Hospital Supply Status for the particular Tender Item for the Hospital Supply Status Period.
- (b) Community Tender Bids are to be submitted on the basis that if your Community Tender Bid is accepted, you will have Sole Supply Status for the particular Tender Item for the Sole Supply Period.
- (c) Combined Community/Hospital Tender Bids are to be submitted on the basis that if your Combined Community/Hospital Tender Bid is accepted, you will have Hospital Supply Status for the particular Tender Item for the Hospital Supply Status Period and Sole Supply Status for the particular Tender Item for the Sole Supply Period.

1.2 Transition Periods

- (a) In relation to hospital supply:
 - (i) there will be two Transition Periods (the First Transition Period and the Final Transition Period) during which the successful tenderer's brand is to be available for supply and purchase by DHB Hospitals. Additionally, where the successful tenderer's brand of the Pharmaceutical is not listed immediately prior to the First Transition Period, the successful tenderer's brand must be available for supply and purchase by DHB Hospitals from the applicable dates specified in clause 3 of Schedule 6;
 - (ii) the First Transition Period is intended to allow for an orderly transition to the arrangements that will apply during the Hospital Supply Status Period;
 - (iii) the Final Transition Period is intended to allow for an orderly transition to any new arrangements following the end of the Hospital Supply Status Period;
 - (iv) DHB Hospitals may purchase DV Pharmaceuticals at any time within the First Transition Period and Final Transition Period without any requirement to comply with the DV Limit.
- (b) Subject to paragraph (d) below, in relation to community supply:
 - (i) there will be two Transition Periods (the First Transition Period and the Final Transition Period) during which the successful tenderer's brand is to be available for supply and subsidised, but may not be the sole subsidised brand of that Tender Item. Additionally, where the successful tenderer's brand of the Pharmaceutical is not listed immediately prior to the First Transition Period, the successful tenderer's brand must be available for supply from the applicable dates specified in clause 3 of Schedule 5;
 - (ii) the First Transition Period is intended to allow for an orderly transition to the arrangements that will apply during the Sole Supply Period;

Schedule 3

- (iii) the Final Transition Period is intended to allow for an orderly transition to any new arrangements following the end of the Sole Supply Period.
- (c) In relation to community and/or hospital supply, PHARMAC may, in its sole discretion:
 - (i) determine a different commencement date for the First Transition Period, including where it considers that a different commencement date is necessary to ensure appropriate stock management or appropriate supply of the Tender Item; and/or
 - (ii) extend the period of the First Transition Period, by determining a different end date, and may do so before or after the commencement date of the First Transition Period. For the avoidance of doubt, in the event that PHARMAC extends the First Transition Period under this clause 1.2(c)(ii):
 - (A) the delisting of all other brands of that form and strength of the Chemical Entity is to be deferred until the actual commencement date of the Sole Supply Period, notwithstanding any date previously notified to suppliers by PHARMAC as being the intended date of delisting;
 - (B) all other brands of that form and strength of the Chemical Entity are to remain listed in accordance with the terms of any existing contract between PHARMAC and the particular pharmaceutical supplier in respect of the relevant brand(s) until such time as that supplier's brand of that form and strength of the Chemical Entity is actually delisted.
- (d) In relation to community supply, if the successful tenderer's brand is the only brand of the Tender Item listed on the Pharmaceutical Schedule as at the Market Notification Date, then the First Transition Period and clause 1.1(a) of Schedule Five will not apply.
- (e) For the avoidance of doubt, any notification by PHARMAC of the delisting of all other brands of that form and strength of the Chemical Entity on the first day of the Sole Supply Period operates solely as advance notice of the intended delisting of those pharmaceuticals and does not constitute a notice of termination of any existing contract for the supply of those other brands.

1.3 Contract

If PHARMAC accepts your:

- (a) Community Tender Bid, then a contract on the terms and conditions set out in:
 - (i) your Tender Bid (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule); and
 - (ii) Schedule Four; and
 - (iii) Schedule Five; and
 - (iv) Schedule Seven (as applicable),will be deemed to have been entered into between you and PHARMAC for Sole Supply Status for the relevant Pharmaceutical and, where applicable, its listing on the Pharmaceutical Schedule;
- (b) Hospital Tender Bid, then a contract on the terms and conditions set out in:

Schedule 3

- (i) your Tender Bid (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule); and
- (ii) Schedule Four; and
- (iii) Schedule Six; and
- (iv) Schedule Seven (as applicable),

will be deemed to have been entered into between you and PHARMAC for Hospital Supply Status for the relevant Pharmaceutical and, where applicable, its listing on the Pharmaceutical Schedule;

- (c) Combined Community/Hospital Tender Bid, then:

- (i) a contract on the terms and conditions set out in:
 - (A) your Tender Bid, to the extent applicable (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule); and
 - (B) Schedule Four; and
 - (C) for the Community Tender Bid element of that Combined Community/Hospital Tender Bid, Schedule Five; and
 - (D) Schedule Seven (as applicable),

will be deemed to have been entered into between you and PHARMAC for Sole Supply Status for the relevant Pharmaceutical and, where applicable, its listing on the Pharmaceutical Schedule; and

- (ii) a separate contract on the terms and conditions set out in:
 - (A) your Tender Bid, to the extent applicable (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule); and
 - (B) Schedule Four; and
 - (C) for the Hospital Tender Bid element of that Combined Community/Hospital Tender Bid, Schedule Six; and
 - (D) Schedule Seven (as applicable),

will be deemed to have been entered into between you and PHARMAC for Hospital Supply Status for the relevant Pharmaceutical and, where applicable, its listing on the Pharmaceutical Schedule.

For the avoidance of doubt, the terms and conditions specified in Schedule Four, Schedule Five, Schedule Six and Schedule Seven, as applicable, apply from the date when PHARMAC notifies you in accordance with clause 7.2 of this Schedule of its acceptance of your Tender Bid, and do not apply solely for the Sole Supply Period or Hospital Supply Status Period, as applicable.

Schedule 3

1.4 Extension of Hospital Supply Status to include Sole Supply Status

- (a) You acknowledge and agree that if your Hospital Tender Bid is for a Tender Item that is specified in the product list in clause 2 of Schedule Two and the Electronic Portal as being a Tender Item for which you may submit a Tender Bid for Sole Supply Status, you may agree (such consent not to be unreasonably withheld), if so requested by PHARMAC:
 - (i) if PHARMAC has not yet accepted a Hospital Tender Bid for the particular Tender Item, to extend your Tender Bid to cover community supply; or
 - (ii) if PHARMAC has accepted your Hospital Tender Bid for the particular Tender Item, to supply the Tender Item for use in the community under Sole Supply Status as soon as practicable after such requirement is notified to you, and in any case no later than three months after that notification, under a separate contract for Sole Supply Status.
- (b) The Community Tender Bid referred to in paragraph (a)(i) above and the contract for Sole Supply Status referred to in paragraph (a)(ii) above will be:
 - (i) at a price that is equal to the Price specified for that Pharmaceutical in your Hospital Tender Bid; and
 - (ii) on the other terms and conditions set out in your Hospital Tender Bid (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule), as applicable; and
 - (iii) for supply in accordance with Schedules Four, Five and Seven; and
 - (iv) for such quantities of the Pharmaceutical as are required for use in the community.
- (c) This clause confers a benefit on, and is enforceable by, the Funder in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

1.5 Extension of Sole Supply Status to include Hospital Supply Status

- (a) You acknowledge and agree that if your Community Tender Bid is for a Tender Item that is specified in the product list in clause 2 of Schedule Two as being a Tender Item for which you may submit a Tender Bid for Hospital Supply Status, you may agree (such consent not to be unreasonably withheld), if so required by PHARMAC:
 - (i) if PHARMAC has not yet accepted a Community Tender Bid for the particular Tender Item, to extend your Tender Bid to cover hospital supply; or
 - (ii) if PHARMAC has accepted your Community Tender Bid for the particular Tender Item, to supply the Tender Item for use in DHB Hospitals under Hospital Supply Status as soon as practicable after such requirement is notified to you, and in any case no later than three months after that notification, under a separate contract for Hospital Supply Status.
- (b) The Hospital Tender Bid referred to in paragraph (a)(i) above and the contract for Hospital Supply Status referred to in paragraph (a)(ii) above will be:
 - (i) at a price that is equal to the Price specified for that Pharmaceutical in your Community Tender Bid; and

Schedule 3

- (ii) on the other terms and conditions set out in your Community Tender Bid (incorporating any variations as a result of negotiations or discussions under clause 1.6 of this Schedule), as applicable; and
 - (iii) for supply in accordance with Schedules Four, Six and Seven; and
 - (iv) for such quantities of the Pharmaceutical as are required for use in DHB Hospitals.
- (c) This clause confers a benefit on, and is enforceable by, DHB Hospitals in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

1.6 PHARMAC may initiate limited negotiations

- (a) Notwithstanding clause 2.7 of this Schedule, PHARMAC may, in its sole discretion, initiate negotiations or discussions with you in relation to your Tender Bid about:
- (i) any of the terms and conditions to apply if your Tender Bid is accepted;
 - (ii) the proposed packaging or pack size of the Tender Item;
 - (iii) your ability to ensure continued availability of the Tender Item throughout the Hospital Supply Status Period and/or Sole Supply Period, as applicable;
 - (iv) the price of the Tender Item, but only where PHARMAC determines, in its sole discretion, that an increased price for the Tender Item may be necessary for practicality of supply of the Tender Item (for example, because of particular packaging requirements);
 - (v) DV Limits and/or DV Pharmaceuticals, in relation to hospital supply;
 - (vi) the Lead Time and/or the Start Date; or
 - (vii) any other matter that PHARMAC considers necessary or appropriate.
- (b) If PHARMAC initiates negotiations or discussions with you under paragraph (a), and as a result there is a change to any of the terms and conditions relating to the supply of a Tender Item, PHARMAC is not obliged to inform the other tenderers of that change, nor give those tenderers an opportunity to amend their bid for that Tender Item, unless the change is one which would result in the terms and conditions being materially different in scope from those set out in this Invitation.
- (c) The initiation and pursuit of any negotiations or discussions under this clause shall not constitute a counter-offer and your original Tender Bid will remain open for acceptance in accordance with clause 4.2(b) of this Schedule in the absence of agreement on any variation to that Tender Bid.

1.7 Termination and amendment of Invitation

PHARMAC may:

- (a) amend this Invitation at any time up to five business days before the Deadline; and/or
- (b) terminate this Invitation at any time before the acceptance of any Tender Bid by giving five business days' written notice.

2. Information about submitting a Tender Bid

2.1 Choice of forms and strengths

Where a Tender Item includes different forms and strengths of a Chemical Entity or entities, your Tender Bid may, but does not need to, include all of the forms and strengths of the Chemical Entity or entities contained in that Tender Item.

2.2 Consents not yet held

You may submit a Tender Bid for a Tender Item where your brand of the Tender Item is yet to obtain all necessary Consents. In those circumstances, you may be required to demonstrate your ability to obtain those consents within a time frame acceptable to PHARMAC. For example, you may be required to demonstrate that you have the dossier for that brand of the Tender Item ready to submit to Medsafe within one month of such a request being made by PHARMAC. For the avoidance of doubt where your brand of the Tender Item is yet to obtain all necessary Consents, any time period to obtain those Consents shall be exclusive of the Lead Time indicated on your Tender Bid.

2.3 Individual Tender Bids

You may submit more than one bid for a Tender Item (for example, you may submit separate bids for different pack sizes (or other equivalent grouping for a Medical Device) of a Tender Item).

2.4 Aggregated Tender Bids

- (a) You may, in addition to submitting a separate Tender Bid for each Tender Item, submit an Aggregated Tender Bid, provided that:
 - (i) in the case of a pharmaceutical that is not a Medical Device, each brand contained in an Aggregated Tender Bid is only a different form and strength of the same Chemical Entity;
 - (ii) you may not aggregate across different chemical entities when submitting a Tender Bid;
 - (iii) you may not aggregate within a single Tender Item (for example, two different brands or pack sizes);
 - (iv) you must also submit a separate Community Tender Bid and/or Hospital Tender Bid, as applicable, for each particular Tender Item.
- (b) Where a Tender Item includes different forms and strengths of a Chemical Entity or different entities (for example, a two-part injection), and you bid for the whole Tender Item, that is not an Aggregated Tender Bid.

2.5 Combined Community/Hospital Tender Bids

You may submit a Combined Community/Hospital Tender Bid, provided that you must also submit a separate Community Tender Bid and a separate Hospital Tender Bid for each Tender Item in respect of which you submit a Combined Community/Hospital Tender Bid.

Schedule 3

2.6 **Aggregated Combined Community/Hospital Tender Bids**

You may submit a Tender Bid that is both an Aggregated Tender Bid and a Combined Community/Hospital Tender Bid, provided that you comply with clauses 2.4 and 2.5 above.

2.7 **No conditions**

You cannot make a conditional Tender Bid nor qualify a Tender Bid in any way.

2.8 **Separate offers**

PHARMAC will treat each Tender Bid as a separate offer.

2.9 **Tender Bid prices**

You must submit, for each Tender Bid, a single price in New Zealand dollars (exclusive of GST), which will be the Price at which you will supply the Tender Item.

3. What to include in your Offer Letter and Tender Submission Form

3.1 **Compulsory use of Offer Letter and Tender Submission Form**

- (a) You must submit your Tender Bid using the Electronic Portal and attach the Offer Letter and a completed Tender Submission Form for each Tender Item for which you wish to submit a bid.
- (b) An electronic version of the Offer Letter is available on the Electronic Portal.

3.2 **Information that must be supplied about you**

In the Offer Letter, you must supply the following information about you:

- (a) your company structure;
- (b) your management and technical skills;
- (c) your financial resources;
- (d) your (or your supplier's) existing supply commitments;
- (e) your (or your supplier's) previous supply performance; and
- (f) your quality assurance processes, where applicable.

3.3 **Information that must be supplied about the Tender Item**

In your Tender Submission Form, you must supply the following information about the Tender Item:

- (a) in the case of a pharmaceutical that is not a Medical Device, the chemical, form, strength, brand name, pack size and type of packaging;

Schedule 3

- (b) for any Pharmaceutical that does not require Consent from Medsafe;
 - (i) evidence and justification as to why Consent from Medsafe is not required for the Tender Item(s);
 - (ii) confirmation that the Tender Item(s) that you are submitting a Tender Bid in respect of meet the relevant standards and/or regulatory requirements for its intended use and what those standards and/or regulatory requirements are; and
 - (iii) details of the Tender Item(s), including excipients and shelf life;
- (c) for any Medical Device:
 - (i) the brand name, pack size (or other equivalent grouping) and type of packaging;
 - (ii) details of the Tender Item(s) and any associated services available in relation to the Tender item(s), including training, education and product support;
 - (iii) confirmation that the Tender Item(s) that you are submitting a Tender Bid in respect of meet the relevant standards and regulatory requirements for its intended use;
 - (iv) information on current usage of and expenditure on the Tender Item(s) by DHBs;
 - (v) confirmation that you have a business continuity plan with a brief summary of the plan;
 - (vi) demonstration of experience and knowledge within the healthcare sector, and specifically DHB Hospitals;
 - (vii) the WAND registration number of the Tender Item(s); and
 - (viii) the name of the sponsor of the Tender Item for the purpose of the Medicines (Database of Medical Devices) Regulations 2003;
- (d) a single price in New Zealand dollars (exclusive of GST) at which you will supply the Tender Item:
 - (i) to wholesalers and other distributors during the Sole Supply Period in respect of a Community Tender Bid; or
 - (ii) to, at a DHB Hospital's discretion, Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding), in respect of a Hospital Tender Bid;
- (e) whether it has all necessary Consents (and if not, what the status of registration is);
- (f) the Lead Time for supply of the Tender Item;
- (g) the name and location of:
 - (i) the manufacturer(s) of the finished product (and name and location of the packaging site, if different); and

Schedule 3

- (ii) the manufacturer(s) of the active ingredients (not required in respect of Medical Devices); and
- (iii) alternative manufacturers of the finished product and active ingredients (if any) (not required in respect of Medical Devices);
- (h) your proposed distribution and supply arrangements for the Tender Item.

3.4 Information that may be supplied about the Tender Item

In your Tender Submission Form, you may supply the following information about the Tender Item:

- (a) For any Pharmaceutical or Medical Device:
 - (i) other markets you currently provide the Pharmaceutical or Medical Device in.

3.5 PHARMAC may request further information

- (a) PHARMAC may request such further information as it considers necessary from or about you for the purposes of clarifying or evaluating your Tender Bid, including (but not limited to):
 - (i) information about your credit status;
 - (ii) information on the price of a Tender Item, but only where PHARMAC requires clarification to confirm the exact price being offered, or where PHARMAC initiates negotiations with you under clause 1.6 of this Schedule;
 - (iii) where a Tender Item is a controlled drug, information about the form in which the Tender Item will be supplied, in which case you must supply that information within 10 business days of PHARMAC requesting the information; and
 - (iv) a sample pack or container of the Tender Item (and if you intend supplying it in a different form from that sample pack or container, information about the form in which it will be supplied), in which case you must supply that sample pack or container or information within 10 business days of PHARMAC requesting it.
- (b) If PHARMAC requests further information from or about you it is not obliged to request the same or any other information from or about any other party.

4. How to submit a Tender Bid

4.1 Submission of Tender Bids

All Tender Bids must be submitted via the Electronic Portal. Tender Bids or any copies of Tender Bids should not be delivered in person, by courier, by post, by facsimile or by email to PHARMAC.

4.2 Key dates

Your Tender Bid must:

- (a) be submitted via the Electronic Portal by no later than the Deadline; and

Schedule 3

- (b) be irrevocable and remain open for acceptance by PHARMAC until, as applicable:
 - (i) Friday, 31 July 2020;
 - (ii) the date specified for a Tender Item in Schedule Two or on the Electronic Portal (if any); or
 - (iii) if PHARMAC so requests at any time, such later date as you agree in writing.

5. Evaluation

5.1 Process of evaluation

The Evaluation Committee, taking such regulatory, legal, medical and other advice as it considers appropriate, will evaluate all conforming Tender Bids that have been checked for conformity under clause 6(a) of this Schedule, and any non-conforming Tender Bids that are admitted for consideration under clause 6(b) of this Schedule.

5.2 Matters for evaluation

The Evaluation Committee will evaluate Tender Bids in light of PHARMAC's statutory objective which is "to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided". In doing so the Evaluation Committee will be guided by the Factors for Consideration (Factors) that form part of PHARMAC's then current Operating Policies and Procedures (OPPs), as published on PHARMAC's website (www.pharmac.govt.nz), to the extent applicable. More information on the Factors can be found at www.pharmac.health.nz/factors-for-consideration.

The requirement for PHARMAC to pursue its statutory objective means that particular emphasis will be given to those aspects of proposals which demonstrate "health outcomes", and those aspects of proposals which demonstrate the impact on the "funding provided" for pharmaceuticals. Those Factors which relate directly to these aspects will be given the greatest weight by the Evaluation Committee but all Factors are important.

The information to be taken into account in applying the Factors by the Evaluation Committee will include, in particular:

- (a) your ability to ensure continued availability of the Tender Item throughout the Sole Supply Period and/or Hospital Supply Status Period and each of the Transition Periods, as applicable, taking into account each of the following separate points:
 - (i) your financial resources;
 - (ii) your management and technical skills;
 - (iii) your, or your supplier's, existing supply commitments;
 - (iv) your, or your supplier's, previous supply performance;
 - (v) your quality assurance processes, where applicable;
 - (vi) the site of manufacture and packaging of the Pharmaceutical, and site of manufacture of the active ingredient;

Schedule 3

- (vii) alternative manufacturers of the finished product and active ingredients (if any);
- (viii) other markets in which you currently supply the Pharmaceutical;
- (ix) your proposed distribution and supply arrangements for the Tender Item; and
- (x) the Lead Time for supply of the Tender Item;
- (b) the pack size (or other relevant grouping for a Medical Device) of the Tender Item and the type of packaging;
- (c) the price of the Tender Item;
- (d) the amount and timing of savings, including non-pharmaceutical savings accruing to the Funder or PHARMAC during the Hospital Supply Status Period and the Sole Supply Period, as applicable;
- (e) either:
 - (i) evidence that you have obtained, and still have, market approval for your brand of the Tender Item, and all necessary Consents; or
 - (ii) evidence that will enable the Evaluation Committee to form a view on the likelihood and timing of your brand of the Tender Item gaining all necessary Consents;
- (f) the name and location of the manufacturer of the finished product and active ingredients of the Tender Item; and
- (g) any other benefits to the Funder of selecting you as the supplier of the Tender Item.

6. Conformity

- (a) PHARMAC may, in its sole discretion, check your Tender Bid for conformity with this Invitation. If PHARMAC does elect to check your Tender Bid, it is not obliged to check all or any other Tender Bids for conformity, provided that in PHARMAC's judgment this would not be unfair to you in comparison to any other party. A Tender Bid will conform if it:
 - (i) is submitted via the Electronic Portal by the Deadline;
 - (ii) is submitted on the Tender Submission Form and an Offer Letter is attached;
 - (iii) has no conditions or qualifications attached;
 - (iv) includes all information required under clauses 3.2 and 3.3 of this Schedule; and
 - (v) otherwise complies, both as to form and substance, with the requirements of this Invitation.
- (b) PHARMAC may, in its sole discretion, provided that in PHARMAC's judgment this would not be unfair to you in comparison to any other party:
 - (i) exclude any non-conforming Tender Bid from consideration; or
 - (ii) consider, and accept, any non-conforming Tender Bid.

7. Decision

7.1 Decision on acceptance of Tender Bid

- (a) The Evaluation Committee will make a recommendation as to which Tender Bid should be accepted to PHARMAC's Board of Directors (or its delegate under Delegated Authority pursuant to Section 73 of the Crown Entities Act 2004, where applicable).
- (b) PHARMAC's Board of Directors (or its delegate, where applicable) will have the sole discretion to decide whether or not to accept a Tender Bid for any Tender Item.
- (c) PHARMAC's Board of Directors (or its delegate, where applicable):
 - (i) will use the Factors in PHARMAC's then current OPPs as applicable, in deciding whether or not to accept a Tender Bid for any Tender Item; and
 - (ii) is not obliged to act in accordance with any recommendation of the Evaluation Committee.

7.2 Notification of acceptance

- (a) Once PHARMAC's Board of Directors (or its delegate, where applicable) has decided under clause 7.1 above which Tender Bid (if any) to accept for a Tender Item, PHARMAC will, within a reasonable period of time, notify the successful tenderer in writing that it has been successful and in addition:
 - (i) subject to paragraph (b) below, if the successful Tender Bid is unconditionally accepted, PHARMAC will, within a reasonable period of time, notify each unsuccessful tenderer in writing of the identity of the successful tenderer; or
 - (ii) subject to paragraph (b) below, if the successful Tender Bid is conditionally accepted, PHARMAC will, within a reasonable period of time of that tender becoming unconditionally accepted, notify each unsuccessful tenderer in writing of the identity of the successful tenderer.
- (b) If for any reason you do not receive written notification from PHARMAC in accordance with paragraph (a) above, you will be deemed to have received the required notification on the date that each Tender Item you bid for is notified in the Pharmaceutical Schedule.

7.3 PHARMAC's rights reserved

- (a) PHARMAC reserves the right to accept or reject any Tender Bid.
- (b) While it is PHARMAC's current intention, unless specified otherwise in Schedule Two or the Electronic Portal, to enter into an agreement to award Hospital Supply Status and/or Sole Supply Status for each Tender Item, PHARMAC will not in any circumstances be bound to accept any or all Tender Bids and, in particular, PHARMAC will not be bound to accept the lowest or any other Tender Bid for a Tender Item.
- (c) Acceptance only occurs if, and when, PHARMAC's Board of Directors (or its delegate, where applicable) resolves to accept a Tender Bid and this acceptance is notified to the successful tenderer.

Schedule 3

- (d) PHARMAC may take any action, including making any adjustments to the tender process that it considers appropriate, acting reasonably (provided that it notifies tenderers materially affected by such adjustments).
- (e) PHARMAC may, at any time, suspend or cancel in whole or in part, this tender process in order to fulfil its public law obligations through consultation, or otherwise. In this situation PHARMAC may (without limitation) ask you to adapt and resubmit your Tender Bid in light of consultation, or alternatively we may request that new Tender Bids be submitted (or in the case of a suspension PHARMAC may also resume the tender process without further change following the end of the period of suspension).

7.4 Conditional acceptance

- (a) Where the successful tenderer's brand of a Tender Item is yet to receive all necessary Consents:
 - (i) the contract referred to in clause 1.3 of this Schedule will be conditional upon such Consents being received within a time period specified by PHARMAC; and
 - (ii) PHARMAC may terminate the contract if such Consents have not been obtained, or in PHARMAC's view are unlikely to be obtained, within the period specified by PHARMAC.
- (b) Acceptance of a Tender Bid by PHARMAC's Board of Directors (or its delegate, where applicable), and the contract referred to in clause 1.3 of this Schedule may be conditional upon you satisfying PHARMAC that you will have sufficient stock of the Tender Item available to commence supply as at a date reasonably determined by PHARMAC.

8. Back-up supply

Back-up Supply Agreements

- (a) PHARMAC may at any time negotiate a Back-up Supply Agreement with another supplier for any Tender Item.
- (b) PHARMAC may, at its sole discretion, seek proposals for Back-up Supply Agreements under a separate process to this Invitation to Tender. PHARMAC does not seek submissions for Back-up Supply Agreements in response to this Invitation to Tender and is not obliged to consider proposals or bids for back-up supply submitted as part of the tender process.

9. Dealing with information

9.1 Confidentiality

Subject to clause 9.2 below, all Confidential Information is confidential to us and our employees, legal advisers, electronic procurement providers and other consultants (including PTAC and its sub-committees), the Ministry of Health, DHBs and the Funder. You acknowledge that it may be necessary or appropriate for PHARMAC to disclose Confidential Information:

- (a) pursuant to the Official Information Act 1982; or
- (b) in publicly notifying any acceptance of your Tender Bid; or

Schedule 3

- (c) otherwise pursuant to PHARMAC's public law or any other legal obligations.

PHARMAC may consult with you before deciding whether to disclose Confidential Information for the purposes described in paragraphs (a) and (c) above, in order to ascertain any objections you may have to the disclosure of any of the Confidential Information. You acknowledge, however, that it is for PHARMAC to decide, in its absolute discretion, whether it is necessary or appropriate to disclose information for any of the above purposes, provided that PHARMAC shall act in good faith in disclosing any Confidential Information. Outside the circumstances described in paragraphs (a) and (c) above, Confidential Information must not be disclosed by either of us (or by our employees, legal advisers and other consultants) unless:

- (d) the information is publicly available without any cause attributable to the disclosing party; or
- (e) the other party has been reasonably informed prior to disclosure, and the disclosure is:
- (i) for the purposes of this Agreement; or
 - (ii) required by law; or
 - (iii) in a form, and of content, agreed to by us.

For the avoidance of doubt, information released by PHARMAC in accordance with paragraphs (a) to (c) above ceases to be Confidential Information and you agree that PHARMAC may release that information again at any time in future without consulting with you or obtaining your prior agreement.

9.2 Use of information

Generalised aggregated information regarding your Tender Bid that does not identify you or that cannot reasonably be expected to identify you or lead to the connection of you with your Tender Bid is not Confidential Information and PHARMAC may use and publish such information as it sees fit.

10. Miscellaneous

10.1 Process contract

In submitting a Tender Bid, you agree that you and PHARMAC are contractually bound to follow the process and comply with the obligations expressly contained in this Invitation.

10.2 Costs

PHARMAC is not liable in any way whatsoever for any direct or indirect costs incurred, or loss (including loss of profit) or damage sustained, by you in respect, or arising out, of this tendering process or the obtaining or granting of Hospital Supply Status and/or Sole Supply Status, as applicable, for your supply of the Tender Item including, without limitation, costs of obtaining all necessary Consents for any Tender Item.

10.3 No reliance

Your Tender Bid is submitted in reliance on your own knowledge, skill and independent advice, and not in reliance on any representations made by PHARMAC (including for these purposes the sales and market information (if any) provided in Schedule Two or on the Electronic Portal).

Schedule 3

10.4 **No further liability**

PHARMAC is not, in any event, liable in contract, tort or any other way whatsoever for any direct or indirect loss (including loss of profit), damage or cost of any kind incurred by you or any other person in relation to this tendering process.

10.5 **No lobbying**

- (a) You are not to initiate any communication with PHARMAC or its advisors, the Minister of Health (or any Associate Ministers), the Ministry of Health (including its operating unit Medsafe), or a District Health Board or any of their officers or directors, at any time with a view to influencing the outcome of the tendering process.
- (b) Failure to comply with this clause will entitle PHARMAC, in its sole discretion, to disqualify you from this tendering process.

10.6 **Enquiries**

If you have any enquiries about this Invitation you should contact Emma Clarke and Nerissa Ramlall at PHARMAC. Any additional information that PHARMAC gives to you as a result of your enquiry will also be given by PHARMAC to other potential tenderers, if PHARMAC determines that such information is material.

10.7 **Jurisdiction and governing law**

We each submit to the exclusive jurisdiction of the New Zealand courts and agree that this Invitation is governed by New Zealand law.

Schedule 4: Contract terms for both Sole Supply Status and Hospital Supply Status

1. General

1.1 Operating Policies and Procedures

- (a) You acknowledge that:
- (i) PHARMAC is required to pursue the objectives, carry out the functions, and otherwise comply with the statutory obligations, prescribed for PHARMAC in the New Zealand Public Health and Disability Act 2000;
 - (ii) PHARMAC is subject to other statutory and public law obligations, which govern PHARMAC's decision-making processes;
 - (iii) PHARMAC has OPPs which provide guidance on the way in which PHARMAC carries out its statutory responsibilities in relation to the management of the Pharmaceutical Schedule;
 - (iv) PHARMAC's OPPs may be amended or updated from time to time, following consultation with relevant groups;
 - (v) the actions which PHARMAC may take under its OPPs include (without limitation):
 - (A) listing new pharmaceuticals;
 - (B) changing guidelines or restrictions on the purchasing, prescribing and dispensing of listed pharmaceuticals;
 - (C) changing the subsidy levels and/or market dynamics for pharmaceuticals as a result of PHARMAC adopting one of the strategies set out in the OPPs or by any other means;
 - (D) amending the basis on which pharmaceuticals are classified into therapeutic groups and sub-groups;
 - (E) delisting pharmaceuticals, or delisting all or part of a therapeutic group or sub-group;
 - (vi) any action taken by PHARMAC pursuant to its OPPs may impact on the listing of the Pharmaceutical.
- (b) PHARMAC agrees not to apply, amend or update its OPPs in order to avoid any of PHARMAC's obligations under this Agreement.

1.2 Amendments to Pharmaceutical Schedule

PHARMAC will consult with you before amending the Pharmaceutical Schedule if a proposed amendment would have a material adverse effect on the listing of the Pharmaceutical.

Schedule 4

1.3 Product identification codes

You agree to obtain and notify PHARMAC by submitting a notification of product changes form of the Pharmacode, the GTIN and the CTPP for the Pharmaceutical as soon as these are notified to you, and in any event:

(a) for brand changes, no later than the earlier of:

- (i) 10 business days following the Market Notification Date; or
- (ii) the 5th of the month immediately prior to the Start Date.

(b) for price changes, on the 12th of the month prior to the Start Date.

For the avoidance of doubt, this requirement does not apply in relation to any Pharmaceutical that is a Medical Device.

1.4 Stock Reporting

You shall provide PHARMAC with reports on stock levels for the Pharmaceuticals upon PHARMAC's request during the Sole Supply Period and/or Hospital Supply Status Period.

1.5 Supplier Code of Conduct

You shall comply with the New Zealand Government's Supplier Code of Conduct (see <https://www.procurement.govt.nz/assets/procurement-property/documents/supplier-code-of-conduct.pdf>).

2. Crown Direction

- (a) You acknowledge that PHARMAC must comply with any Crown Direction.
- (b) PHARMAC may terminate or amend the Agreement, or impose restrictions on the prescribing or dispensing of a Pharmaceutical, at any time during the Sole Supply Period or the Hospital Supply Status Period (as applicable) or the Transition Periods, if the termination, amendment or imposition of restrictions is required to give effect to a Crown Direction.
- (c) In the event that a Crown Direction is issued to PHARMAC that requires an amendment to be made to this Agreement to give effect to that direction:
 - (i) PHARMAC will give you as much notice as practicable of the Crown Direction and of any amendments to this Agreement that are required to give effect to that direction;
 - (ii) the Agreement will be deemed to be amended so as to give effect to the Crown Direction from the date when such direction is due to take effect; and
 - (iii) you may terminate this Agreement on not less than six months' written notice to PHARMAC where the effect of the amendment required under sub-paragraph (ii) above is such that it is no longer viable, financially or otherwise, for you to continue supplying the Pharmaceutical or to perform your obligations under this Agreement.

Schedule 4

3. Audit

- (a) PHARMAC may, from time to time, review your records and any other information you hold that relates to this Agreement with regard to stock levels, registration information and supply issues, for the purposes of auditing your compliance with this Agreement. In these circumstances, PHARMAC, in consultation with you, will determine the terms and manner of any such audit, which as a minimum, must include the following:
- (i) the audit will be conducted by an auditor authorised by PHARMAC;
 - (ii) you agree to co-operate fully with PHARMAC and provide PHARMAC and the auditor with all reasonable assistance to ensure that any audit conducted under this clause is fully and properly completed to PHARMAC's satisfaction, including:
 - (A) allowing the auditor access to your premises, records and other information you hold that relates to this Agreement with regard to stock levels, registration information and supply issues, for the purposes of, and during the course of, conducting the audit;
 - (B) answering promptly any questions from PHARMAC or the auditor concerning any aspect of your compliance with this Agreement.
 - (iii) PHARMAC will give you 10 business days' notice of its intention to conduct an audit under this clause and will ensure that the conduct of any such audit, and access in terms of sub-paragraph (A) above, does not unreasonably disrupt your business operations.
- (b) PHARMAC will notify you in writing if an audit under this clause reveals any non-compliance with this Agreement. You agree to remedy any non-compliance within 10 business days of receiving such notice from PHARMAC or such other period as agreed with PHARMAC.
- (c) In relation to Hospital Supply Status, PHARMAC will use its best endeavours to audit compliance by DHB Hospitals with the DV Limits and related requirements set out under this Agreement.

4. Miscellaneous

4.1 Litigation support

If this Agreement or its terms (including the basis on which the Pharmaceutical is listed):

- (a) give rise to proceedings being issued against PHARMAC; or
- (b) result in PHARMAC being made a party to any proceedings issued by a third party,

you will give PHARMAC all assistance it reasonably requires to gather evidence (including expert medical and clinical evidence) for the purpose of those proceedings.

4.2 Dispute resolution

If there is a dispute between us arising out of, or in connection with, this Agreement, neither of us is to commence any proceedings relating to that dispute until the following procedure has been complied with:

Schedule 4

- (a) the party claiming a dispute has arisen must give written notice to the other party specifying the nature of the dispute;
- (b) we will endeavour, in good faith, to resolve the dispute referred to in the notice by using informal dispute resolution techniques;
- (c) if we do not agree on a dispute resolution technique within 14 days after the date notice of a dispute was given, the dispute is to be mediated according to the standard mediation agreement of LEADR & IAMA (a body corporate incorporated in Australia, registered as an overseas company in New Zealand in accordance with Part 18 of the Companies Act 1993, trading as the Resolution Institute), and the Chair of LEADR & IAMA (or the Chair's nominee) will select the mediator and determine the mediator's remuneration;
- (d) a party seeking urgent interlocutory relief may, by notice to the other party, elect not to comply with the provisions of this clause, but only to the extent of the relief sought, and only for the period required to dispose of the application for interlocutory relief; and
- (e) pending resolution of the dispute, this Agreement will remain in full effect without prejudicing our respective rights and remedies.

For the avoidance of doubt you acknowledge and agree that where a dispute arises in respect of hospital supply, PHARMAC may elect to involve any relevant DHB in any part, or all, of the above procedure.

4.3 Advertising

You must ensure that any Advertisement aimed at consumers of pharmaceuticals which you procure to be published, or in any way participate or assist in publishing, does not breach any applicable:

- (a) statute or regulation, including the Fair Trading Act 1986, Medicines Act 1981 and Medicines Regulations 1984; or
- (b) industry standard, including the Advertising Standards Authority Codes of Practice and Medicines New Zealand Code of Practice.

For the purposes of this clause:

- (c) "**Advertisement**" means any words, whether written, printed or spoken, any pictorial representation or design, any sounds or visual images, or combination of sounds and visual images, or any other form of communication used or appearing to be used to promote:
 - (i) the sale of a Pharmaceutical; or
 - (ii) the use of a method of treatment involving a Pharmaceutical; and
- (d) references to a statute, regulation or industry standard include that statute, regulation or industry standard as amended or replaced from time to time.

4.4 No derogation

For the avoidance of doubt, the express provision of a remedy for, or consequence of, breach of any term of this Agreement does not derogate from any other legal right or remedy available to PHARMAC under this Agreement or otherwise in respect of such breach.

Schedule 4

4.5 No waiver

A failure or delay by either of us to exercise any right arising under this Agreement is not a waiver of that right, and a waiver of a breach of this Agreement is not a waiver of any other breach.

4.5 Agreement prevails

Where any of your terms of supply, whether recorded on your invoices or in credit arrangements entered into or elsewhere, conflict with or detract from any of the terms of this Agreement, the terms of this Agreement will prevail and will apply to the exclusion of any of your terms or documentation.

4.6 Entire agreement

This Agreement:

- (a) is the entire agreement between us regarding the terms on which the Pharmaceutical is, as applicable:
 - (i) listed in Section B of the Pharmaceutical Schedule and subsidised by the Funder; and/or
 - (ii) listed in Section H of the Pharmaceutical Schedule and purchased by DHB Hospitals; and
- (b) supersedes and extinguishes, from the Start Date, all prior agreements and understandings between us, and between you and any District Health Board regarding supply of the Pharmaceutical to DHB Hospitals.

4.7 Amendments

Amendments to this Agreement are only effective if in writing and signed by both of us.

4.8 Assignment

You will not permit any part of this Agreement to be transferred, assigned or sub-contracted (either directly or due to a change of ownership or control) without PHARMAC's prior written consent (such consent not to be unreasonably withheld). Any such consent may be given subject to such reasonable conditions as PHARMAC sees fit but no such consent will relieve you from any liability or obligation under the terms of the Agreement, and you will continue to be responsible for the acts, defaults and neglects of your transferee, assignee or sub-contractor.

4.9 Further assurances

We both agree to execute any further documents and do any further acts within our power as may be reasonably necessary from time to time to give effect to the terms and intentions of this Agreement.

4.10 Contracts Privity

- (a) For the purposes of the Contract and Commercial Law Act 2017, Part 2, Subpart 1, we both acknowledge that your obligations in this Agreement constitute promises which confer or are intended to confer a benefit on the Funder and related persons and/or DHB Hospitals and related persons (as applicable), and are enforceable at the suit of the Funder, any such DHB Hospitals or any related persons.

Schedule 4

- (b) Except as expressly provided in paragraph (a) above, the parties do not intend to create rights in, or grant remedies to, any third party as a beneficiary of this Agreement, and all the provisions of this Agreement shall be for the sole and exclusive benefit of the parties.
- (c) For the avoidance of doubt, you acknowledge that PHARMAC may pursue damages or any other claim (including injunctive or other such relief) under this Agreement on its own account and/or on behalf of the Funder and/or DHB Hospitals (as applicable), in respect of any form of loss or damage incurred by PHARMAC and/or the Funder and/or DHB Hospitals.

4.11 Jurisdiction and governing law

We each submit to the exclusive jurisdiction of the New Zealand courts and agree that this Agreement is governed by New Zealand law.

Schedule 5: Additional contract terms for Sole Supply Status

1. Effect of Sole Supply Status

1.1 Subsidy arrangements

- (a) Subject to clause 3.1 of this Schedule, the Pharmaceutical will be subsidised, and you must supply it, during the First Transition Period at the Price. If any other brands of the Chemical Entity are listed on the Pharmaceutical Schedule, those brands will continue to be subsidised for the First Transition Period at the subsidy applicable to those brands immediately before the commencement of the First Transition Period.
- (b) All other brands of that form and strength of the Chemical Entity will be delisted on the first day of the Sole Supply Period, with the result that you will have Sole Supply Status for that form and strength of the Chemical Entity during the Sole Supply Period.
- (c) Subject to PHARMAC's other rights under this Agreement in relation to the Pharmaceutical, the Pharmaceutical will continue to be fully subsidised, and you must continue to supply it, at the Price throughout the Sole Supply Period.
- (d) Subject to PHARMAC's other rights under this Agreement in relation to the Pharmaceutical, the Pharmaceutical will not be delisted during the Final Transition Period.

1.2 Exclusivity for the Sole Supply Period

- (a) Subject to PHARMAC's other rights under this Agreement in relation to the Pharmaceutical, PHARMAC will not subsidise another supplier's brand of the Pharmaceutical on the Pharmaceutical Schedule at any time during the Sole Supply Period.
- (b) This clause does not prohibit PHARMAC from entering into negotiations or arrangements with, or inviting tenders from, other suppliers to be the sole subsidised supplier of any forms and strengths of the Chemical Entity, if such supply commences after the end of the Sole Supply Period.
- (c) For the avoidance of doubt, PHARMAC may lower the subsidy applicable to a Pharmaceutical during the Final Transition Period as it sees fit, including lowering the subsidy of a Pharmaceutical as a result of the implementation of new tender arrangements.

1.3 Withdrawal of Sole Supply Status

- (a) PHARMAC may withdraw Sole Supply Status in relation to your supply of the Pharmaceutical (in which case clauses 1.1 and 1.2 of this Schedule will no longer apply), by written notice to you at any time during the Sole Supply Period or (in anticipation) during the First Transition Period if:
 - (i) you have failed to notify PHARMAC as required under clause 5.1 of this Schedule;
 - (ii) you are unable to supply the Pharmaceutical in accordance with this Agreement for a period of 30 days;
 - (iii) any Consent for the Pharmaceutical is withdrawn; or

Schedule 5

- (iv) you otherwise fail to supply the Pharmaceutical in accordance with this Agreement.
- (b) In the event that PHARMAC exercises its rights under clause 1.3(a) above in relation to a Pharmaceutical, it may also withdraw Sole Supply Status in relation to your supply of all forms and strengths of that Pharmaceutical (in which case clauses 1.1 and 1.2 of this Schedule will no longer apply), following a recommendation from its clinical advisors, either by the written notice provided under clause 1.3(a) above or by further written notice to you at any time during the Sole Supply Period or (in anticipation) during the First Transition Period.
- (c) Any withdrawal of Sole Supply Status is without prejudice to PHARMAC's rights under clauses 5.2 and 5.3 of this Schedule.

1.4 Suspension of Sole Supply Status

- (a) If, at any time during the Sole Supply Period or (in anticipation) during the First Transition Period, you are unable to meet demand for the Pharmaceutical, or you notify PHARMAC under clause 5.1 of this Schedule of a Potential Out-of-Stock Event, or you otherwise fail to supply the Pharmaceutical in accordance with this Agreement, PHARMAC may suspend Sole Supply Status in relation to your supply of the Pharmaceutical for the period of such inability.
- (b) In the event that PHARMAC exercises its rights under clause 1.4(a) above in relation to a Pharmaceutical, it may also suspend Sole Supply Status in relation to your supply of all forms and strengths of that Pharmaceutical, following a recommendation from its clinical advisors, either by the written notice provided under clause 1.4(a) above or by further written notice to you at any time during the Sole Supply Period or (in anticipation) during the First Transition Period.
- (c) Any suspension of Sole Supply Status is without prejudice to PHARMAC's rights under clauses 5.2 and 5.3 of this Schedule.
- (d) PHARMAC may, at any time, in its sole discretion, notify you of the date on which the suspension of Sole Supply Status under this clause 1.4 ceases and on which date:
 - (i) Sole Supply Status is to be re-implemented in respect of the Pharmaceutical; or
 - (ii) Sole Supply Status is to be withdrawn in accordance with clause 1.3 of this Schedule.

1.5 Subsidy arrangements after the End Date

- (a) Subject to paragraphs (b) and (c) below, the Pharmaceutical is to continue to be the subject of a listing agreement between you and PHARMAC with effect from the End Date, and accordingly:
 - (i) you will cease to have Sole Supply Status for that form and strength of the Chemical Entity; and
 - (ii) the Pharmaceutical will remain listed in Section B of the Pharmaceutical Schedule subject to PHARMAC's standard terms of supply for pharmaceuticals used in the community (as recorded in the then current general listing terms Annex of PHARMAC's standard community contract template).
 - (iii) you may increase the price ex-manufacturer (exclusive of GST) at which you supply the Pharmaceutical to wholesalers and other such distributors on giving PHARMAC

Schedule 5

six months' written notice of that price increase. You may provide PHARMAC with this written notice at any time after, but not before, the End Date;

- (iv) if PHARMAC does not increase the subsidy for the Pharmaceutical to the new price notified under paragraph (a)(iii) above, you may withdraw the Pharmaceutical from supply on not less than six months' prior written notice;
 - (v) if PHARMAC does increase the subsidy for the Pharmaceutical to the new price notified under paragraph (a)(iii) above, you may withdraw the Pharmaceutical from supply on not less than two years' prior written notice (except where the withdrawal is for reasons that PHARMAC considers to be wholly outside of your control, in which case you must first provide to PHARMAC such information as it may require from you in order to satisfy it, in its sole discretion, that you are required to withdraw supply); and
 - (vi) if at the time of providing notice under paragraph (a)(v) above, you advise PHARMAC that you are required to purchase a significant quantity of extra stock of the Pharmaceutical to enable you to continue to supply for the two-year period, and you advise PHARMAC of the total cost of that stock, PHARMAC will either:
 - (A) use reasonable endeavours to enter into an agreement to reimburse you for stock that remains unsold at the end of that two-year period; or
 - (B) release you from your obligations to supply under this paragraph (a).
- (b) PHARMAC may at its sole discretion, with effect from the End Date:
- (i) require that the Pharmaceutical does not continue to be the subject of a listing agreement, in which case PHARMAC will give you written notice not less than three months prior to the End Date; and/or
 - (ii) apply any of the strategies under PHARMAC's then current OPPs to the Pharmaceutical (including delisting the Pharmaceutical after the Final Transition Period).
- (c) In the event PHARMAC applies any of the strategies described in paragraph (b)(ii) above, you may withdraw the Pharmaceutical from supply on not less than six months' prior written notice. You may provide PHARMAC with this written notice at any time after, but not before, the date that the particular strategy takes effect in the Pharmaceutical Schedule.
- (d) Where a Pharmaceutical is designated an ASP, PHARMAC will provide at least two months' written notice of another supplier's brand of the Pharmaceutical being listed on the Pharmaceutical Schedule and a seven-month initial transition period.

2. Consents

2.1 Warranty and indemnity that Consents are held

You warrant that you have, and will maintain, all necessary Consents. If a Consent is not held by you or is withdrawn or the Pharmaceutical is no longer approved for the treatment of any indication for which it is subsidised, then:

- (a) PHARMAC is entitled to terminate this Agreement by 14 days' written notice to you; and

Schedule 5

- (b) whether or not PHARMAC terminates this Agreement under paragraph (a) above, you are to indemnify the Funder for any additional costs incurred by it (or by PHARMAC on its behalf) as a result of that failure to hold all necessary Consents. This clause confers a benefit on (and is enforceable by) the Funder in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

2.2 Changed medicine notification

If the Ministry of Health issues a changed medicine notification in relation to a Pharmaceutical, and as a result a variant of the Pharmaceutical (the “**CMN Pharmaceutical**”) is approved:

- (a) you must immediately notify PHARMAC; and
- (b) PHARMAC may take such action as it considers appropriate in relation to that Pharmaceutical or the CMN Pharmaceutical including (but not limited to):
 - (i) withdrawing Sole Supply Status for the Pharmaceutical;
 - (ii) reviewing the terms of listing of that Pharmaceutical; and
 - (iii) determining whether, and the extent to which, the Funder may subsidise the CMN Pharmaceutical.

3. Price

3.1 Price change

- (a) Subject to clause 3.1(b)(ii), clause 3.1(b)(iii) and clause 3.1(b)(iv) of this Schedule your brand of the Pharmaceutical must be available for supply, and you must supply the Pharmaceutical, at the Price from the 12th day of the month prior to the Start Date, and the Pharmaceutical will be subsidised at the Price from the Start Date.
- (b) In the event your brand of the Pharmaceutical is currently listed on the Pharmaceutical Schedule at the beginning of the First Transition Period:
 - (i) you must ensure that wholesalers and other such distributors change the price at which they supply the Pharmaceutical to the Price on the 12th day of the month prior to the Start Date, and you shall provide price support to wholesalers and other such distributors for a maximum 4 weeks stock on hand (or such other level of stock as agreed between you and PHARMAC) of the Pharmaceutical held at wholesalers and other such distributors, provided that such wholesalers and other such distributors can provide you with stock on hand reports upon request; or
 - (ii) your brand of the Pharmaceutical must be available for supply, and you must supply the Pharmaceutical, at the Price from the 1st day of the month prior to the Start Date, and the Pharmaceutical will be subsidised at the Price from the Start Date (which is conditional upon you having at least 2 months Lead Time for the Pharmaceutical); and
 - (iii) notwithstanding clauses 3.1(b)(i) or (b)(ii) above, if the Price would result in a price increase for your brand of the Pharmaceutical you must supply the Pharmaceutical at the Price from the 22nd day of the month prior to the Start Date, and the Pharmaceutical will be subsidised at the Price from the Start Date; and

Schedule 5

- (iv) notwithstanding clauses 3.1(b)(i), (b)(ii) or (b)(iii) above, PHARMAC may agree a process with you, that results in your brand of the Pharmaceutical, which includes a rebate, being available for supply, and you must supply the Pharmaceutical, at the Price from the 22nd day of the month prior to the Start Date, and you shall provide price support to wholesalers and other such distributors for a maximum 4 weeks stock on hand (or such other level of stock as agreed between you and PHARMAC) of the Pharmaceutical held at wholesalers and other such distributors, provided that such wholesalers and other such distributors can provide you with stock on hand reports upon request.

For the avoidance of doubt if you do not notify PHARMAC in your Tender Bid in the electronic portal which of the options stated in clauses 3.1(b)(i) or (b)(ii) above apply to the Pharmaceutical, clause (b)(i) above shall apply.

- (c) You shall upon request by PHARMAC, provide information on how you intend to manage the price changes stated in clauses 3.1(b)(i) to (b)(iv) above. PHARMAC may, at its sole discretion, publish this information at the time the Tender Item is notified in the Pharmaceutical Schedule in accordance with clause 7.2 of Schedule 3.

3.2 Supply Price

During each of the First Transition Period, the Sole Supply Period and the Final Transition Period, the price at which the Pharmaceutical is supplied by you must not exceed the Price.

3.3 Warranty that Pharmaceutical is supplied at not less than cost price

You warrant that the price at which you are required to supply the Pharmaceutical under this Agreement is greater than the cost price of the Pharmaceutical (including, without limitation, the costs of manufacturing the Pharmaceutical and of supplying it to you for supply in New Zealand).

3.4 No reference pricing during Sole Supply Period

The subsidy payable for the Pharmaceutical will not be reduced as a result of a reduction in the reference price for the therapeutic sub-group of which it is a member during the Sole Supply Period. For the avoidance of doubt, PHARMAC will not be prevented from applying its reference pricing mechanisms to the Pharmaceutical to reduce the subsidy payable for it from the End Date.

3.5 Unsold stock following delisting

You acknowledge and agree that the price at which you are required to supply any Pharmaceutical under this Agreement incorporates, if applicable, any costs incurred by you associated with unsold stock of the Pharmaceutical held by you or any wholesaler or other distributor, after the Pharmaceutical has been delisted or after notification that it will be delisted.

4. Shelf-life of Pharmaceutical

- (a) You will not supply the Pharmaceutical to wholesalers, or other such distributors, or pharmacies if:
 - (i) the remaining shelf-life of the Pharmaceutical is less than six months; or
 - (ii) where the total shelf-life of the Pharmaceutical is less than six months, the remaining shelf-life is less than 75% of the Pharmaceutical's total shelf-life,

Schedule 5

without prior written agreement from PHARMAC.

- (b) If you have an agreement with PHARMAC to supply the Pharmaceutical, where the total shelf-life of the Pharmaceutical is less than six months and the remaining shelf-life is less than 75% of the Pharmaceutical's total shelf-life, and a particular wholesaler, or other such distributor, or pharmacy does not distribute or dispense that Pharmaceutical before its expiry or use-by date, you agree to allow that wholesaler, or other such distributor, or pharmacy to return the Pharmaceutical to you and to provide that wholesaler, or other such distributor, or pharmacy with a credit for the Pharmaceutical.

5. Out-of-stock arrangements

5.1 Notification of Potential Out-of-Stock Event and supply of Alternative Pharmaceutical

- (a) You must notify PHARMAC in writing as soon as you have reasonable cause to believe at any time that you will fail to supply the Pharmaceutical in accordance with this Agreement and, in any event, you must notify PHARMAC if at any time a Potential Out-of-Stock Event occurs, including during the Sole Supply Period or the First Transition Period, in which case PHARMAC may suspend Sole Supply Status in relation to your supply of the Pharmaceutical.
- (b) If a Potential Out-of-Stock Event occurs, or your failure to supply the Pharmaceutical in accordance with this Agreement will result in insufficient stock of the Pharmaceutical being available, then at PHARMAC's option:
 - (i) PHARMAC may implement an arrangement with another supplier to supply an Alternative Pharmaceutical (including an arrangement for back-up supply); or
 - (ii) you must use your best endeavours to procure wholesalers and other such distributors to supply, as soon as practicable, an Alternative Pharmaceutical to pharmacies at the Price, and PHARMAC will subsidise the Alternative Pharmaceutical at the Price.

5.2 General indemnity

You agree to indemnify the Funder if you fail to supply the Pharmaceutical in accordance with this Agreement (other than for reasons that PHARMAC reasonably considers, following discussion with you, to be wholly outside your control) whether as a result of:

- (a) your inability to meet demand for supply of the Pharmaceutical;
- (b) your withdrawal of the Pharmaceutical from supply;
- (c) any failure to have and maintain a Consent as specified in clause 2 of this Schedule;
- (d) any failure to notify PHARMAC in accordance with clause 5.1 above; or
- (e) for any other reason.

This indemnity:

- (f) covers all additional costs, including without limitation all costs (if any) incurred in securing and subsidising an Alternative Pharmaceutical, incurred by the Funder (or by PHARMAC

Schedule 5

on its behalf) as a result of your failure that are additional to any costs specified in clause 5.3; and

- (g) confers a benefit on (and is enforceable by) the Funder in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

5.3 Liquidated damages

- (a) If you fail to supply the Pharmaceutical in accordance with this Agreement (other than for reasons that PHARMAC reasonably considers, following discussion with you, to be wholly outside your control) and:
 - (i) you have not notified PHARMAC under clause 5.1 of this Schedule, then without prejudice to PHARMAC's rights under clause 5.2:
 - (A) subject to paragraph (e) below, you must pay to PHARMAC (for the benefit of PHARMAC and the Funder) liquidated damages for the administrative and/or operational costs incurred by PHARMAC as a result of your failure to supply in the amount of \$50,000 per Pharmaceutical in respect of which you failed to notify PHARMAC; and
 - (B) PHARMAC may withdraw Sole Supply Status in relation to your supply of the Pharmaceutical under clause 1.3 of this Schedule; or
 - (ii) you have notified PHARMAC under clause 5.1 of this Schedule, then without prejudice to PHARMAC's rights under clause 5.2:
 - (A) you are not liable to pay any liquidated damages under this clause 5.3; and
 - (B) if you fail to supply the Pharmaceutical in accordance with this Agreement for more than 30 days, PHARMAC may withdraw Sole Supply Status in relation to your supply of the Pharmaceutical under clause 1.3 of this Schedule.
- (b) If, having notified PHARMAC under clause 5.1 of this Schedule, you remain able to, and you continue to, supply the Pharmaceutical, or an Alternative Pharmaceutical in accordance with clause 5.1(b)(ii) of this Schedule, such that there is no interruption to supply of the Pharmaceutical or of the Alternative Pharmaceutical in accordance with this Agreement, you will not be liable for any costs unless PHARMAC, in its sole discretion, has considered it necessary to enter into an arrangement with an alternative supplier under which PHARMAC has agreed to make a payment to that supplier to ensure continuity of supply, in which case you must indemnify the Funder or PHARMAC for that payment. Such indemnity will be limited to an amount of \$10,000.
- (c) You acknowledge and agree that:
 - (i) the amounts of liquidated damages in this clause represent a reasonable estimate of the administrative and operational costs incurred by PHARMAC (including the use of staff and loss of opportunity as a result of use of staff time, and communication costs), the estimate being based on PHARMAC's previous experience; and
 - (ii) the amounts referred to as liquidated damages are not intended to include any penalty element nor any amount for costs relating to the securing of an Alternative Pharmaceutical, or the subsidisation of an Alternative Pharmaceutical,

Schedule 5

provided that PHARMAC may, in its sole discretion, require you to pay less than the amount specified as liquidated damages if it is satisfied that the actual costs in the particular circumstances are less than the relevant amount so specified.

- (d) Where a Pharmaceutical in respect of which you are liable to pay liquidated damages pursuant to clause 5.3(a)(i)(A) above also has Hospital Supply Status and where you would otherwise be liable to pay the same amount of liquidated damages in respect of any corresponding failure under the terms of such Hospital Supply Status, you will only be required to pay liquidated damages of \$50,000 in total in respect of both supply failures.
- (e) All amounts referred to in this clause are plus GST.

5.4 Failure to supply

References in this clause 5 and elsewhere in this Schedule to your failure or inability to supply the Pharmaceutical in accordance with this Agreement, or your inability to meet demand for the Pharmaceutical, or insufficient stock of the Pharmaceutical being available, include, but are not limited to, circumstances where:

- (a) no stock of the Pharmaceutical is physically held by you or on your behalf in New Zealand;
- (b) the only stock of the Pharmaceutical physically held by you or on your behalf in New Zealand is stock to which clause 4(a)(i) or (ii) of this Schedule applies and no agreement has been reached with PHARMAC in terms of clause 4(a) of this Schedule;
- (c) you fail, directly or indirectly, to ensure that all orders for the Pharmaceutical are filled (without restricting quantities that may be ordered), including in particular where, for reasons attributable (wholly or partly) to you, not all patients for whom the Pharmaceutical is prescribed receive the full amount of the Pharmaceutical they require, or to which they are entitled, under their prescriptions, within the required time frames for dispensing under the then current contract, or notice under section 88 of the New Zealand Public Health and Disability Act 2000, in respect of pharmacy services;
- (d) you fail to supply the Pharmaceutical on and from the Start Date.

5.5 Default interest and recovery costs

If payment of any amount required to be paid by you under this clause 5 is not made by you, in full, by the due date for payment of that amount as notified to you in writing by PHARMAC, then:

- (a) interest will accrue in such sum as remains unpaid at a rate per annum equal to the relevant SME overdraft rate (weighted average rate) of the Reserve Bank of New Zealand plus five percentage points, calculated and compounded on a daily basis, from the due date until such time as the sum due (including interest) is paid in full. This obligation to pay default interest is to arise without the need for a notice or demand from PHARMAC for such default interest; and
- (b) PHARMAC may take any action, including legal action, without first needing to implement the dispute resolution procedure contained in clause 4.2 of Schedule Four, to recover that amount and you agree to pay to PHARMAC actual enforcement costs incurred in relation to that action.

6. Termination and restrictions

6.1 Termination and restrictions for clinical reasons

PHARMAC reserves the right, but only after consultation with you and a relevant medical adviser (being either the Ministry of Health, PTAC or its sub-committees), to:

- (a) terminate this Agreement at any time during the Sole Supply Period or the First Transition Period if the medical adviser determines for clinical reasons that it is no longer appropriate to have either:
 - (i) a sole subsidised supplier of that form and strength of the Chemical Entity; or
 - (ii) the Pharmaceutical as the sole subsidised brand; and/or
- (b) impose at any time during the Sole Supply Period or the Transition Periods restrictions on the prescribing or dispensing of a Pharmaceutical if those restrictions are necessary for clinical reasons.

6.2 Termination following an audit

PHARMAC may terminate the Agreement, or withdraw Sole Supply Status in relation to a Pharmaceutical, at any time during the Sole Supply Period or the Transition Periods, if you fail to remedy any area of non-compliance in accordance with clause 3(b) of Schedule Four.

7. Guarantee

- (a) PHARMAC may require an entity acceptable to it to provide a guarantee (in a form satisfactory to PHARMAC) of your performance obligations under clauses 5.2 and 5.3 of this Schedule including, without limitation, the payment of any sum payable under the indemnity or as liquidated damages pursuant to those clauses for any failure to supply the Pharmaceutical in accordance with this Agreement during the Sole Supply Period.
- (b) The guarantor's liability under such a guarantee will be limited to a total of \$100,000 per Chemical Entity for all claims made by PHARMAC under the guarantee.

Schedule 6: Additional contract terms for Hospital Supply Status

1. Effect of Hospital Supply Status

1.1 Pricing arrangements

- (a) Subject to PHARMAC's other rights under this Agreement and clause 3.1 of this Schedule, on and from the Start Date, during the remainder of the First Transition Period and during the Hospital Supply Status Period, the Pharmaceutical is to be:
 - (i) listed at the Price set out in Section H of the Pharmaceutical Schedule;
 - (ii) sold by you to, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding), at the Price.
- (b) Where the Pharmaceutical is included in an order by a DHB Hospital for pharmaceuticals where the total value (excluding GST) of the order is less than \$1,000, you may invoice the DHB Hospital, in accordance with clause 4.1 below, for the cost of freight for that particular order. For the avoidance of doubt, this clause 1.1(b) does not entitle you to invoice a DHB Hospital for any other costs in relation to the particular order.
- (c) Subject to PHARMAC's other rights under this Agreement in relation to the Pharmaceutical (including under clause 1.6 of this Schedule), and provided that there are no Alternative Pharmaceuticals listed in Section H of the Pharmaceutical Schedule at the start of the Final Transition Period, the Pharmaceutical:
 - (i) is to continue to be listed, sold and purchased at the Price referred to in clauses 1.1(a)(i) and (ii) above during the Final Transition Period and beyond; and
 - (ii) is not to be delisted during the Final Transition Period.

1.2 Supplier for Hospital Supply Status Period

- (a) Subject to:
 - (i) PHARMAC's other rights under this Agreement in relation to the Pharmaceutical; and
 - (ii) clauses 1.4 and 1.5 of this Schedule relating to the DV Limit for the Pharmaceutical,

your brand of the Pharmaceutical will be the brand listed in Section H of the Pharmaceutical Schedule, and purchased by DHB Hospitals at any time during the Hospital Supply Status Period, as the brand having Hospital Supply Status.

- (b) This clause does not prohibit PHARMAC (on behalf of DHB Hospitals) from entering into negotiations or arrangements with, or inviting tenders from, other suppliers to be the supplier of any forms and strengths of the particular Pharmaceutical with Hospital Supply Status, or a relevant Alternative Pharmaceutical having a status equivalent to Hospital Supply Status, if notification of such an arrangement (once finalised) occurs, and such supply commences, after the end of the Hospital Supply Status Period.

Schedule 6

1.3 DV Pharmaceuticals

- (a) PHARMAC may amend the relevant list of DV Pharmaceuticals specified in Section H of the Pharmaceutical Schedule, from time to time, in accordance with this clause 1.3, whereby:
 - (i) PHARMAC is only to remove a pharmaceutical listed as a DV Pharmaceutical if PHARMAC:
 - (A) has first obtained your agreement; or
 - (B) has a direction from Medsafe or its successor, or a recommendation from PTAC or its sub-committees, based on a significant clinical issue;
 - (ii) PHARMAC may add a pharmaceutical to the relevant list of DV Pharmaceuticals specified in Section H of the Pharmaceutical Schedule if such pharmaceutical is identified as a DV Pharmaceutical during the Hospital Supply Status Period or the First Transition Period by PHARMAC following a recommendation from PTAC or its sub-committees.
- (b) PHARMAC must consult with you prior to the removal of any pharmaceutical from the relevant list of DV Pharmaceuticals specified in Section H of the Pharmaceutical Schedule.

1.4 DV Limit

- (a) PHARMAC may, from time to time during the Hospital Supply Status Period or the First Transition Period, amend the DV Limit of the Pharmaceutical following what PHARMAC considers to be appropriate consultation with PTAC or its sub-committees, provided that PHARMAC may only increase the DV Limit without your prior agreement if it has a direction from Medsafe or its successor, or a recommendation from PTAC or its sub-committees, based on a significant clinical issue.
- (b) Subject to clause 1.5 of this Schedule you acknowledge and agree that while you have Hospital Supply Status:
 - (i) DHB Hospitals may purchase DV Pharmaceuticals at any time within the First Transition Period and Final Transition Period without any requirement to comply with the DV Limit;
 - (ii) provided that DHB Hospitals collectively do not exceed the National DV Limit for the relevant Pharmaceutical, a DHB Hospital may purchase DV Pharmaceuticals at any time within the Hospital Supply Status Period;
 - (iii) without derogating from any other rights available to PHARMAC or DHB Hospitals under this Agreement or otherwise, if you fail to supply the Pharmaceutical in accordance with this Agreement (other than for a reason that PHARMAC reasonably considers, following discussion with you, to be wholly outside your control) within the Hospital Supply Status Period, then the relevant DHB Hospital is not required to comply with the DV Limit for the Pharmaceutical during that period of non-supply and the calendar month during which that non-supply occurred will be excluded in any review of the DV Limit in accordance with clause 1.5 below;
 - (iv) if a DHB Hospital's usage of any DV Pharmaceuticals, in percentage terms, reaches or exceeds the percentage at which the Individual DV Limit is set for the relevant Pharmaceutical, that DHB Hospital may negotiate with you to agree to

Schedule 6

vary the application of the Individual DV Limit to the DHB Hospital in respect of particular patients with exceptional needs.

1.5 DV Limit Compliance

(a) For the purposes of this clause 1.5:

(i) **“Relevant Period”** means:

- (A) the initial period starting on the day that the Hospital Supply Status Period begins up to and including 30 June 2021; or
- (B) for a Pharmaceutical listed on or prior to 30 June 2021, the period commencing on 1 July 2021 and ending on 30 June 2022 or, for a Pharmaceutical listed after 30 June 2022, the initial period starting on the date that the Hospital Supply Status Period begins up to and including 30 June 2022; or
- (C) for a Pharmaceutical listed on or prior to 30 June 2022, the period commencing on 1 July 2022 and ending on 30 June 2023, or, for a Pharmaceutical listed after 30 June 2022, the initial period starting on the date that the Hospital Supply Status Period begins up to and including 30 June 2023,

provided that for the purposes of carrying out the calculations in this clause 1.5 any calendar months that fall within those periods when there is any failure to supply the Pharmaceutical in accordance with this Agreement will be excluded.

(ii) **“Actual National DV Limit Indicator”** means, for a particular Pharmaceutical in any Relevant Period, such sum, expressed as a percentage, as is equal to:

$$\frac{\text{Total DV Pharmaceuticals Volume}}{\text{Total DV Pharmaceuticals Volume} + \text{Total Pharmaceutical Volume}} \times 100;$$

(iii) **“Total DV Pharmaceuticals Volume”** means, for a particular Pharmaceutical in any Relevant Period, the total number of Units of all DV Pharmaceuticals of the relevant Pharmaceutical with Hospital Supply Status purchased by DHB Hospitals, as calculated by PHARMAC, following your request in accordance with clause 1.5(b) below, on the basis of the data extracted by PHARMAC from the electronic records used by it; and

(iv) **“Total Pharmaceutical Volume”** means, for a particular Pharmaceutical with Hospital Supply Status in any Relevant Period, the total number of Units of that Pharmaceutical purchased by DHB Hospitals, as calculated by PHARMAC following your request in accordance with clause 1.5(b) below, on the basis of the data extracted by PHARMAC from the electronic records used by it.

(b) If you reasonably believe that DHB Hospitals' percentage usage of DV Pharmaceuticals collectively exceeds the National DV Limit for a particular Pharmaceutical, you may at any time, but not more often than three-monthly, request that PHARMAC carry out calculations in accordance with the procedure set out in this clause 1.5 for the proportion of the Relevant Period that has passed to the date of your request, and PHARMAC may, in its discretion, agree to carry out the calculations for the Total DV Pharmaceuticals Volume, the Total Pharmaceutical Volume and the Actual National DV Limit Indicator, provided that if PHARMAC refuses to carry out such calculations, it will provide you with the reasons for refusing to do so.

Schedule 6

- (c) It is acknowledged, for the avoidance of doubt, that if the Actual National DV Limit Indicator is less than the National DV Limit specified for the relevant Chemical Entity in Schedule Two and the Electronic Portal then, regardless of whether an individual DHB Hospital's percentage usage of DV Pharmaceuticals has exceeded the Individual DV Limit percentage for that Pharmaceutical, PHARMAC may decide, in its sole discretion, not to take any further action.
- (d) If the Actual National DV Limit Indicator is greater than the National DV Limit, PHARMAC will use its best endeavours to identify which individual DHB Hospitals' percentage usage of DV Pharmaceuticals have exceeded the Individual DV Limit percentage for that Pharmaceutical. You acknowledge that if PHARMAC cannot do this on the basis of information held by it, it may be necessary to obtain any further information you can provide. If neither of us can establish or quantify non-compliance by an individual DHB Hospital with the Individual DV Limit, then you acknowledge that PHARMAC may not be able to calculate for you, and you may not be able to obtain, financial compensation under clause 1.5(f)(ii) below. In that event you acknowledge, for the avoidance of doubt, that PHARMAC is not liable to pay any financial compensation on behalf of the relevant DHB.
- (e) If an individual DHB Hospital's percentage usage of DV Pharmaceuticals has exceeded the Individual DV Limit percentage for that Pharmaceutical as a result of DV Pharmaceutical usage that has been agreed to by you in accordance with clause 1.4(b)(iv) above then PHARMAC will not take any further action.
- (f) Subject to paragraph (e) above, PHARMAC will address the issue of non-compliance with any individual DHB Hospital or DHB Hospitals identified in accordance with paragraph (d) above by:
- (i) using its best endeavours to ensure that the relevant DHB Hospital complies with the DV Limit for that Pharmaceutical in the remainder of that Relevant Period (if applicable) and in any subsequent Relevant Period or Relevant Periods; and/or
 - (ii) following the end of a Relevant Period, and only once in respect of any Relevant Period, determining what financial compensation is payable by that DHB for its contribution towards exceeding the National DV Limit (where PHARMAC is able to quantify this based on the information available to it), being the greater amount of \$1,000 or such sum as is equal to:

DHB Deviation x Adjusted Price

where:

(A) **"Adjusted Price"** means the Unit Price, for a particular Pharmaceutical in any Relevant Period, divided by two;

(B) **"DHB Deviation"** is equal to:

$(\text{Total Contribution for DHB}_x \div \text{Total Contribution for Exceeding DHBs}) \times \text{Total DV Pharmaceuticals Volume in Excess of DV Limit}$

where:

"Total Contribution for DHB_x" means, for:

(a) a particular Pharmaceutical; and

Schedule 6

(b) a particular DHB Hospital,

in any Relevant Period, the total number of Units of all DV Pharmaceuticals of the relevant Pharmaceutical with Hospital Supply Status purchased by that DHB Hospital minus the number of Units of DV Pharmaceuticals that corresponds to the percentage of the Individual Total Market Volume represented by the Individual DV Limit percentage for that Pharmaceutical, as calculated by PHARMAC for such Relevant Period on the basis of the data extracted by PHARMAC from the electronic records used by it;

“Total Contribution for Exceeding DHBs” means, for a particular Pharmaceutical in any Relevant Period, the sum of the Total Contribution for DHB_x for each DHB Hospital identified by PHARMAC in accordance with paragraph (d) above as exceeding the Individual DV Limit for that Relevant Period, as calculated by PHARMAC for such Relevant Period on the basis of the data extracted by PHARMAC from the electronic records used by it;

“Total DV Pharmaceuticals Volume in Excess of DV Limit” means, for a particular Pharmaceutical in any Relevant Period, the total number of Units of all DV Pharmaceuticals of the relevant Pharmaceutical with Hospital Supply Status purchased by DHB Hospitals in excess of the National DV Limit for that Relevant Period, as calculated by PHARMAC on the basis of the data extracted by PHARMAC from the electronic records used by it;

- (iii) PHARMAC will notify you and the relevant DHB in writing of any DV Limit compensation payable in accordance with clause 1.5(f)(ii) above. You may then invoice the relevant DHB for the amount of DV Limit compensation payable, as calculated and notified to you by PHARMAC. You must provide to PHARMAC a copy of any such invoice, and evidence of any payment received from the DHB in respect of that invoice, within 10 business days of sending such invoice or receiving such payment, respectively.
- (iv) If you have not received the amount of any DV Limit compensation payable in accordance with clause 1.5(f)(ii) above from the DHB within 60 business days of invoicing the DHB for the amount owing, then you may take such further actions (other than ceasing to supply) directly with the DHB as you consider appropriate to recover the amount owing to you. In that event you acknowledge, for the avoidance of doubt, that PHARMAC is not liable to pay any financial compensation on behalf of the relevant DHB.
- (v) For the avoidance of doubt, for the purposes of calculating the Total DV Pharmaceuticals Volume, the Total Contribution for DHB_x and the Total DV Pharmaceuticals Volume in Excess of DV Limit in this clause 1.5, if a pharmaceutical is added to, or removed from, the list of DV Pharmaceuticals during the Relevant Period in accordance with clause 1.3 of this Schedule, then only the number of Units of that pharmaceutical purchased by DHB Hospitals during the portion of the Relevant Period in which that pharmaceutical was a DV Pharmaceutical are to be included in those calculations.

1.6 Supply arrangements after the End Date

- (a) Subject to paragraphs (b) and (c) below, the Pharmaceutical is to continue to be the subject of a listing agreement between you and PHARMAC with effect from the End Date, and accordingly:

Schedule 6

- (i) you will cease to have Hospital Supply Status for that form and strength of the Pharmaceutical (in the case of any Pharmaceutical that is not a Medical Device); or
 - (ii) you will cease to have Hospital Supply Status in respect of an item conforming to the individual specifications described for the item in the product list in clause 2 of Schedule Two which the Pharmaceutical was listed as conforming with (in the case of any Pharmaceutical that is a Medical Device); and
 - (iii) the Pharmaceutical will remain listed in Section H of the Pharmaceutical Schedule subject to PHARMAC's standard terms of supply for pharmaceuticals used in DHB Hospitals (as recorded in the then current general listing terms Annex of PHARMAC's standard hospital contract template);
 - (iv) you may increase the price (exclusive of GST) at which you supply the Pharmaceutical to, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding), on giving PHARMAC six months' written notice of that price increase. You may provide PHARMAC with this written notice at any time after, but not before, the End Date;
 - (v) you may withdraw the Pharmaceutical from supply on not less than two years' prior written notice (except where the withdrawal is for reasons that PHARMAC considers to be wholly outside of your control, in which case you must first provide to PHARMAC such information as it may require from you in order to satisfy it, in its sole discretion, that you are required to withdraw supply); and
 - (vi) if at the time of providing notice under paragraph (a)(iv) above, you advise PHARMAC that you are required to purchase a significant quantity of extra stock of the Pharmaceutical to enable you to continue to supply for the two-year period, and you advise PHARMAC of the total cost of that stock, PHARMAC will either:
 - (A) use reasonable endeavours to enter into an agreement to reimburse you for stock that remains unsold at the end of that two-year period; or
 - (B) release you from your obligations to supply under this paragraph (a).
- (b) PHARMAC may, at its sole discretion, with effect from the End Date:
- (i) require that the Pharmaceutical does not continue to be the subject of a listing agreement, in which case PHARMAC will give you written notice not less than three months prior to the End Date; and/or
 - (ii) apply any of the strategies under PHARMAC's then current OPPs to the Pharmaceutical (including delisting the Pharmaceutical after the Final Transition Period).
- (c) In the event PHARMAC applies any of the strategies described in paragraph (b)(ii) above, you may withdraw the Pharmaceutical from supply on not less than six months' prior written notice. You may provide PHARMAC with this written notice at any time after, but not before, the date that the particular strategy takes effect in the Pharmaceutical Schedule.

Schedule 6

1.7 Withdrawal of Hospital Supply Status

- (a) PHARMAC may withdraw Hospital Supply Status in relation to your supply of the Pharmaceutical (in which case clauses 1.1, 1.2 and 1.3 of this Schedule will no longer apply), by written notice to you at any time during the Hospital Supply Status Period or (in anticipation) during the First Transition Period if:
 - (i) you have failed to notify PHARMAC as required under clause 7.1 of this Schedule;
 - (ii) you fail, for a period of 30 days, to supply the Pharmaceutical in accordance with this Agreement to any of the DHB Hospitals including to, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding);
 - (iii) any Consent for the Pharmaceutical required under clause 2 of this Schedule is withdrawn;
 - (iv) you have failed to comply with clause 6 of this Schedule on more than one occasion; or
 - (v) you otherwise fail to supply the Pharmaceutical in accordance with this Agreement.
- (b) In the event that PHARMAC exercises its rights under clause 1.7(a) above in relation to a Pharmaceutical, it may also withdraw Hospital Supply Status in relation to your supply of all forms and strengths of that Pharmaceutical (or your supply of all other Medical Devices under this Agreement, where PHARMAC has exercised its rights under clause 1.7(a) above in respect of a Medical Device) (in which case clauses 1.1, 1.2 and 1.3 of this Schedule will no longer apply), following a recommendation from its clinical advisors, either by the written notice provided under clause 1.7(a) above or by further written notice to you at any time during the Hospital Supply Period or (in anticipation) during the First Transition Period.
- (c) Any withdrawal of Hospital Supply Status is without prejudice to PHARMAC's rights under clauses 7.2 and 7.3 of this Schedule.

1.8 Suspension of Hospital Supply Status

- (a) If, at any time during the Hospital Supply Status Period or (in anticipation) during the First Transition Period, you are unable to meet demand for the Pharmaceutical, or you notify PHARMAC under clause 7.1 of this Schedule of a Potential Out-of-Stock Event, or you otherwise fail to supply the Pharmaceutical in accordance with this Agreement, then:
 - (i) PHARMAC may suspend Hospital Supply Status in relation to your supply of the Pharmaceutical for the period of such inability; and
 - (ii) DHB Hospitals may purchase DV Pharmaceuticals during the period when Hospital Supply Status is suspended without the requirement to comply with the DV Limit for the relevant Pharmaceutical.
- (b) In the event that PHARMAC exercises its rights under clause 1.8(a) above in relation to a Pharmaceutical, it may also suspend Hospital Supply Status in relation to your supply of all forms and strengths of that Pharmaceutical (or your supply of all other

Schedule 6

Medical Devices under this Agreement, where PHARMAC has exercised its rights under clause 1.8(a) above in respect of a Medical Device), following a recommendation from its clinical advisors, either by the written notice provided under clause 1.8(a) above or by further written notice to you at any time during the Hospital Supply Period or (in anticipation) during the First Transition Period.

- (c) Any suspension of Hospital Supply Status is without prejudice to PHARMAC's rights under clauses 7.2 and 7.3 of this Schedule.
- (d) PHARMAC may, at any time, in its sole discretion, notify you of the date on which the suspension of Hospital Supply Status under this clause 1.8 ceases and on which date:
 - (i) Hospital Supply Status is to be re-implemented in respect of the Pharmaceutical;
or
 - (ii) Hospital Supply Status is to be withdrawn in accordance with clause 1.7 of this Schedule.

2. Consents

2.1 Warranty and indemnity that Consents are held

You warrant that you have, and will maintain, all necessary Consents. If a Consent is not held by you or is withdrawn or the Pharmaceutical is no longer approved for the treatment of any indication for which it is listed in Section H of the Pharmaceutical Schedule, then:

- (a) PHARMAC is entitled to terminate this Agreement by 14 days' written notice to you; and
- (b) whether or not PHARMAC terminates this Agreement under paragraph (a) above, you are to indemnify the Funder for any additional costs incurred by it (or by PHARMAC on its behalf) as a result of that failure to hold all necessary Consents. This clause confers a benefit on (and is enforceable by) the Funder in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

2.2 Changed medicine notification

If the Ministry of Health issues a changed medicine notification in relation to a Pharmaceutical, and as a result a variant of the Pharmaceutical (the "**CMN Pharmaceutical**") is approved:

- (a) you must immediately notify PHARMAC; and
- (b) PHARMAC may take such action as it considers appropriate in relation to that Pharmaceutical or the CMN Pharmaceutical including (but not limited to):
 - (i) withdrawing Hospital Supply Status for the Pharmaceutical;
 - (ii) reviewing the terms of listing of that Pharmaceutical; and
 - (iii) determining whether, and the extent to which, DHB Hospitals may purchase the CMN Pharmaceutical.

Schedule 6

3. Price

3.1 Price change

- (a) Subject to clause 3.1(b)(ii), clause 3.1(b)(iii) and clause 3.1(b)(iv) of this Schedule, you must change the price at which you supply the Pharmaceutical to, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding), to the Price with effect from the 12th day of the month prior to the Start Date. If your brand of the Pharmaceutical is not listed on the Pharmaceutical Schedule at the beginning of the First Transition Period, it must be available for supply or sale, and you must supply or sell it, at the Price on and from the 12th day of the month prior to the Start Date.
- (b) In the event your brand of the Pharmaceutical is currently listed on the Pharmaceutical Schedule at the beginning of the First Transition Period:
- (i) you must ensure that wholesalers and other such distributors change the price at which they supply the Pharmaceutical to the Price on the 12th day of the month prior to the Start Date, and you shall provide price support to wholesalers and other such distributors for a maximum 4 weeks stock on hand (or such other level of stock as agreed between you and PHARMAC) of the Pharmaceutical held at wholesalers and other such distributors, provided that such wholesalers and other such distributors can provide you with stock on hand reports upon request; or
 - (ii) your brand of the Pharmaceutical must be available for supply, and you must supply the Pharmaceutical, at the Price from the 1st day of the month prior to the Start Date, and the Pharmaceutical will be subsidised at the Price from the Start Date (which is conditional upon you having at least 2 months Lead Time for the Pharmaceutical); and
 - (iii) notwithstanding clauses 3.1(b)(i) or (b)(ii) above, if the Price would result in a price increase for your brand of the Pharmaceutical you must supply the Pharmaceutical at the Price from the 22nd day of the month prior to the Start Date, and the Pharmaceutical will be subsidised at the Price from the Start Date; and
 - (iv) notwithstanding clauses 3.1(b)(i), (b)(ii) or (b)(iii) above, PHARMAC may agree a process with you, that results in your brand of the Pharmaceutical, which includes a rebate, being available for supply, and you must supply the Pharmaceutical, at the Price from the 22nd day of the month prior to the Start Date, and you shall provide price support to wholesalers and other such distributors for a maximum 4 weeks stock on hand (or such other level of stock as agreed between you and PHARMAC) of the Pharmaceutical held at wholesalers and other such distributors, provided that such wholesalers and other such distributors can provide you with stock on hand reports upon request.

For the avoidance of doubt if you do not notify PHARMAC in your Tender Bid in the electronic portal which of the options stated in clauses 3.1(b)(i) or (b)(ii) above apply to the Pharmaceutical, clause (b)(i) above shall apply.

- (c) You shall upon request by PHARMAC, provide information on how you intend to manage the price changes stated in clauses 3.1(b)(i) to (b)(iv) above. PHARMAC may, at its sole discretion, publish this information at the time the Tender Item is notified in the Pharmaceutical Schedule in accordance with clause 7.2 of Schedule 3.

Schedule 6

3.2 Supply price

Subject to clause 3.1 of this Schedule, during each of the First Transition Period, the Hospital Supply Status Period and the Final Transition Period, if applicable in accordance with clause 1.1(b) of this Schedule, the price at which the Pharmaceutical is supplied by you to, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding), must not exceed the Price.

3.3 Supply at lower price

Notwithstanding clauses 3.1 and 3.2 above but subject to clause 3.4 below, you may supply the Pharmaceutical to, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding) at a price lower than the Price, provided that where you decide to supply the Pharmaceutical in respect of any one or more DHB Hospital(s) at a price lower than the Price, you must supply the Pharmaceutical at the same lower price to all DHB Hospitals in respect of which you supply the Pharmaceutical, in which case that lower price will be deemed to be the Price of that Pharmaceutical for the purposes of this Agreement.

3.4 Warranty that Pharmaceutical is supplied at not less than cost price

You warrant that the Price at which you are required to supply the Pharmaceutical under this Agreement is greater than the cost price of the Pharmaceutical (including, without limitation, the costs of manufacturing the Pharmaceutical and of supplying it to you for supply in New Zealand).

3.5 Unsold stock following delisting

You acknowledge and agree that the price at which you are required to supply any Pharmaceutical under this Agreement incorporates, if applicable, any costs incurred by you associated with unsold stock of the Pharmaceutical held by you or any wholesaler or other distributor, after the Pharmaceutical has been delisted or after notification that it will be delisted.

4. Invoicing and Payment

4.1 Invoice

You are to invoice DHB Hospitals at the end of each month, but no later than the tenth day following the month to which the invoice in respect of the Pharmaceutical relates, specifying for the Pharmaceutical supplied during that month:

- (a) your delivery note reference number;
- (b) the particular DHB's purchase order reference number (if applicable);
- (c) the net amount payable in respect of the Pharmaceutical supplied to that DHB in accordance with this Agreement;
- (d) full details in respect of the Pharmaceutical supplied to that DHB in accordance with this Agreement, including the:
 - (i) DHB's item codes;

Schedule 6

- (ii) quantity of the Pharmaceutical supplied;
 - (iii) price of the Pharmaceutical;
 - (iv) cost of freight for orders that included the Pharmaceutical (only where applicable under clause 1.1(b) above);
 - (v) total cost for the total amount of the Pharmaceutical supplied; and
- (e) any other information that DHB Hospital requires you to supply.
- (f) The provisions of Clause 4.1 do not apply to the extent that both parties have agreed to alternative or varied invoicing arrangements in respect of a particular Pharmaceutical.

4.2 Payment

- (a) Provided that the Pharmaceutical has been supplied in accordance with this Agreement, and the particular DHB receives an invoice in accordance with clause 4.1 above, payment by the DHB Hospital to you of the amount required to be paid by it is expected to occur:
- (i) by electronic funds transfer or such other method of payment as is designated by that DHB Hospital;
 - (ii) on the 20th day of the month following the month to which the invoice for the Pharmaceutical relates, or, if the 20th day of the month is not a business day, then on the next business day following the 20th of the month.
- (b) Where you invoice a DHB Hospital later than the tenth day following the month to which the invoice in respect of the Pharmaceutical relates then, provided that the Pharmaceutical has been supplied in accordance with this Agreement, and the invoice otherwise accords with clause 4.1 above, payment by the DHB Hospital to you of the amount required to be paid by it is expected to occur:
- (i) by electronic funds transfer or such other method of payment as is designated by that DHB Hospital;
 - (ii) on the 20th day of the month following the month in which you invoice the DHB for the Pharmaceutical, or, if the 20th day of the month is not a business day, then on the next business day following the 20th of the month.

4.3 Future payment

- (a) A particular DHB Hospital's failure to dispute any invoice prior to payment does not prejudice that DHB Hospital's right subsequently to dispute the correctness of such an invoice, nor its ability to recover any amount of overpayment from you.
- (b) A DHB Hospital may withhold, deduct or set off the amount of any overpayment or any amount recoverable by that DHB Hospital from you under this Agreement from any future amount owing to you.

Schedule 6

4.4 Contracts Privity

This clause 4 confers a benefit on (and is enforceable by) DHB Hospitals in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

5. Emergency and disaster supply

In the event of an emergency or disaster affecting any DHB Hospital, or an emergency or disaster on a national level, you will use your best endeavours to provide such quantities of the Pharmaceutical as are required by the relevant DHB Hospital(s). Your obligations under this clause include, but are not limited to, using your best endeavours to:

- (a) source the Pharmaceutical from other suppliers and distributors within New Zealand; and
- (b) source the Pharmaceutical or a pharmaceutical that is the same brand as the Pharmaceutical from any overseas manufacturer, supplier or distributor, and air-freighting that stock to New Zealand (for which the relevant DHB Hospital will meet all reasonable costs) for supply, either under Medsafe's explicit consent to import, sell or distribute the Pharmaceutical or under section 29 of the Medicines Act 1981, to DHB Hospitals.

6. Defective and short-dated Pharmaceuticals

6.1 Pharmaceutical recall

- (a) In the event that you are required by the Ministry of Health or any other authorities to recall the Pharmaceutical or a particular batch of the Pharmaceutical, you will notify PHARMAC and the relevant DHB Hospitals immediately you become aware of the need to recall the Pharmaceutical or that batch of the Pharmaceutical.
- (b) You will use your best endeavours to provide replacement Pharmaceuticals to DHB Hospitals as soon as possible.
- (c) If you fail to provide replacement Pharmaceuticals or an Alternative Pharmaceutical within what DHBs consider to be a reasonable time frame, then DHB Hospital(s) may purchase an Alternative Pharmaceutical elsewhere. Any reasonable additional costs incurred by DHB Hospital(s) in purchasing such an Alternative Pharmaceutical will be met by you on demand by PHARMAC or the DHB Hospital(s) and will be recoverable from you as a debt due to PHARMAC and to the DHB Hospital(s), as applicable.
- (d) In the event that the Pharmaceutical or a particular batch of the Pharmaceutical is recalled as contemplated by paragraph (a) above, you shall immediately refund to the relevant DHB Hospitals all money paid by them to you for or on account of the Pharmaceutical or that batch of the Pharmaceutical and such money will be recoverable from you as a debt due to the relevant DHB Hospitals, unless you have provided a replacement Pharmaceutical to the relevant DHB Hospitals' satisfaction.
- (e) This clause confers a benefit on (and is enforceable by) DHB Hospitals in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

6.2 Shelf-life of Pharmaceutical

- (a) You will not supply the Pharmaceutical if:

Schedule 6

- (i) the remaining shelf-life of the Pharmaceutical is less than six months; or
 - (ii) where the total shelf-life of the Pharmaceutical is less than six months, the remaining shelf-life is less than 75% of the Pharmaceutical's total shelf-life,
- without prior agreement from the relevant DHB Hospital.
- (b) If you have an agreement with the relevant DHB Hospital to supply the Pharmaceutical, where the total shelf-life of the Pharmaceutical is less than six months and the remaining shelf-life is less than 75% of the Pharmaceutical's total shelf-life, and that DHB Hospital does not use the Pharmaceutical before its expiry or use-by date, you agree to allow that DHB Hospital to return the Pharmaceutical to you and to provide that DHB Hospital with a credit for the Pharmaceutical.
 - (c) This clause confers a benefit on (and is enforceable by) DHB Hospitals in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

7. Out-of-stock arrangements

7.1 Notification of Potential Out-of-Stock Event and supply of Alternative Pharmaceutical

- (a) You must notify PHARMAC in writing as soon as you have reasonable cause to believe at any time that you will fail to supply the Pharmaceutical in accordance with this Agreement and, in any event, you must notify PHARMAC and the relevant DHB Hospitals if at any time a Potential Out-of-Stock Event occurs, including during the Hospital Supply Period or the First Transition Period.
- (b) If a Potential Out-of-Stock Event occurs, or your failure to supply the Pharmaceutical in accordance with this Agreement will result in insufficient stock of the Pharmaceutical being available, then at PHARMAC's option:
 - (i) PHARMAC may implement an arrangement with another supplier to supply an Alternative Pharmaceutical (including an arrangement for back-up supply); and/or
 - (ii) you must use your best endeavours to procure, as soon as practicable, an Alternative Pharmaceutical for supply to, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding), at the Price, and if you are unable to do so you will pay to DHB Hospitals any additional costs incurred by DHB Hospitals as a result of the purchase price for the Alternative Pharmaceutical being higher than the Price.

7.2 General indemnity

You agree to indemnify DHB Hospitals and PHARMAC if you fail to supply the Pharmaceutical in accordance with this Agreement (other than for reasons that PHARMAC reasonably considers, following discussion with you, to be wholly outside your control) whether as a result of:

- (a) your inability to meet demand for supply of the Pharmaceutical;
- (b) your withdrawal of the Pharmaceutical from supply;

Schedule 6

- (c) any failure to have and maintain a Consent as specified in clause 2 of this Schedule;
- (d) any failure to notify PHARMAC in accordance with clause 7.1 above; or
- (e) for any other reason.

This indemnity:

- (f) covers all additional costs, including without limitation all costs (if any) incurred in securing and purchasing an Alternative Pharmaceutical, incurred by DHB Hospitals (or by PHARMAC on their behalf) as a result of your failure that are additional to any costs specified in clause 7.3; and
- (g) confers a benefit on (and is enforceable by) DHB Hospitals in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

7.3 Liquidated damages

- (a) If you fail to supply the Pharmaceutical in accordance with this Agreement (other than for reasons that PHARMAC reasonably considers, following discussion with you, to be wholly outside your control) and:
 - (i) you have not notified PHARMAC and the relevant DHB Hospitals under clause 7.1 of this Schedule, then without prejudice to PHARMAC's and the relevant DHB Hospitals' rights under clause 7.2 above, but subject to paragraph (e) below, you must pay to PHARMAC (for the benefit of PHARMAC and DHB Hospitals) liquidated damages for the administrative and/or operational costs incurred by PHARMAC and DHB Hospitals as a result of your failure to supply in the amount of \$50,000 per Pharmaceutical in respect of which you failed to notify PHARMAC; or
 - (ii) you have notified PHARMAC and the relevant DHB Hospitals under clause 7.1 of this Schedule, then without prejudice to PHARMAC's and the relevant DHB Hospitals' rights under clause 7.2 above you are not liable to pay any liquidated damages under this clause 7.3.
- (b) If, having notified PHARMAC and the relevant DHB Hospitals under clause 7.1 of this Schedule, you remain able to, and you continue to, supply the Pharmaceutical, or an Alternative Pharmaceutical in accordance with clause 7.1(b)(ii) of this Schedule, such that there is no interruption to supply of the Pharmaceutical or of the Alternative Pharmaceutical in accordance with this Agreement, you will not be liable for any costs unless PHARMAC, in its sole discretion, has considered it necessary to enter into an arrangement with an alternative supplier under which PHARMAC or the relevant DHB Hospitals have agreed to make a payment to that supplier to ensure continuity of supply, in which case you must indemnify the relevant DHB Hospitals and PHARMAC for that payment. Such indemnity will be limited to an amount of \$10,000 per Pharmaceutical.
- (c) You acknowledge and agree that:
 - (i) the amounts of liquidated damages in this clause represent a reasonable estimate of the administrative and operational costs incurred by PHARMAC and DHB Hospitals (including the use of staff and loss of opportunity as a result of use of staff time, and communication costs), the estimate being based on PHARMAC's and DHB Hospitals' previous experience; and

Schedule 6

- (ii) the amounts referred to as liquidated damages are not intended to include any penalty element nor any amount for costs relating to the securing of an Alternative Pharmaceutical, or the purchasing of an Alternative Pharmaceutical,

provided that PHARMAC may, in its sole discretion, require you to pay less than the amount specified as liquidated damages if it is satisfied that the actual costs in the particular circumstances are less than the relevant amount so specified.

- (d) Where a Pharmaceutical in respect of which you are liable to pay liquidated damages pursuant to clause 7.3(a)(i) above also has Sole Supply Status and where you would otherwise be liable to pay the same amount of liquidated damages in respect of any corresponding failure under the terms of such Sole Supply Status, you will only be required to pay liquidated damages of \$50,000 in total in respect of both supply failures.
- (e) All amounts referred to in this clause are plus GST.

7.4 Failure to supply

References in this clause 7 and elsewhere in this Schedule to your failure or inability to supply the Pharmaceutical in accordance with this Agreement, or your inability to meet demand for supply of the Pharmaceutical, or insufficient stock of the Pharmaceutical being available, include, but are not limited to, circumstances where:

- (a) no stock of the Pharmaceutical is physically held by you or on your behalf in New Zealand;
- (b) the only stock of the Pharmaceutical physically held by you or on your behalf in New Zealand is stock to which clause 6.2(a)(i) or (ii) of this Schedule applies and no agreement has been reached with the relevant DHB Hospital in terms of clause 6.2(a) of this Schedule;
- (c) you fail, directly or indirectly, to ensure that all orders for the Pharmaceutical are filled (without restricting quantities that may be ordered), including in particular where not all patients for whom the Pharmaceutical is prescribed receive the full amount of the Pharmaceutical they require, or to which they are entitled, under their prescriptions, without delay;
- (d) you fail to supply the Pharmaceutical on and from the Start Date.

7.5 Default interest and recovery costs

If payment of any amount required to be paid by you under this clause 7 is not made by you, in full, by the due date for payment of that amount as notified to you in writing by PHARMAC, then:

- (a) interest will accrue in such sum as remains unpaid at a rate per annum equal to the relevant SME overdraft rate (weighted average rate) of the Reserve Bank of New Zealand plus five percentage points, calculated and compounded on a daily basis, from the due date until such time as the sum due (including interest) is paid in full. This obligation to pay default interest is to arise without the need for a notice or demand from PHARMAC for such default interest; and
- (b) PHARMAC may take any action, including legal action, without first needing to implement the dispute resolution procedure contained in clause 4.2 of Schedule Four, to recover that amount and you agree to pay to PHARMAC actual enforcement costs incurred in relation to that action.

Schedule 6

8. Termination and restrictions

8.1 Termination and restrictions for clinical reasons

PHARMAC reserves the right, but only after consultation with you and a relevant medical adviser (being either the Ministry of Health, PTAC or a sub-committee of PTAC), to:

- (a) terminate this Agreement at any time during the Hospital Supply Status Period or the First Transition Period if the medical adviser determines for clinical reasons that it is no longer appropriate to have:
 - (i) in the case of any Pharmaceutical that is not a Medical Device, any Pharmaceutical, including the Pharmaceutical or any relevant Alternative Pharmaceutical, having Hospital Supply Status of that form and strength of the Pharmaceutical with Hospital Supply Status;
 - (ii) in the case of any Pharmaceutical that is a Medical Device, any Pharmaceutical, including the Pharmaceutical or any relevant Alternative Pharmaceutical, having Hospital Supply Status; or
 - (iii) the Pharmaceutical as the brand having Hospital Supply Status; and/or
- (b) impose at any time during the Hospital Supply Status Period or the Transition Periods restrictions on the prescribing or dispensing of a Pharmaceutical if those restrictions are necessary for clinical reasons.

8.2 Termination following an audit

PHARMAC may terminate the Agreement, or withdraw Hospital Supply Status in relation to, or revise DV Limits for, a Pharmaceutical, at any time during the Hospital Supply Status Period or the Transition Periods, if you fail to remedy any area of non-compliance in accordance with clause 3(b) of Schedule Four.

9. Guarantee

- (a) PHARMAC may require an entity acceptable to it to provide a guarantee (in a form satisfactory to PHARMAC) of your performance obligations under clauses 7.2 and 7.3 of this Schedule including, without limitation, the payment of any sum payable under the indemnity or as liquidated damages pursuant to those clauses for any failure to supply the Pharmaceutical in accordance with this Agreement during the Hospital Supply Status Period.
- (b) The guarantor's liability under such a guarantee will be limited to a total of \$100,000 per Pharmaceutical for all claims made by PHARMAC under the guarantee.

10. Access by PHARMAC to price and volume data

- (a) You acknowledge that PHARMAC and its agents will require access to price and volume data held by you and DHB Hospitals in respect of the Pharmaceutical covered by this Agreement to assist PHARMAC to carry out its statutory function in relation to managing the purchasing of hospital pharmaceuticals on behalf of DHBs.
- (b) Notwithstanding any other provisions in this Agreement, including clauses 9.1 and 9.2 of Schedule Three regarding confidential information, you agree that where the

Schedule 6

circumstances in this clause apply, a DHB Hospital may provide PHARMAC and its agents with any price and volume data held by that DHB Hospital in respect of a Pharmaceutical covered by this Agreement and PHARMAC and its agents may provide such data on DHBs.

- (c) You agree that within 10 business days following any request from PHARMAC, you will provide PHARMAC with volume data in respect of the Pharmaceutical covered by this Agreement for each month of the period specified in that request.

11. PCTs

11.1 Listing in Section B of the Pharmaceutical Schedule

- (a) Where the Pharmaceutical is a PCT, you acknowledge and agree that PHARMAC may list the Pharmaceutical in Section B of the Pharmaceutical Schedule:
 - (i) at a price that is equal to (or subject to your agreement, less than) the Price;
 - (ii) subject to the rules and restrictions applying to PCTs in Sections A to G of the Pharmaceutical Schedule.
- (b) If PHARMAC lists the Pharmaceutical in Section B of the Pharmaceutical Schedule pursuant to paragraph (a) above, you acknowledge and agree that:
 - (i) such listing will be for reasons relating to claiming and will not, unless otherwise advised in writing by PHARMAC, enable you to supply the Pharmaceutical for use in the community;
 - (ii) listing of the Pharmaceutical in Section B will, at PHARMAC's option, be additional to or instead of listing in Part II of Section H;
 - (iii) references to the "listing" of the Pharmaceutical will, where applicable, be to the listing of the Pharmaceutical in Section B of the Pharmaceutical Schedule (and references to "list", "listed", "delist", "delisted", and "delisting" are to be interpreted accordingly); and
 - (iv) the standard terms of listing of the Pharmaceutical in Section B of the Pharmaceutical Schedule will, except to the extent otherwise advised in writing by PHARMAC, be the terms set out in Schedule Four and this Schedule, and for that purpose all references in Schedule Four and this Schedule to "Section H" will be deemed to be references to "Section B".
- (c) This clause confers a benefit on (and is enforceable by) DHB Hospitals in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.
- (d) Where the Pharmaceutical is a PCT, clause 7.1 of this Schedule will be deleted and replaced by the following:
 - 7.1 Notification of Potential Out-of-Stock Event and supply of Alternative Pharmaceutical.**
 - (a) You must notify PHARMAC in writing as soon as you have reasonable cause to believe that you will fail to supply a Pharmaceutical in accordance with this Agreement and, in any event, you must notify PHARMAC and the relevant DHB Hospitals if at any time a Potential

Schedule 6

Out-of-Stock Event occurs, including during the Hospital Supply Status Period or the First Transition Period.

- (b) If you fail to supply a Pharmaceutical in accordance with this Agreement for more than 1 business day to any DHB Hospital, then:
 - (i) you must use your best endeavours to procure, within what the relevant DHB Hospitals consider to be a reasonable period of time, an Alternative Pharmaceutical for supply to, at a DHB Hospital's discretion, any Designated Delivery Points, and/or Contract Manufacturers (expressly for the purpose of compounding) at the Price; and
 - (ii) if you fail to procure an Alternative Pharmaceutical at the Price in accordance with sub-clause (i) above (other than for reasons that PHARMAC reasonably considers, following discussion with you, to be wholly outside your control) then, at PHARMAC's option:
 - (A) you must pay to PHARMAC (for the benefit of PHARMAC and DHB Hospitals) any additional costs that PHARMAC incurs or that the relevant DHB Hospitals incur as a result of the purchase of the Alternative Pharmaceutical; or
 - (B) PHARMAC may implement an arrangement with another supplier to supply an Alternative Pharmaceutical (including an arrangement for back-up supply), and you must pay to PHARMAC (for the benefit of PHARMAC and DHB Hospitals) any additional costs that PHARMAC incurs or that the relevant DHB Hospitals incur as a result of the purchase of the Alternative Pharmaceutical.
- (c) This clause confers a benefit on (and is enforceable by) DHB Hospitals in accordance with the Contract and Commercial Law Act 2017, Part 2, Subpart 1.

Schedule 7: Additional Special Terms

1. Lacosamide

In respect of the identified Tender Items in Schedule 2 (lacosamide (current access) tab 50 mg, 100 mg, 150 mg and/or 200 mg or lacosamide (widened access) tab 50 mg, 100 mg, 150 mg and/or 200 mg) ("Lacosamide Tender Items") and notwithstanding any other provision in this Agreement concerning the Sole Supply Status of the Lacosamide Tender Items, and without limiting any other actions that it may be necessary or appropriate for PHARMAC to take in response to patient safety concerns, PHARMAC may grant subsidised access, on a strictly limited basis, to an alternative brand of the relevant Lacosamide Tender Items during the Sole Supply Period to the extent that this is necessary to enable a limited number of patients to continue treatment following adverse effects or efficacy concerns in their treatment with the relevant Lacosamide Tender Items, in accordance with the following condition:

- The maximum number of patients who are treated with the alternative brand of Lacosamide Tender Items shall not exceed 30 patients per calendar year, unless otherwise agreed, during the Sole Supply Period.

For the avoidance of doubt, this clause does not apply to the lacosamide (current access) inj 10 mg per ml, 20 ml Tender Item.